Highly regulable promoter for heterologous gene expression

BACKGROUND OF THE INVENTION
1. Field of the Invention
The present invention relates to novel nucleic acid sequences which encode an operon involved in L-arabinose utilization. The operon includes a promoter which is both inducible and repressible and can be used to promote expression of genes in prokaryotics.
2. Description of the Related Art
Bacillus subtilis, an endospore-forming Gram positive bacteria, is able to grow on L-arabinose as the sole carbon source. L-arabinose residues are found widely distributed among many heteropolysaccharides of different plant tissues, such as arabinans, arabinogalactans, xylans, and arabinoxylans. Bacillus species in its natural reservoir, the soil, participate in the early stages of plant material decomposition, and B. subtilis secretes three enzymes, and endo-arabanase and two arabinosidases, capable of releasing arabinosyl oligomers and L-arabinose from plant cell walls [Kaji and Seheki, Biochim. Biophys. Acta., 410:354-360 (1975); Weinstein and Albersheim, Plant Physiol., 63:425-432 (1979)]. The pathway of L-arabinose utilization in B. subtilis was described by Lepesant and Dedonder [C R Acad. Sci., Ser.D:2683-2686 (1967a)]. After entering the cell, L-arabinose is sequentially converted to L-ribulose, L-ribulose-5-phosphate, and D-xylulose-5-phosphate by the action of L-arabinose isomerase, L-ribulokinase and L-ribulose 5-phosphate 4-epimerase, respectively. D-xylulose-5-phosphate is further catabolized through the pentose-phosphate pathway. Mutants unable to use L-arabinose as sole carbon source, deficient in one of the three enzymes involved in L-arabinose catabolism, were characterized as well as constitutive mutants for all the three enzymes [Lepesant and Dedonder, 1967a, supra; Lepesant and Dedonder, C R Acad. Sci., Ser.D:2832-2835 (1967b)]. The synthesis of these enzymes was shown to be inducible by L-arabinose and the isomerase activity subjected to catabolite repression by glucose and glycerol [Lepesant and Dedonder, 1967a, supra].
A collection of Ara.sup.- B. subtilis mutants was isolated, biochemically characterized and the three metabolic genes, araA, araB and araD coding for L-arabinose isomerase, L-ribulokinase and L-ribulose 5-phosphate 4-epimerase, respectively, were identified and mapped between aroG and leuA, at about 256.degree. on the B. subtilis genetic map [Paveia and Archer, Broteria Genetica, Lisboa, XIII(LXXX):149-159 (1992a); Paveia and Archer, Broteria Genetica, Lisboa, XIII(LXXX):161-167 (1992b)]. Two additional classes of mutations affecting L-arabinose utilization were identified; one included mutations conferring and Ara.sup.- phenotype to strains bearing the araA, araB and araD wild types alleles [Paveia and Archer, 1992a, supra; Paveia and Archer, 1992b, supra] and another comprised mutants showing constitutive expression of the three genes [Sa-Nogueira et al., J. Bacteriol, 170:2855-2857 (1988)]. These mutations were mapped between the cysB and hisA markers, at about 294.degree. on the B.subtilis genetic map, and define another ara locus named araC. Expression of L-arabinose isomerase is severely repressed during growth in media containing L-arabinose plus glucose. Since L-arabinose isomerase expression is still regulated by catabolite repression in strains which contain constitutive mutations, araC.sup.C, L-arabinose transport does not play a major role in catabolite repression of expression of the metabolic enzymes [Sa-Nogueira et al., 1988, supra]. The genes araA, araB and araD, have been cloned and by complementation experiments its products were shown to be functionally homologous to their Escherichia coli counterparts. Transformation experiments involving defined restriction fragments from the cloned genes showed that they are adjacent and probably constitute an operon with the order A-B-D [Sa-Nogueira and Lencastre, J. Bacteriol., 171:4088-4091 (1989)], unlike the B-A-D order found in the E. coli operon [Englesberg et al., Proc. Natl. Acad. Sci. USA, 80:6790-6794 (1969)].
Expression of cloned genes introduced into bacteria has been, and is still, a mechanism for producing large amounts of a protein of interest for diagnostic and therapeutic purposes. In order to efficiently produce proteins in a prokaryotic host, a strong, regulated promoter is an essential element of the expression system.
Prokaryotic promoters used in the past include the bacteriophage lambda p.sub.L promoter, which is regulated by a temperature-sensitive repressor which represses transcription from that promoter at low temperatures. The p.sub.L promoter is used in an E. coli strain which contains a defective lambda prophage which encodes the repressor. This system is particularly suited for the expression of proteins which are toxic to E. coli. However, although the system is repressible, it does not provide a mechanism for inducibility.
Another prokaryotic promoter is the trp-lac promoter or tac promoter, which has been used to produce high levels of proteins in E. coli. This promoter is induced in the presence of isopropylthio-.beta.-D-galactoside (IPTG). However, in order to subject the promoter to repression it must be used in an E. coli strain which produces lac repressor protein.
The bacteriophage T7 promoter can be used to express proteins in bacteria which are not normally efficiently transcribed by E. coli RNA polymerase. However, this system requires the use of an exogenous T7 RNA polymerase, and may require the use of specialized host cells, or supplemental infection with a bacteriophage in order to maintain low expression levels of proteins which are toxic to E. coli.
Therefore, in view of the aforementioned deficiencies attendant with prior art methods of controlling gene expression in prokaryotic hosts, it is apparent that there exists a need in the art for a promoter system for the expression of exogenous DNA in prokaryotes, which is highly regulable, i.e., is both inducible and repressible.
SUMMARY OF THE INVENTION
Briefly, the present invention features a promoter which is derived from an operon which contains three genes involved in L-arabinose utilization, araA, araB and araD which code L-arabinose isomerase, L-ribulokinase and L-ribulose 5-phosphate 4-epimerase (araA, araB and araD respectively). The operon additionally contains ribosome binding sites preceding each of the structural genes for L-arabinose utilization, and six regions which may be involved in transcription regulation, including four inverted repeats and two direct repeats.
In accordance with the present invention, an isolated nucleic acid molecule is provided which promotes the expression of genes in prokaryotes, and is both inducible and repressible on the addition of exogenous inducer or repressor respectively. The araC repressor is endogenous.
In a further embodiment, the genes encoding enzymes involved in L-arabinose utilization in B. subtilis are provided.
In its broadest aspect, the present invention extends to nucleic acid sequences encoding a promoter having the following characteristics:
a) promoting expression of genes in prokaryotes;
b) being inducible with L-arabinose; and
c) being repressible with glucose.
In a specific example, the promoter is contained by the sequence of SEQ ID NO:1, the operon has the sequence of SEQ ID NO:11, and the L-arabinose utilization enzymes have a nucleotide sequence of SEQ ID NO:35, 36 or 37.
In a still further aspect, the present invention extends to vectors for the expression of proteins in prokaryotes, and to the L-arabinose utilization enzymes which are expressed by the operon.
In a particular embodiment, the present invention relates to all members of the herein disclosed family of L-arabinose utilizing enzymes, particularly those having SEQ ID NOS:12, 13 and 14.
The present invention also relates to a recombinant DNA molecule or cloned gene, or a degenerate variant thereof, which encodes an operon which is preferably a nucleic acid molecule, in particular a recombinant DNA molecule or cloned gene, encoding the operon which has a nucleotide sequence or is complementary to a DNA sequence shown in FIG. 2 (SEQ ID NO:11).
The B. subtilis DNA sequences of the operon or promoter of the present invention or portions thereof, may be prepared as probes to screen for complementary sequences and genomic clones in the same or alternate species. The present invention extends to probes so prepared that may be provided for screening cDNA and genomic libraries for the operon or promoter. For example, the probes may be prepared with a variety of known vectors, such as the phage .lambda. vector. The present invention also includes the preparation of plasmids including such vectors.
In a further embodiment of the invention, the full DNA sequence of the recombinant DNA molecule or the isolated promoter and regulatory regions are operatively linked as an expression control sequence to a gene encoding a protein to be expressed which may be introduced into an appropriate host. The invention accordingly extends to unicellular hosts transformed with the vector comprising a DNA sequence encoding the present operon or promoter, and more particularly, the complete DNA sequence determined from the sequences set forth above and in SEQ ID NOS:1 or 11.
According to other preferred features of certain preferred embodiments of the present invention, a recombinant expression system is provided to produce biologically active proteins which are eukaryotic or prokaryotic in origin.
The concept of the inducible/repressible operon or promoter contemplates that specific factors exist for correspondingly specific sequences within the operon, which lead to induction or repression in the presence of compounds such as L-arabinose, glucose and the like, as described earlier. Accordingly, the exact structure of each operon or promoter, and the corresponding factors, will understandably vary so as to achieve binding and activity specificity. It is this specificity and the direct involvement of the inducers and repressors in the chain of events leading to gene activation, that offers the promise of highly regulated procaryotic expression.
The present invention naturally contemplates several means for preparation of the operon or promoter, including as illustrated herein known recombinant and PCR techniques, and the invention is accordingly intended to cover such synthetic preparations within its scope. The isolation of the cDNA amino acid sequences disclosed herein facilitates the reproduction of the operon by such recombinant techniques, and accordingly, the invention extends to expression vectors containing the disclosed DNA sequences for expression in host systems by recombinant DNA techniques, and to the resulting transformed hosts.
The invention includes an assay system for screening of potential compounds effective to modulate transcriptional activity of target prokaryotic cells by interrupting or potentiating the activity of the operon or promoter. In one instance, the test compound could be administered to a cellular sample with the inducer or repressor that induces or represses the operon or promoter, or an extract containing the compound, to determine its effect upon the activity of the inducer or repressor to the operon or promoter DNA by comparison with a control.
The assay system could more importantly be adapted to identify factors that are capable of binding to the regulatory regions of the operon or promoter e.g. transcription factors or proteins, thereby inhibiting or potentiating transcriptional activity. Such drugs might be used to modulate the levels of expression from the promoters.
The present invention likewise extends to the development of antibodies against the enzymes involved in the utilization of L-arabinose (i.e; the Ara proteins), including naturally raised and recombinantly prepared antibodies. For example, the antibodies could be used to screen expression libraries to obtain the gene or genes that encode the Ara protein(s). Such antibodies could include both polyclonal and monoclonal antibodies prepared by known genetic techniques, as well as bi-specific (chimeric) antibodies, and antibodies including other functionalities suiting them for additional diagnostic use conjunctive with their capability of modulating transcriptional activity.
In the instance where a radioactive label, such as the isotopes .sup.3 H, .sup.14 C, .sup.32 P, .sup.35 S, .sup.36 Cl, .sup.51 Cr, .sup.57 Co, .sup.58 Co, .sup.59 Fe, .sup.90 Y, .sup.125 I, .sup.131 I, and .sup.186 Re are used, known currently available counting procedures may be utilized. In the instance where the label is an enzyme, detection may be accomplished by any of the presently utilized colorimetric, spectrophotometric, fluorospectrophotometric, amperometric or gasometric techniques known in the art.
Accordingly, it is a principal object of the present invention to provide an isolated nucleic acid molecule, containing a sequence which promotes the expression of a protein in a prokaryotic host, wherein the sequence encoding the protein is operably positioned in proper reading frame 3' to the promoting sequence, and the expression is inducible in the presence of an appropriate exogenously supplied inducer or repressible in the presence of an appropriate exogenously supplied repressor.
In a particular embodiment, the nucleic acid has the sequence of SEQ ID NO:1; a sequence complementary to SEQ ID NO:1; or a homologous sequence which is substantially similar to SEQ ID NO:1.
A further object of the present invention is to provide a vector for the expression of a protein in a prokaryotic host which includes that nucleic acid sequence.
Another object of the invention is to provide a prokaryotic host transformed with the vector.
A still further object of the invention is to provide an isolated nucleic acid including the promoter sequence operably positioned in proper reading frame with at least one of an araA gene, an araB gene and an araD gene.
In a particular embodiment, the nucleic acid further includes a ribosome binding site 5' to each ara gene and/or at least one region which functions as an operator. In specific embodiments, the region includes an indirect or direct repeat sequence or a transcription terminator.
In one embodiment, the isolated nucleic acid has the sequence of:
a) SEQ ID NO:11;
b) a sequence which is substantially homologous to SEQ ID NO:11; or
c) a fragment of any of (a) or (b) which retains the biological activity of SEQ ID NO:11.
Yet another object of the invention is to provide an isolated DNA molecule encoding a B. subtilis L-arabinose isomerase, or a fragment thereof, selected from the group of:
a) the DNA sequence of SEQ ID NO:35;
b) a DNA sequence complementary to SEQ ID NO:35;
c) DNA sequences that hybridize to any of the foregoing DNA sequences under standard hybridization conditions; and
d) DNA sequences that code on expression for an amino acid sequence encoded by any of the foregoing DNA sequences.
In a particular embodiment, the L-arabinose isomerase has an apparent molecular weight of approximately 56 kD, and contains approximately 496 amino acids.
In specific embodiments, the L-arabinose isomerase has the following sequence:
a) SEQ ID NO:12;
b) a sequence which is substantially homologous to SEQ ID NO:12; or
c) a fragment of any of (a) or (b) which retains the biological activity of SEQ ID NO:12.
Still another object of the invention is to provide an isolated DNA molecule including a DNA sequence or degenerate variant thereof, which encodes an L-ribulokinase, or a fragment thereof, selected from the group consisting of:
a) the DNA sequence of SEQ ID NO:36;
b) a DNA sequence complementary to SEQ ID NO:36;
c) DNA sequences that hybridize to any of the foregoing DNA sequences under standard hybridization conditions; and
d) DNA sequences that code on expression for an amino acid sequence encoded by any of the foregoing DNA sequences.
Another object of the invention is to provide the L-ribulokinase encoded by the DNA molecule.
In a particular embodiment the L-ribulokinase has an apparent molecular weight of approximately 61 kD and/or contains approximately 560 amino acids.
In specific embodiments, the L-ribulokinase has the following sequence:
a) SEQ ID NO:13;
b) a sequence which is substantially homologous to SEQ ID NO:13; or
c) a fragment of any of (a) or (b) which retains the biological activity of SEQ ID NO:13.
A further object of the invention is to provide an isolated DNA molecule comprising a DNA sequence or degenerate variant thereof, which encodes an L-ribulose 5-phosphate-4-epimerase, or a fragment thereof, selected from the group consisting of:
a) the DNA sequence of SEQ ID NO:37;
b) a DNA sequence complementary to SEQ ID NO:37;
c) DNA sequences that hybridize to any of the foregoing DNA sequences under standard hybridization conditions; and
d) DNA sequences that code on expression for an amino acid sequence encoded by any of the foregoing DNA sequences.
Another object of the invention is to provide the L-ribulose 5-phosphate-4-epimerase encoded by the DNA molecule.
In specific embodiments the L-ribulose 5-phosphate-4-epimerase has an apparent molecular weight of approximately 26 kD and/or contains approximately 229 amino acids.
In specific embodiments the L-ribulose 5-phosphate-4-epimerase has the following sequence:
a) SEQ ID NO:14;
b) a sequence which is substantially homologous to SEQ ID NO:14; or
c) a fragment of any of (a) or (b) which retains the biological activity of SEQ ID NO:14.
Another object of the invention is to provide the isolated DNA molecules attached to detectable labels.
In specific embodiments, the detectable label is an enzyme, is fluorescent or radioactive.
Yet another object of the invention is to provide an antibody to the L-arabinose isomerase, the L-ribulokinase or L-ribulose 5-phosphate-4-epimerase.
In specific embodiments, the antibody may be polyclonal or monoclonal, and may be labelled with a detectable marker such as an enzyme, or a fluorescent or radioactive marker.
A further object of the invention is to provide a method for detecting proteins which regulate the present promoter sequence, including the steps of:
a) incubating a sample in which a regulator protein may be present with the DNA sequence of SEQ ID NOS:2, 3, 4, 5, 6, 7 or 38;
b) isolating any protein bound to the DNA sequences of step (a); and
c) correlating the binding of the protein to the ability of the protein to regulate the promoter.
Other objects and advantages will become apparent to those skilled in the art from a review of the ensuing description which proceeds with reference to the following illustrative drawings.

BRIEF DESCRIPTION OF THE DRAWINGS
FIG. 1. Physical and genetic map of the ara region of the chromosome. The location and direction of transcription of the nine open reading frames (araA, araB, araD, araL, araM, araN, araP, araQ and abfA), predicted from the analysis of the nucleotide sequence, are indicated by arrows. The promoter (P) of the ara operon, defined by primer extension, is located upstream the araA gene and the two region of dyad symmetry that could represent the terminators of the ara transcriptional unit are located downstream the abfA gene. The position for each restriction site, according to the nucleotide sequence is given in the partial restriction map. The region to the right of the EcoRI site (position 11755) is not drawn to scale. The open boxes, below the physical map, represent the three fragments used as probes for Northern analysis of the ara transcripts and the striped boxes () represent the extension of the inserts in the indicated plasmids. The sites of different insertion-deletion mutations resulting from replacement of wild-type sequences, by double-crossover events, with in vitro-engineered fragments of the ara region, present in plasmids pSNL11, pSNL12 and pSN22, are also shown. Plasmids pSNL7, pSS2, pTN10, pTN14, pSNL13 and pSNL14 were integrated into the host chromosome by means of a single crossover (Campbell-type) recombinational event that occurred in the region of homology.
FIGS. 2A-E. Nucleotide sequence (SEQ ID NO:11) and translation of the B. subtilis ara region. The nucleotide sequence of the non transcribed strand is shown in the 5' to 3' direction. The predicted primary structure of the polypeptides encoded by the ara region are give in single letter code. The transcription start site (+1), defined by primer extension analysis, the -35 and -10 regions of the promoter and the putative ribosome binding sites (rbs) are underlined. Stop codons are represented by asterisks. Convergent arrows represent different regions of dyad symmetry (IR) and the two inverted represents though to act as transcriptional terminators for the ara operon are indicated by the letters T.sub.1 and T.sub.2. The catabolic repression associated sequences (position 191 to 204 and position 260 to 273) are underlined, The complementary sequence of the two primers A and B, used in primer extension analysis are represented below the sequence. The araA'-lacZ and araB'-lacZ fusion sites, confirmed by sequencing, are shown by an arrow.
FIG. 3. Intercistronic regions and putative transcription termination sites of the ara operon (SEQ ID NOS:22, 23, 27, 28, 29, 30, 31, 33, 38, 39, 40, 41, 42, and 43). The DNA sequence of the non-transcribed strand is shown. The initiation codon is indicated above each triplet by "met", while the stop codons are indicated below each triplet by "end". The possible pairing with the 3' end of 16S rRNA is indicated above each sequence (ribosome binding site). The free energy (AG.sup.0) of interaction for each putative ribosome binding site and for the predicted stem-loop structures of the putative terminators of the ara operon, T1 and T2, were calculated according to the rules of Tinoco et al., Nature New. Biol. 246:40-41 (1973).
FIGS. 4A-B. A. Alignment of a segment of the predicted sequence of AraN protein (SEQ ID NO:48) with the signature sequence (SEQ ID NO:47) of cluster 1 binding proteins, from binding-dependent transport systems, according to Tam and Saier, Microbiol Rev 57:320-346 (1993). Numbers in parenthesis indicate the positions of the last amino acid residues. The highly conserved lysine residue (K) is in boldface and the amino acid residues that match the signature sequence are underlined. B. Alignment of the amino terminal sequence (deduced from the nucleotide sequence) of AbfA from B. subtilis (B. su.) (SEQ ID NO:49) with the N-terminal sequence of .alpha.-L-arabinofuranosidase sequence from B. stearothermophilus (B. st.) (SEQ ID NO:50) Double dots represent identical amino acids and single dots represent conservative changes.
FIGS. 5A-B. A. Hydropathic index for the deduced amino acid sequences of AraP and AraQ protein according to the algorithm of Kyte and Doolittle, J Mol Biol 157:105-132 (1982). The hydropathy profiles are plotted from the N-terminus to the C-terminus by averaging hydropathy values over a window of ten residues. Hydrophobic segments which could correspond to membrane-spanning regions are labeled I-VI. B. Alignment of a hydrophilic segment, at approximately 100 residues from the C-terminus of the predicted sequence of AraP (SEQ ID NO:51) and AraQ (SEQ ID NO:53) proteins, with the consensus sequence (SEQ ID NO:52) for the group of integral cytoplasmic membrane proteins from binding protein-dependent transport systems (Saurin et al., Mol. Microbiol 12:993-1004 (1994) which includes permeases involved in the transport of disaccharide and glycerol phosphate. The general consensus for integral membrane proteins from binding protein-dependent permeases, EAA - - - G - - - I-LP (SEQ ID NO:44), where (-) represents any amino acid (Dassa et al., EMBO J. 4:2287-2293 (1985), is underlined. The distance of the invariant glycine residue from the C-terminus is represented in parenthesis. Double dots represented identical amino acids and single dots represent conservative changes.
FIGS. 6A-C. Northern analysis of the ara operon-specific transcripts. A. B. and C: Lanel, 10 .mu.g of total RNA extracted from the uninduced wild type strain B. subtilis 168T+; Lanes 2, 3, and 4; 2.5 .mu.g, 5 .mu.g and 10 .mu.g, respectively of total RNA extracted from the induced wild type stran B. subtilis 168T+ L-arabinose (see methods); Lane L, 4 .mu.g of the RNA ladder (9.5-0.24 kb; Givco/BRL). The samples were run in: A. 1% (w/v) and B., C. 1.2% (w/v) agarose formaldehyde denaturing gel. The .sup.32 P-labeled probes used were synthesized from: A. 1.6 kb EcoRI-PstI fragment (position 249 to 1897, Probe 1 FIG. 1); B. a 0.8 kb Ncol-EcoRV fragment (position 5270 to 6079, Prob 2, FIG. 1) C. a 0.7 kb PstI-AvaI fragment (position 9538 to 10275, Probe 3, FIG. 1). L: 4 .mu.g of the RNA ladder (9.5-0.24 kb; Gibco/BRL) was probed with .sup.32 P labeled 2 DNA and also visualized by staining with ethidium bromide. The transcript of about 11 kb comprising all genes and detected with the three probes is indicated by an arrow.
FIG. 7. Primer extension analysis of the ara operon promoter. Two radio labeled oligonucleotide primers A and B complementary to two different regions downstream from the araABD promoter: primer A (5'-GAAGCATGTAAACTGCCCC-3', SEQ ID NO:25), complementary to a region of araA mRNA located between nucleotides 216 to 234 (FIG. 2) and primer B (5'-CCAGCGTCTCTTCCCCG-3', SEQ ID NO:26), complementary to a region of the araA mRNA located between nucleotides 283 to 300 (FIG. 2), were hybridized with B. subtilis BR151 RNA isolated from exponentially growing cells in the presence (1) or absence (2) of L-arabinose. After extension, the products were analyzed by gel electrophoresis, together with a set of dideoxynucleotide-chain termination sequencing (SEQ ID NO:54) reactions using the same primers and a single stranded M13 DNA template which includes entire araA gene and an additional 228 bp of its 5'-flanking sequence.
FIG. 8. Expression of the ara operon measured by determination of the levels of .beta.-galactosidase (given as Miller units) present in exponentially growing cells, Strains of B. subtilis harboring transcriptional lacZ fusions were grown on C minimal medium supplemented with casein hydrolysate 1% (w/v) and either arabinose 0.4% (w/v) or arabinose 0.4% (w/v) and glucose 0.4% (w/v) (see Methods). Time is expressed in minutes after induction. .diamond. IQB101 (araB'-lacZ erm Ara-Em.sup.r lacZ+); .quadrature. IQB103 (araa'-lacZcat Ara+Cm.sup.r lacZ+); .DELTA. IQB 102 (araB-erm lacZ Ara-Em.sup.r lacZ-), negative control; .largecircle. IQB104 (araA'-catlacZ Ara+Cm.sup.r lacZ-), negative control. For each strain the results represent the average, in Miller units, from two independent experiments.
FIG. 9. Comparison of B. subtilis araA, araB and araD gene products (SEQ ID NOS:12,13 and 14) with the E. coli and S. typhimurium AraA (SEQ ID NOS:16,17), B (SEQ ID NOS:18,19), and D (SEQ ID NOS:20,21) proteins. For S. typhimurium only, the amino acids that are different relative to E. coli are indicated. The alignments were made by the FASTA algorithm [Pearson and Lipman, Proc. Natl. Acad Sci. USA, 85:2444-2448 (1988)]. Dashes represent gaps introduced to maximize sequence similarities. Double dots indicate amino acid identity and single dots indicate a conservative amino acid change.
FIG. 10. Construction of araB-lacZ transcriptional fusions, and integration of the fusions into the chromosomes of B. subtilis by a double crossover. Plasmid pSNL11 was constructed by insertion of the lacZ and erm genes into the araB gene at the unique Eco RV site of the 1.7 Kb HincII-EcoRI fragment (shaded area). Strain IQB102 was obtained by the same procedure using plasmid pSNL12 which has lacZ and erm genes cloned in the opposite orientation as described in the methods. The double crossover event on both cases disrupted the araB gene which resulted in insertional inactivation of the gene. The location of the ara genes is shown by the upper empty bars. The promoter (P) of the ara operon is indicated by the arrow preceding araA gene. HcII/S represents the Hinc II site cloned into Sma I site; Bg/II, (B); Eco RI, (E); Eco RV, (Ev); Hind II, (H); Nco I, (N); Pst I, (P).
FIG. 11. (A) Physical map of the ara operon. Only relevant restriction sites are shown: Eco RI (E); Eco RV (Ev); Hind III (H); Kpn I (K); Pst I (P); Pvu I (Pv); Sma I (S). The location and direction of transcription of the four open reading frames (araA, araB, araD and ORF4 are indicated by arrows. The promoter (P) of the ara operon is indicated by the arrow preceding araA. (B) The nucleotide sequence of the promoter region. The -35 and -10 regions of the promoter are shown in boxes. The transcription start site (+1) and the two sequences similar to the consensus sequence for catabolite repression (CR-TGWNANCGNTNWCA) (SEQ ID NO:8), are underlined. Convergent arrows indicate four different regions of dyad symmetry (IR1, IR2, IR3 and IR4) (SEQ ID NOS:2-5, respectively) and direct arrows indicate regions of direct repeats (DR). The ribosome binding site (RBS) preceding the araA coding regions is shown in bold letters.

DETAILED DESCRIPTION OF INVENTION
The present invention provides an isolated nucleic acid molecule which promotes the expression of genes in prokaryotes, and is both inducible and repressible upon the addition of exogenous inducer or repressor, respectively.
In particular, the present invention provides the promoter for the Bacillus subtilis L-arabinose (ara) operon that is induced by L-arabinose and repressed by glucose. The ara operon is located at about 256.degree. on the Bacillus subtilis genetic map, and comprises nine genes with a total length of 11 kb.
Therefore, if appearing herein, the following terms shall have the definitions set out below.
The "ara" operon is a single transcriptional unit that comprises nine genes, araA, araB, araD, araL, araM, araN, araP, araQ, and abfA whose expression is directed by a strong .sigma.-A like promoter identified within a 150 bp DNA fragment upstream from the translation site of the araA gene.
A "promoter sequence" is a DNA regulatory region capable of binding RNA polymerase in a cell and initiating transcription of a downstream (3' direction) coding sequence. For purposes of defining the present invention, the promoter sequence is bounded at its 3' terminus by the transcription initiation site and extends upstream (5' direction) to include the minimum number of bases or elements necessary to initiate transcription at levels detectable above background. Within the promoter sequence will be found a transcription initiation site as well as protein binding domains (consensus sequences) responsible for the binding of RNA polymerase. Prokaryotic promoters contain Shine-Dalgarno sequences in addition to the -10 and -35 consensus sequences.
The "promoter of the present invention" is identified within a 150 bp DNA fragment upstream from the translation site of the araA gene. Situated 7 and 30 bp upstream from the ara operon transcription start site are sequences identical to the consensus -35 and -10 regions (TTGACA-17bp-TATAAT, SEQ ID NO:38) respectively, of promoters recognized by Bacillus subtilis .sigma.-A containing RNA polymerase. The promoter of the present invention also contains three inverted repeats, putative operator-like sequences, in the -35 and -10 regions and a potential hairpin-loop structure with a .DELTA.G value of -19.2 kcal/mol centered 27 bp upstream from the -35 region. The promoter is induced by L-arabinose and repressed by glucose.
Thus there are at least six regions likely to be involved in transcription regulation identified near the promoter of the present invention (FIG. 11) (SEQ ID NO:1). The first two were found upstream from the -35 region: an inverted repeat of ten nucleotides (IR1) located upstream from the -35 region (position -49 to -77, FIG. 11 (SEQ ID NO:2) and two direct repeats (comprise between position -66 to -113, FIG. 11). Downstream from IR1, three other inverted repeats were found: the first, IR2, located in the -35 region (SEQ ID NO:3); the second, IR3, located in the -10 region; and the third (SEQ ID NO:4); IR4, in the +4-+20 region (SEQ ID NO:5) (FIG. 11). All these sequences may be putative operator-like regions, and IR1 might also be a putative transcription terminator of a gene located upstream from the cloned fragment. Downstream from the transcription start site, the DNA sequence, +20-ATAGGTTTATTTTCTATCATTAGT ACGT-+47 (SEQ ID NO:6) (FIG. 11) show some similarity to the sequence recognized by the product of the regulatory gene, araC, at the E.coli araBAD promoter ATAGCATTTTTATCCATAAGATTAGCGG (SEQ ID NO:7) (Brunell, A. and Schleif, R., 1989).
An "expression control sequence" is a DNA sequence that controls and regulates the transcription and translation of another DNA sequence. A coding sequence is "under the control" of transcriptional and translational control sequences in a cell when RNA polymerase transcribes the coding sequence into mRNA, which is then translated into the protein encoded by the coding sequence.
A DNA sequence is "operatively linked" to an expression control sequence when the expression control sequence controls and regulates the transcription and translation of that DNA sequence. The term "operatively linked" includes having an appropriate start signal (e.g., ATG) in front of the DNA sequence to be expressed and maintaining the correct reading frame to permit expression of the DNA sequence under the control of the expression control sequence and production of the desired product encoded by the DNA sequence. If a gene that one desires to insert into a recombinant DNA molecule does not contain an appropriate start signal, such a start signal can be inserted in front of the gene.
The term "primer" as used herein refers to an oligonucleotide, whether occurring naturally as in a purified restriction digest or produced synthetically, which is capable of acting as a point of initiation of synthesis when placed under conditions in which synthesis of a primer extension product, which is complementary to a nucleic acid strand, is induced, i.e., in the presence of nucleotides and an inducing agent such as a DNA polymerase and at a suitable temperature and pH. The primer may be either single-stranded or double-stranded and must be sufficiently long to prime the synthesis of the desired extension product in the presence of the inducing agent. The exact length of the primer will depend upon many factors, including temperature, source of primer and use of the method. For example, for diagnostic applications, depending on the complexity of the target sequence, the oligonucleotide primer typically contains 15-25 or more nucleotides, although it may contain fewer nucleotides.
The primers herein are selected to be "substantially" complementary to different strands of a particular target DNA sequence. This means that the primers must be sufficiently complementary to hybridize with their respective strands. Therefore, the primer sequence need not reflect the exact sequence of the template. For example, a non-complementary nucleotide fragment may be attached to the 5' end of the primer, with the remainder of the primer sequence being complementary to the strand. Alternatively, non-complementary bases or longer sequences can be interspersed into the primer, provided that the primer sequence has sufficient complementarily with the sequence of the strand to hybridize therewith and thereby form the template for the synthesis of the extension product.
A "DNA molecule" refers to the polymeric form of deoxyribonucleotides (adenine, guanine, thymine, or cytosine) in its either single stranded form, or a double-stranded helix. This term refers only to the primary and secondary structure of the molecule, and does not limit it to any particular tertiary forms. Thus, this term includes double-stranded DNA found, inter alia, in linear DNA molecules (e.g., restriction fragments), viruses, plasmids, and chromosomes. In discussing the structure of particular double-stranded DNA molecules, sequences may be described herein according to the normal convention of giving only the sequence in the 5' to 3' direction along the nontranscribed strand of DNA (i.e., the strand having a sequence homologous to the mRNA).
An "origin of replication" refers to those DNA sequences that participate in DNA synthesis.
A DNA "coding sequence" is a double-stranded DNA sequence which is transcribed and translated into a polypeptide in vivo when placed under the control of appropriate regulatory sequences. The boundaries of the coding sequence are determined by a start codon at the 5' (amino) terminus and a translation stop codon at the 3' (carboxyl) terminus. A coding sequence can include, but is not limited to, prokaryotic sequences, cDNA from eukaryotic mRNA, genomic DNA sequences from eukaryotic (e.g., mammalian) DNA, and even synthetic DNA sequences. A polyadenylation signal and transcription termination sequence will usually be located 3' to the coding sequence.
A "cassette" refers to a segment of DNA that can be inserted into a vector at specific restriction sites. The segment of DNA encodes a polypeptide of interest, and the cassette and restriction sites are designed to ensure insertion of the cassette in the proper reading frame for transcription and translation.
Transcriptional and translational control sequences are DNA regulatory sequences, such as promoters, enhancers, polyadenylation signals, terminators, and the like, that provide for the expression of a coding sequence in a host cell.
A "signal sequence" can be included before the coding sequence. This sequence encodes a signal peptide, N-terminal to the polypeptide, that communicates to the host cell to direct the polypeptide to the cell surface or secrete the polypeptide into the media, and this signal peptide is clipped off by the host cell before the protein leaves the cell. Signal sequences can be found associated with a variety of proteins native to prokaryotes and eukaryotes.
The term "oligonucleotide", as used herein in referring to a probe of the present invention, is defined as a molecule comprised of two or more ribonucleotides, preferably more than three. Its exact size will depend upon many factors which, in turn, depend upon the ultimate function and use of the oligonucleotide.
As used herein, the terms "restriction endonucleases" and "restriction enzymes" refer to bacterial enzymes, each of which cut double-stranded DNA at or near a specific nucleotide sequence.
A "replicon" is any genetic element (e.g., plasmid, chromosome, virus) that functions as an autonomous unit of DNA replication in vivo; i.e., capable of replication under its own control.
A "vector" is a replicon, such as plasmid, phage or cosmid, to which another DNA segment may be attached so as to bring about the replication of the attached segment.
A cell has been "transformed" by exogenous or heterologous DNA when such DNA has been introduced inside the cell. The transforming DNA may or may not be integrated (covalently linked) into chromosomal DNA making up the genome of the cell. In prokaryotes, yeast, and mammalian cells for example, the transforming DNA may be maintained on an episomal element such as a plasmid. A "clone" is a population of cells derived from a single cell or common ancestor by mitosis. A "cell line" is a clone of a primary cell that is capable of stable growth in vitro for many generations.
Two DNA sequences are "substantially similar" when at least about 75% (preferably at least about 80%, and most preferably at least about 90 or 95%) of the nucleotides match over the defined length of the DNA sequences. Likewise, two protein sequences are "substantially similar" when at least about 75% (preferably at least about 80% and most preferably at least about 90 or 95%) of the amino acids match or are conservative substitutions, as described below. Substantially similar genes and proteins, as defined above, are preferably homologous. Sequences that are substantially homologous can be identified by comparing the sequences using standard software available in sequence data banks, or in a Southern hybridization experiment under, for example, stringent conditions as defined for that particular system. Defining appropriate hybridization conditions is within the skill of the art. See, e.g., Sambrook et al., supra; DNA Cloning, Vols. I & II, supra; Nucleic Acid Hybridization, supra.
A "heterologous" region of the DNA construct is an identifiable segment of DNA within a larger DNA molecule that is not found in association with the larger molecule in nature. Thus, when the heterologous region encodes a mammalian gene, the gene will usually be flanked by DNA that does not flank the mammalian genomic DNA in the genome of the source organism. Another example of a heterologous coding sequence is a construct where the coding sequence itself is not found in nature (e.g., a cDNA where the genomic coding sequence contains introns, or synthetic sequences having codons different than the native gene). Allelic variations or naturally-occurring mutational events do not give rise to a heterologous region of DNA as defined herein.
The terms "Ara proteins", "proteins involved in utilization of L-arabinose", "L-arabinose utilization enzymes", and any variants not specifically listed, may be used herein interchangeably, and as used throughout the present application and claims refer to proteinaceous material including single or multiple proteins, and extends to those proteins having the amino acid sequence data described herein and presented in FIG. 9 (SEQ ID NOS:12, 13 and 14), and the profile of activities set forth herein and in the Claims. Accordingly, proteins displaying substantially equivalent or altered activity are likewise contemplated. These modifications may be deliberate, for example, such as modifications obtained through site-directed mutagenesis, or may be accidental, such as those obtained through mutations in hosts that are producers of the complex or its named subunits. Also, the terms "Ara proteins", "proteins involved in utilization of L-arabinose", "L-arabinose utilization enzymes" are intended to include within their scope proteins specifically recited herein as well as all substantially homologous analogs and allelic variations.
The amino acid residues described herein are preferred to be in the "L" isomeric form. However, residues in the "D" isomeric form can be substituted for any L-amino acid residue, as long as the desired functional property of immunoglobulin-binding is retained by the polypeptide. NH.sub.2 refers to the free amino group present at the amino terminus of a polypeptide. COOH refers to the free carboxy group present at the carboxy terminus of a polypeptide. In keeping with standard polypeptide nomenclature, J. Biol. Chem., 243:3552-59 (1969), abbreviations for amino acid residues are shown in the following Table of Correspondence:
______________________________________TABLE OF CORRESPONDENCESYMBOL1-Letter 3-Letter AMINO ACID______________________________________Y Tyr tyrosineG Gly glycineF Phe phenylalanineM Met methionineA Ala alanineS Ser serineI Ile isoleucineL Leu leucineT Thr threonineV Val valineP Pro prolineK Lys lysineH His histidineQ Gln glutamineE Glu glutamic acidW Trp tryptophanR Arg arginineD Asp aspartic acidN Asn asparagineC Cys cysteine______________________________________
It should be noted that all amino-acid residue sequences are represented herein by formulae whose left and right orientation is in the conventional direction of amino-terminus to carboxy-terminus. Furthermore, it should be noted that a dash at the beginning or end of an amino acid residue sequence indicates a peptide bond to a further sequence of one or more amino-acid residues. The above Table is presented to correlate the three-letter and one-letter notations which may appear alternately herein.
An "antibody" is any immunoglobulin, including antibodies and fragments thereof, that binds a specific epitope. The term encompasses polyclonal, monoclonal, and chimeric antibodies, the last mentioned described in further detail in U.S. Pat. Nos. 4,816,397 and 4,816,567.
An "antibody combining site" is that structural portion of an antibody molecule comprised of heavy and light chain variable and hypervariable regions that specifically binds antigen.
The phrase "antibody molecule" in its various grammatical forms as used herein contemplates both an intact immunoglobulin molecule and an immunologically active portion of an immunoglobulin molecule.
Exemplary antibody molecules are intact immunoglobulin molecules, substantially intact immunoglobulin molecules and those portions of an immunoglobulin molecule that contains the paratope, including those portions known in the art as Fab, Fab', F(ab').sub.2 and F(v), which portions are preferred for use in the therapeutic methods described herein.
Fab and F(ab').sub.2 portions of antibody molecules are prepared by the proteolytic reaction of papain and pepsin, respectively, on substantially intact antibody molecules by methods that are well-known. See for example, U.S. Pat. No. 4,342,566 to Theofilopolous et al. Fab' antibody molecule portions are also well-known and are produced from F(ab').sub.2 portions followed by reduction of the disulfide bonds linking the two heavy chain portions as with mercaptoethanol, and followed by alkylation of the resulting protein mercaptan with a reagent such as iodoacetamide. An antibody containing intact antibody molecules is preferred herein.
The phrase "monoclonal antibody" in its various grammatical forms refers to an antibody having only one species of antibody combining site capable of immunoreacting with a particular antigen. A monoclonal antibody thus typically displays a single binding affinity for any antigen with which it immunoreacts. A monoclonal antibody may therefore contain an antibody molecule having a plurality of antibody combining sites, each immunospecific for a different antigen; e.g., a bispecific (chimeric) monoclonal antibody.
The phrase "pharmaceutically acceptable" refers to molecular entities and compositions that are physiologically tolerable and do not typically produce an allergic or similar untoward reaction, such as gastric upset, dizziness and the like, when administered to a human.
The phrase "therapeutically effective amount" is used herein to mean an amount sufficient to prevent, and preferably reduce by at least about 30 percent, more preferably by at least 50 percent, most preferably by at least 90 percent, a clinically significant change in the S phase activity of a target cellular mass, or other feature of pathology such as for example, elevated blood pressure, fever or white cell count as may attend its presence and activity.
The term "standard hybridization conditions" refers to salt and temperature conditions substantially equivalent to 5.times.SSC and 65.degree. C. for both hybridization and wash.
In accordance with the present invention there may be employed conventional molecular biology, microbiology, and recombinant DNA techniques within the skill of the art. Such techniques are explained fully in the literature. See, e.g., Sambrook, Fritsch & Maniatis, Molecular Cloning: A Laboratory Manual, Second Edition (1989) Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. (herein "Sambrook et al., 1989"); "DNA Cloning: A Practical Approach," Volumes I and II (D. N. Glover ed. 1985); "Oligonucleotide Synthesis" (M. J. Gait ed. 1984); "Nucleic Acid Hybridization" [B. D. Hames & S. J. Higgins eds. (1985)]; "Transcription And Translation" [B. D. Hames & S. J. Higgins, eds. (1984)]; "Animal Cell Culture" [R. I. Freshney, ed. (1986)]; "Immobilized Cells And Enzymes" [IRL Press, (1986)]; B. Perbal, "A Practical Guide To Molecular Cloning" (1984).
In its primary aspect, the present invention concerns the identification of an operon encoding enzymes involved in L-arabinose utilization.
In a particular embodiment, the present invention relates to an operon isolated from B. subtilis.
As stated above, the present invention also relates to a recombinant DNA molecule or cloned gene, or a degenerate variant thereof, which encodes an L-arabinose isomerase, or a fragment thereof, that possesses a molecular weight of about 56 kD and an amino acid sequence set forth in FIG. 2 (SEQ ID NO:12); preferably a nucleic acid molecule, in particular a recombinant DNA molecule or cloned gene, encoding the 56 kD L-arabinose isomerase has a nucleotide sequence or is complementary to a DNA sequence shown in FIG. 2 (SEQ ID NO:35).
The present invention also relates to a recombinant DNA molecule or cloned gene, or a degenerate variant thereof, which encodes an L-ribulokinase, or a fragment thereof, that possesses a molecular weight of about 61 kD and an amino acid sequence set forth in FIG. 2 (SEQ ID NO:13); preferably a nucleic acid molecule, in particular a recombinant DNA molecule or cloned gene, encoding the 61 kD L-ribulokinase has a nucleotide sequence or is complementary to a DNA sequence shown in FIG. 2 (SEQ ID NO:36).
Likewise the present invention also relates to a recombinant DNA molecule or cloned gene, or a degenerate variant thereof, which encodes an L-ribulose-5-phosphate-4-epimerase, or a fragment thereof, that possesses a molecular weight of about 26 kD and an amino acid sequence set forth in FIG. 2 (SEQ ID NO:14); preferably a nucleic acid molecule, in particular a recombinant DNA molecule or cloned gene, encoding the 26 kD L-ribulose-5-phosphate-4-epimerase has a nucleotide sequence or is complementary to a DNA sequence shown in FIG. 2 (SEQ ID NO:37).
The possibilities for both diagnostic uses and uses in protein expression systems derive from the fact that factors appear to participate in direct and causal interaction with the regulatory regions of the operon which induce or repress transcription and accordingly gene activation. As suggested earlier and elaborated further on herein, the present invention contemplates pharmaceutical intervention in the cascade of reactions in which the regulatory regions are implicated, to modulate the activity initiated by the factors bound to there regulatory regions.
Thus, in instances where it is desired to repress the transcriptional activity directed by the promoter, an appropriate repressor of the operon could be introduced, which either acts with those factors causally connected with gene activation or which itself binds a repressor region of the operon. Correspondingly, instances where insufficient gene activation is taking place could be remedied by the introduction of the inducer of the operon or its chemical or pharmaceutical cognates, analogs, and the like. Alternatively, a factor which interacts with the repressor may also be used to inhibit repression, resulting in increased gene activity.
Another feature of this invention is the expression of the DNA sequences disclosed herein as well as use of the promoter of the L-arabinose operon for expressing exogenous DNA. As is well known in the art, DNA sequences may be expressed by operatively linking them to an expression control sequence in an appropriate expression vector and employing that expression vector to transform an appropriate unicellular host.
Such operative linking of a DNA sequence of this invention to an expression control sequence, of course, includes, if not already part of the DNA sequence, the provision of an initiation codon, ATG, in the correct reading frame upstream of the DNA sequence and a termination codon and 3' regulatory sequence.
A wide variety of host/expression vector combinations may be designed employing the DNA sequences of this invention. Useful expression vectors, for example, may consist of segments of chromosomal, non-chromosomal and synthetic DNA sequences. Suitable vectors include derivatives of and known bacterial plasmids, e.g., E. coli plasmids col E1, pCR1, pBR322, pMB9 and their derivatives, plasmids such as RP4; phage DNAS, e.g., the numerous derivatives of phage .lambda., e.g., NM989, and other phage DNA, e.g., M13 and filamentous single stranded phage DNA; yeast plasmids such as the 2.mu. plasmid or derivatives thereof; vectors derived from combinations of plasmids and phage DNAS, such as plasmids that have been modified to employ phage DNA or other expression control sequences; and the like.
A wide variety of unicellular host cells are useful in the expression of DNA sequences by this invention. These hosts may include well known prokaryotic hosts, such as strains of E. coli, Pseudomonas, Bacillus, and Streptomyces.
It will be understood that not all exogenous DNA sequences may be regulated by the vectors, expression control sequences and hosts of the invention. Neither will all hosts function equally well with the same expression system. However, one skilled in the art will be able to select the proper vectors, expression control sequences, and hosts without undue experimentation to accomplish the desired expression without departing from the scope of this invention. For example, in selecting a vector, the host must be considered because the vector must function in it. The vector's copy number, the ability to control that copy number, and the expression of any other proteins encoded by the vector, such as antibiotic markers, will also be considered.
In selecting an expression control sequence, a variety of factors will normally be considered. These include, for example, the relative strength of the system, its controllability, and its compatibility with the particular DNA sequence or gene to be expressed, particularly as regards potential secondary structures. Suitable unicellular hosts will be selected by consideration of, e.g., their compatibility with the chosen vector, their secretion characteristics, their ability to fold proteins correctly, and their fermentation requirements, as well as the toxicity to the host of the product encoded by the DNA sequences to be expressed, and the ease of purification of the expression products.
Considering these and other factors a person skilled in the art will be able to construct a variety of vector/expression control sequence/host combinations that will express the DNA sequences of this invention on fermentation or in large scale culture.
It is further intended that L-arabinose enzyme analogs may be prepared from nucleotide sequences of the protein complex/subunit derived within the scope of the present invention. Analogs, such as fragments, may be produced, for example, by pepsin digestion of enzyme containing material. Other analogs, such as muteins, can be produced by standard site-directed mutagenesis of enzyme coding sequences. Analogs exhibiting "L-arabinose utilizing activity" such as small molecules, whether functioning as promoters or inhibitors, may be identified by known in vivo and/or in vitro assays.
As mentioned above, a DNA sequence encoding the operon, the promoter or the enzymes of the operon can be prepared synthetically rather than cloned. The DNA sequence can be designed with the appropriate codons for the particular enzyme's amino acid sequence. In general, one will select preferred codons for the intended host if the sequence will be used for expression. The complete sequence is assembled from overlapping oligonucleotides prepared by standard methods and assembled into a complete coding sequence. See, e.g., Edge, Nature, 292:756 (1981); Nambair et al., Science, 223:1299 (1984); Jay et al., J. Biol. Chem., 259:6311 (1984).
Synthetic DNA sequences allow convenient construction of genes which will express enzyme analogs or "muteins". Alternatively, DNA encoding muteins can be made by site-directed mutagenesis of native enzyme genes or cDNAs, and muteins can be made directly using conventional polypeptide synthesis.
A general method for site-specific incorporation of unnatural amino acids into proteins is described in Christopher J. Noren, Spencer J. Anthony-Cahill, Michael C. Griffith, Peter G. Schultz, Science, 244:182-188 (April 1989). This method may be used to create analogs with unnatural amino acids.
In accordance with the above, an assay system for screening potential factors effective to modulate the activity of the operon may be prepared. The operon may be introduced into a test system, and the prospective factor may also be introduced into the resulting cell culture, and the culture thereafter examined to observe any changes in the transcriptional activity from the operon due either to the addition of the prospective factor alone, or due to the effect of added quantities of the known enzymes, repressors or inducers.
Preliminary Considerations
The three genes involved in L-arabinose utilization, araA, araB and araD were previously identified by mutations conferring an Ara.sup.- phenotype and were mapped between aroG and leuA on the Bacillus subtilis chromosome [Paveia et al., 1992, supra]. These enzymes were shown to be inducible and the isomerase activity subject to catabolite repression [Lepezant and Dedonder, 1967, supra].
Two different classes of mutations affecting L-arabinose utilization which map at another locus, araC, located between the cysB and hisA markers, have also been identified [Sa-Nogueira et al., 1988, supra]. The first class includes mutations, conferring an Ara.sup.- phenotype to strains bearing the araA, araB and araD wild type alleles. Mutants of the second class show constitutive expression of the araA, and araB and araD genes. These mutations define a locus, araC, which might play a role in the regulation of L-arabinose utilization. Constitutive mutants still retain catabolite repression of L-arabinose isomerase expression, suggesting that a mechanism other than inducer exclusion, plays a role in the carbon regulation of isomerase expression [Sa-Nogueira et al., 1988, supra].
By the present invention, these genes have been cloned from Bacillus subtilis and the gene order established as araABD, unlike the one found in E. coli which is araBAD [Sa-Nogueira and Lencastre, 1989, supra].
To understand further the genetics and regulation of L-arabinose utilization in B. subtilis, studied the structure and transcription of the araA, araB and araD genes were studied. The results obtained show that the three genes involved in the early steps of L-arabinose utilization are organized in an operon, araABD, and .sigma.A-like promoter was identified within a 150 bp DNA fragment upstream from the translation start site of the araA gene.
This operon appears to be regulated mainly at the transcriptional level because the synthesis of the ara mRNA is induced by L-arabinose and is repressed by glucose.
The following examples are presented in order to more fully illustrate the preferred embodiments of the invention. They should in no way be construed, however, as limiting the broad scope of the invention.
EXAMPLES
Example 1
Nucleotide Sequence, Genetic Organization and Expression of the Bacillus subtilis L-Arabonose Operon
Introduction
The cloning of an additional 7.1 kb chromosomal fragment, located downstream from the araD gene, and the nucleotide sequence of over 11 kb is reported. This region contains a cluster of nine genes: the metabolic genes araA, araB, araD, and six new genes here named araL, araM araN, araP,araQ, and abfA. All genes are comprised of a single transcriptional unit, called the ara operon, whose expression is directed by a single .sigma.-A type promoter identified within a 150 bp DNA fragment upstream from the translation start site of the araA gene. The araN, araP and araQ products are likely components of a binding-protein-dependent transport system and the abfA gene most probably codes for an .alpha.-L-arabinofuranosidase. The promoter region of the ara operon is defined and examined and its expression and regulation using transcriptional fusions of this operon to the E. coli lacZ gene are disclosed. These results indicate that the ara operon is regulated at the transcriptional level because expression from the ara promoter is induced by L-arabinose and repressed by glucose.
Results
Insertional inactivation of the araB gene and cloning of an intact copy of araA gene
The location of the araa locus at one end of the cloned fragment in pSNL1 (FIG. 1), together with the absence of araA complementation with pSNL1, suggested that only part of the araA gene was present in this plasmid (Sa-Nogueira & Lencastre, Bacillus subtilis J Bacteriol 170:2855-2857 (1988). To clone the entire araA gene, a DNA fragment containing part of the araA and araB genes were inserted into the integrational vector pJM783 (see Experimental procedures). The resulting plasmid, pSNL7 was used to transform B. subtilis 168T+ to Cm.sup.r. The plasmid integrates into the B. subtilis chromosome at the ara region of homology by a Campbell-type recombination mechanism, which causes disruption of the araB gene (FIG. 1); the structure of the resulting strain IQB100 was confirmed by Southern Hybridization (data not shown). This strain was unable to grow on minimal medium, containing L-arabinose as sole carbon source. Furthermore, it showed resistance to ribitol in the presence of L-arabinose on minimal medium plates supplemented with casein hydrolysate 1% (w/v). In B. subtilis (Paveia & Archer, Bacillus subtilis. Broteria Genetics, Lisboa XIII (LXXX): 149-159 (1992a) like in E. col (Katz, J. Bacteriol 102: 593-595 (1970) these results indicate a defective araB gene. Chromosomal DNA from IQB100 digested with HindIII was used to rescue the entire araA gene and its upstream region (see Experimental procedures). The structure of the recircularized plasmid, pSNL9, was analyzed and it contains a 950 pb fragment of DNA upstream to the previously cloned DNA in plasmid pSNL7 (FIG. 1).
Cloning of the chromosomal region extending downstream from the araD gene
To clone the region located downstream from the araD gene an integrational plasmid pSS2, carrying sequences of araD and araL (FIG. 1), was transformed into the wild type strain 168T+. After integration via single cross-over recombination, confirmed by Southern hybridization analysis (data not shown), the resulting strain IQB202 presented an Ara+ phenotype; however, the growth on minimal medium plates with L-arabinose as the sole carbon source was slower than the one observed with the wild type strain 168t+ (see discussion below). Total chromosomal DNA from IQB 202, was digested with EcoRI, selfligated and transformed into E. coli (see Experimental Procedures). The resulting plasmid pSS3 includes a 3.0 kb insert located downstream to the fragment cloned in pSS2. In order to obtain a fragment that would contain the downstream region from araN, we performed a second chromosome walking step, using integrational plasmid pTN10 (FIG. 1). This procedure created plasmid pTN13 that carried an additional 3.2 kb of DNA adjacent to the previously cloned fragment in plasmid pTN10 (FIG. 1). Strain IQB204 which resulted from the integration of plasmid pTN10 (FIG. 1) into the chromosome of the wild type strain 168T+, via a Campbell-type recombination (confirmed by Southern hybridization analysis; data now shown) showed a Ara+ phenotype similar to that seen with IQB202. A third chromosome walking step rightwards from pTN13, using integrational plasmid pTN14 (FIG. 1) isolated a 4.7 kb SmaI fragment (plasmid pSN5). Plasmid pTN14 when integrated into the chromosome, strain IQB205 (the correct integration was checked by Southern blot analysis; data not shown), caused a Ara+phenotype. The structure of the inserts of pSS3, pTN13 and pSN5 was compared to that of the corresponding areas of chromosomal DNA by Southern blot analysis (data not shown) and the results revealed that no detectable rearrangement occurred during the cloning process.
DNA Sequence and deduced products of the ara genes
Appropriate restriction fragments selected on the basis of the physical maps of pSNL1, pSNL9, pSS3, pTN13 and pSN5, were subcloned into M13mp18 and M13mp19 and used as templates to determined the nucleotide sequence of the 11 kb DNA region shown in FIG. 1; both strands were sequenced, across all the restriction sites used for cloning (see Experimental procedures). Sequence analysis revealed the presence of nine open reading frames (ORFs) in the region; the first three, by its position in the sequenced fragments of pSNL1 and pSNL9 and according to our previous results (Sa-Nogueira & Lencastre, Bacillus subtilis J Bacteriol 170:2855-2857 (1989), were identified with the araA, araB and araD genes (FIG. 1). The araA, araB and araD genes could encode a 496, 560, and 229 amino acid products of 56.2 kDa, 60.9 kDa, and 25.7 kDa, respectively (FIG. 2). The six ORFs found downstream from the araD gene, herein named araL, M, N, P, Q and abfa (FIG. 1), of 269, 394, 433, 313, 281 and 499 codons, are capable of encoding putative products of 29 kDa, 43.1 kDa, 48.7 kDa, 35 kDa, 31.8 kDa and 57 kDa, respectively (FIG. 2). All ORFs are preceded by strong ribosome binding sites with the exception of araL which is a weak ribosome binding sit (FIG. 3). The intercistronic regions are very short and overlapping was observed between the araD and araL coding sequences, and between araL and araM, suggesting translational coupling. Two potential hairpin-loop structures, situated next to the UAA stop codon of the abfA gene (T.sub.1 and T.sub.2 FIG. 3), probably correspond to transcription terminators. The absence of transcriptional signals among the nine coding regions suggested that they form a large operon transcribed from a promoter (described below) positioned 104 nucleotides upstream from the araA start codon (FIG. 2).
Comparison of the primary structures of the products predicted to be encoded by the ara genes with sequences in the GenBank revealed significant similarities with other bacterial proteins of known function and the results are summarized on Table 1. The putative product of araM, a hydrophilic protein, did not show any significant similarity. The araA, araB and araD gene products exhibited a high level of identity to the L-arabinose isomerase, L-ribolukinase and L-ribulose 5 phosphate-4-epimerase, respectively, of E. coli and S. thyphimurium. The product of the araL gene, a hydrophilic protein, displayed similarity to the NagD gene product of unknown function, which belongs to the nag regulon E. coli involved in the metabolism of N-acetyl glucosamine (Plumbrigde, Mol Microbiol 3:505-515 (1989)). The N terminal region of the predicted sequence also shared 28.1% and 29.2% identity (over 121 and 106 amino acid residues, respectively, data not shown) with two 4-nitrophenylphosphatases, Pho2 and Pho13, Schizosaccharomyces pombe (Yang et al. 1991) and Saccharomyces cereviseae (Kaneko et al., 1989), respectively. The predicted primary structure of araN showed similarity to known sugar-binding proteins that belong to the family of binding-protein-dependent transport systems (Table 1). Although the identity was not very high there was a significant sequence conservation within the N-terminal of these proteins which display a signature sequence, according to Tam and Saier (1993). On the basis of this signature sequence (FIG. 4A) AraN can be included in the cluster 1 binding proteins (according to Tam and Saier 1993), together with the above mentioned proteins involved in the transport of malto-oligosacharides and multiple sugars. The hydropathic profile of AraN indicate that it is mainly a hydrophilic protein; however its N-terminal region (FIG. 2) displayed characteristics of signal peptides of secretory precursor proteins: positively charged N terminus, a hydrophobic core and a sequence IAGCSA (starting at amino acid 19, FIG. 2) which corresponds to the consensus sequence for the precursors of lipoprotein (reviewed in Hayashi and Wu, 1990). The predicted products of araP and araQ exhibited hydropathy profiles (according to Kyte and Doolittle, 1982) characteristics of integral membrane proteins: six major regions of high hydrophobicity (hydrophatic index>1,0), each composed of at least 20 amino acids which could be capable to spanning the membrane (FIG. 5A). AraP and AraQ shared an identity of 19.6% and showed significant similarity with integral cytoplasmic membrane proteins involved in prokaryotic binding-protein dependent transport systems (Table 1). As most of these integral membrane proteins, AraP and AraQ have conserved hydrophilic segment (FIG. 5B) at approximately 100 residues from the C-terminus with the consensus "EAAxxxGxxxxxxIxLP" (SEQ ID NO: 44) (Dassa and Hofnung, 1985). Furthermore, on the basis of this signature sequence they can be included in the disaccharide sub-cluster proposed by Saurin et al., 1994 together with the above mentioned proteins involved in the transport of malto-oligosaccharides, multiple sugars and .alpha.-glycerol phosphate. The deduced product AbfA, a hydrophilic protein, displays a N-terminal region (FIG. 4B) which resembles a signal peptide of exoproteins: positively charged N terminus and a hydrophobic core (reviewed on Gierasch, 1989 and Nagarajan, 1993). The primary structure of the putative product of abfA is closely related to the .alpha.-L-arabinofuranosidase of Streptomyces lividans (Table 1) and the N-terminal region (FIG. 4) is 74% identical and 96% similar to the sequences N-terminus of purified .alpha.-L-arabinofuranosidase from B. stearothermophilus (Gilead and Shoham, 1995). These observations strongly suggest that the abfA gene encodes for an .alpha.-L-arabinofuranosidase.
RNA Transcript analysis of the L-arabinose gene region
Total RNA from cells grown in the presence and absence of L-arabinose, was isolated, blotted and hybridized to three different DNA probes (Probes 1,2, and 3 of FIG. 1) each specific to one gene of the ara region (araA, araM and abfA, respectively). The Northern blot analysis (FIG. 6) revealed that the ara genes are organized in a large polycistronic operon, and that transcripts could be detected only if the cells were grown in the presence of L-arabinose. In addition to a transcript of 11 kb comprising all genes and detected with the three probes, clearly several other signals of different intensities were obtained depending on the probe used (FIG. 6). Using the araA-specific probe, we detected five different transcripts of 8.2 kb, 6.4 kb, 5.8 kb, 4 kb and 1.9 kb. Two additional transcripts of 8.2 kb and 6.4 kb were visualized with the araM-specific probe and three hybridization signals were obtained with the abfA-specific probe: 8.3 kb, 4.8 kb and 1.1 kb. These different minor transcripts might be generated by premature transcription termination of processing of the multicistronic message. Stable secondary structures were identified at the correspondent sites within the araB, araL, araN, and araQ sequences (FIG. 2).
The promoter region and transcriptional start site of the ara operon
To determine the transcriptional start site of the ara operon, total RNA was extracted during the exponential growth of wild type cultures in the presence and in the absence of L-arabinose. Reverse-transcripts were obtained using an end labeled 17-mer (primer b, FIG. 2), designed to hybridize to part of the mRNA coding for the araA gene, and characterized by electrophoresis (see Experimental procedures). A Single extension products was detected with RNA isolated from cells grown in the presence of L-arabinose, the size of which suggests that transcription of the ara operon starts at a G residue situate 97 nucleotides upstream from the araA start codon (FIG. 7). No extension product was seen when RNA was isolated from cell grown in the absence of L-arabinose. The same transcription start point was obtained using a second primer (primer A, FIG. 2) designed to hybridize to part of the mRNA 50 bases upstream from the first primer (FIG. 7). the synthesis of the ara operon message is induced by L-arabinose and driven by a strong promoter as evaluated by the intensity of the reverse-transcript signal obtained. Situated 7 and 30 bp upstream from the ara operon transcription start site are sequences identical to the consensus -35 and -10 regions (TTGACA -17 bp-TATAAT, SEQ ID NO:38), respectively, of promoters recognized by B. subtilis o-A containing RNA polymerase (Moran et al. 1982). Sequence analysis of the promoter region revealed the existence of three inverted repeats, putative operator-like sequence, in the -35 and -10 regions (FIG. 2). A potential hairpin-loop structure with a AG value of -19.2 kcal mol-1 (Tinoco et al. 1973), centered 27 bp upstream from the -35 region (FIG. 2), probably corresponds to ta transcription terminator of a gene located upstream from the cloned DNA fragment.
Expression of the ara operon is induced by L-arabinose and repressed by glucose
To study the regulation of expression of the operon we constructed transcriptional lacZ fusions at this locus. The replicative plasmids of pSNA11 and pSNL12 were obtained by inserting a lacZ-erm cassette marker into the araB gene in both orientations) see Experimental procedures). After linearization, the two plasmids were used separately to transform the wild type 168T+ strain, with selection Em.sup.r. this resulted in the integration of the lacZ and erm genes into the chromosome at the araB locus (the exact position is depicted FIG. 1) through a double cross-over. The structure of the resulting strains, IQB101 (araB'-lacZerm) and IQB102 (araB'-erm lacZ), was confirmed by Southern hybridization (data now shown). both strains were unable to grow on L-arabinose as sole carbon source which confirmed the insertional inactivation of the araB gene. The integrating plasmids pSNL13 and pSNL14 were constructed by subcloning a 470 bp DNA fragment, which contains the 5' end of the ara transcriptional unit (FIG. 1), into pJM783 (see Experimental procedures) in both orientations. Plasmid pSNL13 contains lacZ gene in the same orientation as the araA region sequences and pSNL14 in opposite orientation. The two plasmids were used to separately to transform wild type 168T+ strain to Cm.sup.r and integrated into the chromosome by a Campbell-type recombinational event. The structure of the resulting strains, IQB103 (araA'-lacZcat) and IQB104 (ARAa'-catlacZ), was confirmed by Southern hybridization (data now shown) and because the integration was not disruptive both strains displayed an Ara+phenotype. The LacZ phenotype of the four strains was tested on minimal C medium plates supplemented with casein hydrolysate 1% (w/v) and X-Gal. Upon addition of L-arabinose to the medium, strains IQB101 and IQB 103 presented a dark blue phenotype whereas those IQB102 and IQB104 remained white, confirming that the expression of the operon is driven from a promoter located upstream from araA, and induced by L-arabinose. Furthermore, addition of other pentoses such as D-xylose and D-ribose failed to induce a LacZ+phenotype in strain IQB103. The regulation of the ara operon expression was examined in cultures during mid exponential phase growth in minimal C medium supplemented with casein hydrolysate 1% (w/v) as described in Experimental procedures. The levels and patterns of lacZ expression in IQB101 (araB,-lacZermAra-lacZ+) IQB103 (araA'-lacZcat; Ara+lacZ+); IQB102 (araB'-ermlacZ;Ara-lacZ-) negative control, and IQB104 (araA'cat-lacZ; Ara+lacZ) negative control, determined in the presence of L-arabinose and L-arabinose plus glucose are shown in FIG. 8. When the four strains were grown in the absence of inducer the level of accumulated .beta.-galactosidase activity, at time t=20 min, were 4.4U, 4.8U, 2.8U and 1.8U (Miller units), respectively (data not shown). In the presence of L-arabinose the pattern of expression observed in strains IQN101 (araB'lacZ Ara) and IQB103 (araA'-lacZ Ara+) was very similar (FIG. 8) but the levels of accumulated .beta.-galactosidase activity in the araB null mutant were less than 60% relatively to the wild type strain (discuss below). Addition of glucose reduced the level of expression to less than 12% in both Ara+ and Ara- backgrounds (FIG. 8). These data demonstrate that L-arabinose in an inducer which stimulates that expression of the ara operon at the transcriptional level and transcription is subjected to catabolite repression by glucose. Furthermore, the prediction that the expression of the ara operon is driven from a strong promoter, made on the basis of the intensity of the reverse transcript signal observed in primer extension analysis, was confirmed when .beta.-galactosidase activity was measured in strain IQB103 (araA'-lacZcat Ara+).
The araL, M, N, P, Q and abfA genes are not required for L-arabinose utilization
Integrational plasmids pSS2, pTN10, and pTN13, carrying fragments internal to araL, araN, and araQ genes respectively, were transformed in the wild type strain 168T+ (see above). Their integration interrupts the transcription unit at the downstream end of each fragment (FIG. 1). Transformants obtained with pSS2 and pTN10, strains IQB202 and IQB204 respectively, exhibited an Ara+ phenotype however, their growth on minimal medium plates with L-arabinose as the sole carbon source was slightly slower than the one observed with the wild type strain 168T+. This phenotype was not observed with strain IQB205 in which pTN13 disrupted the operon at the end of the araQ gene. In order to confirm that the araL, M, N, P, Q and abfA with a spectinomycin resistance cassette and then using it to replace the corresponding chromosomal sequences (see Experimental procedures). Plasmid pSN22 (FIG. 1) was linearized with SacI and used to transform the wild type strain 168T+ to resistance to spectinomycin (Sp.sup.r). The resulting strain IQB206, was kanamycin sensitive which indicated that the Sp.sup.r phenotype was the result of a double-cross over event that occurred on both sides of the cassette inserted between the araL and abfA sequences (FIG. 1). This mutant strain was able to grow on minimal medium pates with L-arabinose but displayed a phenotype even more drastic than the one exhibited with strains IQB202 and IQB204. To quantify this observation we determined the specific growth rate of the deletion-insertion mutant and the wild type strain on liquid minimal C medium with L-arabinose as the sole carbon source, as described in Experimental procedures. The double time of stain IQB206 was 1.8 fold higher than the wild type strain 168T+, 193.4 min-7.2 and 107.7 min+3.6 (average of three independent experiments+standard error), respectively. These results confirmed that the genes located downstream from araD in the operon are not essential for L-arabinose utilization, however their absence in the deletion mutant affects the specific growth rate in minimal medium with L-arabinose as the sole carbon source when compared to the wild type (discuss below).
Discussion
The present work describes a new catabolic operon involved in the utilization of L-arabinose in B. subtilis, which we designated ara. The arabinose metabolic genes araA, araB and araD coding for L-arabinose isomerase, L-ribulokinase and L-ribulose 5-phosphate 4-epimerase, respectively, were previously cloned and by complementation experiments the products of the araB and araD genes shown to be functionally homologous to their Escherichia coli counterparts (Sa-Nogueira & Lencastre, J Bacteriol 171:4088-4091, 1989). These genes, whose inactivation leads to an Ara-phenotype, were found to be the first three open reading frames of a nine cistron transcriptional unit whose total length is 11 kb. To our knowledge this operon is the largest catabolic operon described in B. subtilis. As expected from the occurrence of genetic complementation, the deduced products araA, araB, and araD, from B. subtilis display a very high level of identity to the corresponding enzymes from E. coli and S. thyphimurium, which indicates that this metabolic pathway was fundamentally conserved during evolution. In B. subtilis the metabolic gene order, araABD, coincide with the order of the enzymatic steps carried out by the proteins that they encode for. This order is different from the one found in the operons of Enterobacteriaceae members E. coli and S. thyphimurium, araBAD, so it seems that the three genes did not act as a unitary block in the evolution of the abacterial ara genes.
The six ORFs found downstream from the araD gene, here named araL, M, N, P, Q and abfA, are not required for L-arabinose utilization. This was shown in a mutant strain IQB206 bearing a deletion, in the region downstream from the araD, comprising all genes. The function of araL and araM is unknown. The putative product of araM did not show any significant similarity with other bacterial proteins of known function and the weak similarities displayed by araL did not suggest any particular function. Interestingly the amino terminal sequences of araL share an identity of 18.7% over 193 residues with the C terminal sequences of araM (data now shown). The primary sequences of the products of the araN, araP, and araQ genes strongly suggest that they have a similar function to that of a super family of membrane-bound nutrient transport systems (Higgins et al., J. Bioenerg. Biomemb. 22:571-592 (1990)). Sequence similarities to known import proteins and the organization of the genes in the operon revealed the presence of three components from these transport systems. First, the amino terminus of araN has a predicted signal peptide and sequences typical of Gram-Positive lipoprotein (IAGCSA (SEQ ID NO:45), starting at amino acid 19, FIG. 2). We therefore suggest that araN might be anchored to the cytoplasmic membrane via an amino-lipid group (Gilson et al., Mycoplasma EMBO J. 7:3971-3974 (1988) and Perego et al., Biochemistry, Physiology and Molecular Genetics 645-624 (1991)). Second araP and araQ gene products, as other characterized integral cytoplasmic membrane proteins have hydropathy profiles which are virtually super impassable and some of their residues are apparently conserved (FIG. 5). Finally, araN, araP, and araQ belong to the same operon and the ligand-specific binding protein, araN, is encoded by the promoter-proemial gene, a situation common to these systems. In B. subtilis the phosphotransferase system is not involved in the transport of L-arabinose into the cell (Gay et al. Mol. Gen. Genet. 121:355-368 (1973), therefore it is tempting to propose that araN, araP and araQ are components of a high affinity transport system for L-arabinose. However, no evident ATP-binding protein connected with energy coupling of the transport system was found in the operon.
The transport of L-arabinose across E. coli cytoplasmic membrane requires the expression of either the high-affinity transport operon, araFGH a binding protein-dependent system (Brown and Hogg et al., J. Bacteriol 111:606-613 (1972); Horazdowvsky and Hogg et al., J. Bacteriol 171:3053-3059 (1989); Kolodrubetz and Schleif, et al., J. Bacteriol 148:472-479 (1981)) or the low-affinity transport operon, araE a proton synporter (Novotny and Englesberg, et al., Biochim. Biophys. Acta. 117:217-230 (1996). The existence of two parallel uptake systems thwarts usual genetic attempts at isolation of mutants defective in either of the transport systems. The Ara+ phenotype displayed by the B. subtilis deletion mutant strain IQB206 (.tangle-solidup.araL-abfA::spc) together with the 1.8 fold increase in the doubling time observed on liquid minimal medium with L-arabinose as the sole carbon source, relatively to the wild type strain, is typical of a transport mutant when the microorganism has alternative transport systems for the same substrate. Interestingly, the primary structure of AraP and AraQ showed each similarity with AraH, the integral cytoplasmic membrane protein from E. coli, and the same result was observed between AraN and ARaF, the E. coli arabinose binding protein (data now shown). Furthermore, on the basis of their signature sequences AraN, AraP and AraQ can be included in the disaccharide sub-cluster (FIG. 4 and FIG. 5) together with proteins involved in the high-affinity transport of malto-oligosaccharides and multiple sugars. In connection, B. subtilis secretes three enzymes involve in degradation of L-arabinose polymers, an endo-arabanase and two arabinosidases, and the purified endo-arabanase was shown to be capable of releasing arabinosyl oligomers from plant cell walls (Kaji and Saheki et al., Biochim. Biophys. Acta. 410:354-360 (1975); Weinstein and Albersheim, et al., Physiol. 63:425-432 (1979)); these observations are suggestive of a wider substrate range for the B. subtilis AraN binding protein. The last gene of the ara operon, abfA, based on the strong similarity observed between the primary structure of its putative product and other bacterial arabinosidases, most probably codes for the .alpha.-L-arabinofuranosidase purified and described by Weinstein and Albersheim et al., Physiol. 63:425-432 (1979).
Expression of the ara operon is induced by L-arabinose and driven by a strong promoter located upstream the araA gene. This has been demonstrated in this study by Northern blot experiments and primer extension analysis. Examination of the ara operon promoter reveals -35 and -10 sequences, relative to its transcriptional start site (show in FIG. 2), separated by an optimal spacing of 17 bp identical to the consensus sequences derived from the analysis of many .delta.A dependent promoters (Moran et al., Mol. Gen. Genet. 186:339-346 (1982)). These sequences were shown to be important for the interaction of .delta.A with their cognate promoters (reviewed in Moran 1993 653-667). The presence of a strong promoter raises the possibility that transcription of ara is negatively regulated like in other well characterized B. subtilis catabolic operons, such as xyl (Gartner et al., Mol. Gen. Genet. 232:415-422 (1992) gnt (Fujita and Fujita, Proc Natl Acad Sci USA 84:4524-4528 (1987); Miwa and Fujita, J. Biol. Chem. 263:13252-13257 (1988); in fact the product of the araC gene recently cloned, is negative regulator of the ara operon (Sa-Nogueira and Mota, unpublished). To characterize the regulation of ara expression in greater detail we constructed transcriptional fusions of the ara promoters to the E. coli lacZ gene in Ara+ and Ara- strains. The induction by L-arabinose in strain IQB103 (araA-lacZ Ara-) and IQB103 (araA'-lacZ Ara+) was very similar. Interestingly however, the levels of accumulated .beta.-galactosidase activity in IQB101 (araB'-lacZ Ara-) were less than 60% of the fully induced level in wild type starting. Since in this strain the ara transcription unit is interrupted at the level of the araB gene (FIG. 1), and a role in the transport of L-arabinose was proposed for the downstream genes araN, araP, and araQ this effect cold be due to less accumulated intracellular L-arabinose which prevents fully expression of the ara promoter. Another possible explanation is that the products of the araL and araM genes could stimulate transcription from the ara promoter. Addition of glucose reduced the level of expression to less than 12% in both Ara+ and Ara- backgrounds indicating that repression of the ara operon by glucose acts at the transcriptional level.
Although the regulatory system mediating catabolite repression in B. subtilis is unknown there is some evidence that it is accomplished by a negative regulatory mechanism (reviewed in Chambliss, 1993, 213-219; Hueck and Hillen, Mol. Microbiol. 15:395-401 (1995); Saeir et al., Microbiology 142:217-230 (1996). This evidence is based on the location and sequences of cis-acting sites (CREs) responsible for catabolite repression of several B. subtili genes and operons (Weickert & Chambliss, Proc. Natl. Acad. Sci. USA 87:6238-6242 (1990); Chambliss, (1993), 213-219; Hueck and Hillen, Mol. Microbiol. 15:395-401 (1995). Moreover, catabolite repression of most genes regulated via these cis-acting sites is also affected by the trans acting factors CcpA and Hpr (reviewed in Hueck and Hillen, Mol. Microbiol. 15:395-401 (1995) and Saeir et al., Microbiology 142:217-230 (1996). Sequence analysis suggests that CcpA is a DNA-binding protein but it is not known whether CcpA is directly involved in the mechanism of catabolite repression (Chambliss, 1993, 213-219; Fujita & Miwa, J. Bacteriol 176:511-513 (1994). Hpr, an intermediate in the PTS sugar transport system, of several Gram-positive bacteria can be phosphorylated at a serine residue at position 46 by an ATP-dependent kinase which is activated in the presence of fructose-1,6-diphosphate (FDP) (Deutsch and Saier, Proc. Natl. Acad. Sci. USA 62:1100-1107 (1983); Reizer et al., J. Cell. Biochem. 51:19-24 (1993). Experiments with B. subtilis strains carrying a mutation which unable phosphorylation of Hpr at position 46, showed that catabolite repression of various operons was relieved (Deutscher et al., J. Bacteriol 176:3336-3344 (1994). It has been proposed that Hpr-ser-P might interact with CcpA and that this interaction might allow CcpA to bind to the CRE (Deutscher et al., J. Bacteriol 176:3336-3344 (1994). Strong evidence to this proposal was obtained by Deutscher et al., Mol. Microbiol 15:1049-1053 (1995), by showing that Hpr-ser-P of B. subtilis can bind to CcpA of B. megaterium, in vitro DNA-binding experiments conducted by Kim et al., J. Bacteriol 1775129-5134 (1995), showed that B. subtilis CcpA protein binds specifically and with high affinity to the CRE in the amyO control region in the absence of Hpr-ser-P. Ramseier et al., Microbiol Lett. 129:207-214 (1995), observed binding of B. megaterium CcpA to the CRE of the xyl operon of B. subtilis at low protein concentrations and showed that Hpr-ser-P diminished the extent of binding. Different results were obtained by Fujita et al., Mol. Microbiol 17:953-960 (1995), with the gnt operon. The authors observed that specific binding of B. subtilis CcpA to the CRE of this operon required the presence of Hpr-ser-P. CREs of catabolic genes and operons are located either in the promoter regions, where the binding of a resultatory protein probably interferes with transcription initiation, or in the downstream regions (reviewed in Hueck and HIllen, Mol. Microbiol. 15:395-401 (1995). The latter genes and operons also contain sequences with each similarities to CRE overlapping the respective promoters. Miwa and Fujita, J. Biochem 113:665-671 (1993) have proposed that catabolite repression of the gnt operon might utilize a transcriptional blockage mechanism. In the case of the hut operon two active CREs were found, one at the promoter and the other within the hutP gene, and a looping mechanism involving cooperatively bound CREs has been proposed to interfere with transcription initiation (Wray et al., 1994). Furthermore, the transition-state regulator AbrB is capable of specifically binding to hut CRE in vitro and an abrB null mutation leads to more efficient.backslash.catabolite repression of some genes in B. subtilis, including L-arabinose isomerase. Thus, AbrB has been suggested to complete for binding to CRE with CcpA (Fisher et al., J. Bacteriol 176:1903-1912 (1994). The promoter region of the ara operon contain a sequence very similar to the CRE consensus sequence (TGWNANCGNTNWCA, SEQ ID NO:8; W=A,T) located between the between the transcription start site and the translation start site of the araA (position 191 to 204, FIG. 2). A second sequence, which shows weak similarity with the CRE consensus sequence was found within the araA gene (position 260 to 273, FIG. 2). Since inducer exclusion does not play a major role in carbon regulation of expression of the ara metabolic genes (Sa-Nogueira & Lencastre, Bacillus subtilis J Bacteriol 170:2855-2857 (1988), as it was observed in the hut operon (Chasin and Magasanik, J. Biol. Chem. 243:5165-5178 (1968), it will thus be interesting to investigate the role of CcpA, Hpr, and AbrB, in the catabolic repression of the ara operon and whether these sequences are cis-acting sites responsible for catabolic repression of the ara genes.
Experimental procedures
Bacterial strains and growth conditions
The B. subtilis strains used in this study are listed on Table 2. E. coli DH5.alpha. (GIBCO BRL, Life Technologies European Division) was used as a host for all plasmids and E. coli DH5.alpha. (BRL) for the propagation and amplification of recombinant M13 bacteriophages. E. coli strains were grown on LB (Luria-Bertani medium; Miller, (1972). Ampicillin (75 .mu.g ml-1), or IPTG (isopropyl .beta.-thiogalactopyranoside, 1 mM) were added as appropriate. B. subtilis strains were grown on LB (Luria-Bertain medium; Miller (1972), SP medium (Martin et al., Mol. Gen. Genet. 208:177-184 (1987), or C minimal medium (Pascal et al., Biochem 53:1059-1066 (1971). Chloramphenicol (5 .mu.g ml-1)m erythromycin (1 .mu.g ml-1), kanamycin (25 .mu.g ml-1) or spectinomycin (50 -g ml-1) were added as appropriate. Solid medium was made with LB, SP or C medium contain 1.5% (w/v) Bacto Agar (Difco). To test for growth of B. subtilis integrant strains on L-arabinose as sole carbon source, strains were plated on minimal C medium plates supplemented with casein hydrolysate 1% (w/v). L-arabinose 0.1% (w/v) and ribitol 1% (w/v). To determine the specific growth rates, the B. subtilis strains were grown in liquid C medium with L-arabinose 0.4% (w/v) as sole carbon source. The cell cultures were incubated in a water shaker (Aralab, Equipamentos de Laboratorio Lda, Oeiras, Portugal) with aeration by shaking 130 rpm and the cell growth was monitored in a UltrospecIII spectrophotometer (Pharmacia LKB Biochrom Ltd. Cambridge, England) as A600. For the .beta.-galactosidase assays and the RNA preparation the B. subtilis strains were grown in liquid C medium supplemented with casein hydrolysate 1% (w/v) and L-arabinose and glucose were added to the cultures when necessary at a final concentration of 0.4% (w/v).
Plasmid constructions
Plasmid pSNL7 was constructed by subcloning a 959 bp Smai-Pst DNA fragment (nucleotide 938 to 1897, FIG. 1) from pSNL1 (Sa-Nogueira & Lencastre, Bacillus subtilis J Bacteriol 170:2855-2857 (1988) between the Smali and PstI sites of the integrational vector pJM783 (Perego, Mol. Microbiol. 6:173-185 (1983). This step inactivates the ampicillin resistance gene (Amp.sup.r) of the vector and selection in E. coli was made for chloramphenicol resistant (Cm.sup.r). Plasmid pSNL9 was obtained by cutting chromosomal DNA from B. subtilis IQB100, in which pSNL7 had integrated into the araB region by a single crossover (Campbell-type) recombination event (FIG. 1), with HindIII, followed by circularization of this DNA at low concentration. This ligation mixture was transformed into E. coli, and Cm.sup.r transformants were selected as described above. To construct plasmid pSS2, we digested pSNL1 (Sa-Nogueira & Lencastre, Bacillus subtilis J Bacteriol 170:2855-2857 (1989) with HIndIII and XholI and cloned a purified fragment of 965 pb (nucleotide 3815 to 4780, FIG. 1) between the HIndIII and SalI sites of the integrating vector pJH101 (Ferrari et al., J. Bacteriol 154:1531-1515 (1983). Plasmid pSS3 was constructed by digestion of chromosomal DNA from B. subtilis IQB202, in which pSS2 had integrated into the araL region by a single crossover (Campbell-type) recombination event (FIG. 1), with EcoRI, followed by circularization of this DNA at low concentration. This litigation mixture was transformed into E. coli, and Ap.sup.r transformants were selected as described above. Subcloning of the 789 pb HindIII-HincII DNA fragment (nucleotide 6545 to 7334, FIG. 1) from pSS3 between the HindIII and EcoRV sites of the integrational vector pJH101 (Ferrari et al. J. Bacteriol 154:1531-1515 (1983) yielded plasmid pTN10. Plasmid pTN13 was obtained by the same procedure described for pSS3 after digestion of chromosomal DNA from B. subtilis IQB204, in which pTN10 had integrated into the araN region by a single crossover (Campbell-type) recombination event (FIG. 1) with Ncol. Plasmid pTN14 was constructed by subcloning the 678 pb SmaI-BgII DNA fragment (nucleotide 8242 to 8920, FIG. 1) from pTN13 between the BamHI and SstI (fill-in) sites of pJM783 (Perego, biochemistry, physiology and molecular genetics 645-624 (1991). To construct pSN5 the same methodology used to obtain pSS4 and pTN13 was applied, after cutting chromosomal DNA from B. subtilis IQB205, in which pTN14 had integrated into the araQ region by a single crossover (Campbell-type) recombination event (FIG. 1) with SmaI. Subcloning the 1.7 kb EcoRI-HincII fragment (nucleotide 2681 to 4416, FIG. 1) from pSNL1 (Sa-Nogueira & Lencastre, Bacillus subtilis J Bacteriol 170:2855-2857 (1989) between the EcoRI and SmaI sites of pMK4 (Sullivan et al., Gene. 29:21-26 (1984), yielded plasmid pSNL10. PlasmidspSNL11 and pSNL12 were obtained as follows. A 4.5 kb BamHI-HindIII fragment extracted from pMC11 (Debarbouille et al., J. Bacteriol 172:3966-3963 (1990), containing the lacZ and erm genes from pTV32 (Perkins & Youngman, Acad. Sci. USA 83:140-144 (1991), was purified, made blunt with the "Klenow fragment" of DNA polymerase I and then subcloned in both orientations at the unique EcoRV restriction site (nucleotide 3214, FIG. 1) of pSNL10. pSNL11 contains the lacZ gene in the same orientation as the EcoRI0EcoRV araB fragment (nucleotide 2681 to 3214, FIG. 1), which was confirmed by DNA sequencing, and pSN112 in opposite orientation. Subcloning a 470 bp DraI-EcoRVDNA fragment (nucleotide 82 to 552, FIG. 1) from pSNL9 at the unique SmaI site of the integrational vector pJM783 (Perego, biochemistry, physiology and molecular genetics 645-624 (1991), in both orientations, yielded plasmids pSNL13 and pSNL14. pSNL13 contains the lacZ gene in the same orientation as the araA region sequences, which was confirmed by DNA sequencing, and pSNL14 in opposite orientation. Plasmid pSN20 was construct by the 1.2 kb EcoRV-HincII fragment (nucleotide 3214 to 4416, FIG. 1) from pSS4 into the SmaI site of pAH248 (see above). Subcloning of the 1.7 kb EcoRV fragment from pSN5 (nucleotide 10632 to about 12332, FIG. 1) into the HincII site of plasmid pAH250 (see below) yielded plasmid pSN21. Plasmid pAH248 (a gift from A. O. Henries and C. P. Moran Jr.) is a pGem7-zf(+) (Promega Corporation, Madison, USA) derivative that contains a kanamycin resistance gene cloned between its Xhol and EcoRI sites. Plasmid pAH250 (Henriques, A. O., B. W., Beall and C. P. Moran Jr., unpublished) is a pBlueprint SK(+) (Stratagene, LaJolla Calif., USA) derivative that contains a specitnomycin resistant gene cloned between its EcoRV site. To construct pSN22, we digested pSN20 with PstI and NsiI and cloned a purified fragment of about 2790 bp, which contains the kanamycin resistance gene, between the SmaI site of pSN21.
DNA manipulations and sequencing
DNA manipulation was carried out according to Sambrook et al. (1989). Enzymes were purchased from commercial suppliers and used according to the manufacturers' instructions. DNA sequencing was performed by the method of Sanger et al., Proc. Natl. Acad. Sci. USA 74:140-144 (1977) with the Sequenase Kit (T.sub.7 DNA polymerase; United States Biochemical Corporation, USB). Sequencing templates were prepared by a combination of subcloning appropriate fragments from pSNL1 and PSNL9 into the polycloning site of M13mp19 or M13mp18 (Yanisch-Perron et al., Gene 33:103-119 (1985) and sequential deletion of the recombinant M13 derivatives, by the method of Dale et al., Plasmid 13:31-40 (1985), using the Cyclone Biosystem Kit (IBI, International Biotechnologies, Inc.). The DNA sequence was determined on both strands and across all the restriction sites used for subcloning. The primer 5'-CCTCTTCGCTATTACGC-3' (SEQ ID NO:46), complementary to the coding sequences of the LacZ gene was used to sequence the transcriptional LacZ fusions.
Bacterialtransformation
B. subtilis DNA transformations were performed according to the method of Anagnostopoulos & Spizizen (1961). E. coli transformations were carried out according to standard methods (Sambrook et al., 1989).
.beta.-Galactosidase assays
Strains of B. subtilis harboring transcriptional lacZ fusions were grown on 75 ml of C medium supplemented with casein hydrolysate 1% w/v. During each logarithmic phase, optical density at 600 nm (OD.sub.600) of 0.11-0.15, 25 ml of the culture were transferred to two different flasks, 25 ml to each flask, and L-arabinose at a final concentration of 0.4% (w/v) was added to one of the cultures and to the other L-arabinose and glucose at a final concentration of 0.4% (w/v) was added to one of the cultures and to the other L-arabinose and glucose at a final concentration of 0.4% (w/v) were added. At this time, To, a 100 .mu.l aliquot of cell culture were collected, harvested and stored at -70.degree. C. overnight. Exponential growth of the three cultures was followed by measuring absorbance and at 30 min intervals 100 .mu.l of cell culture samples were removed, treated as described above, until the cultures reached an OD.sub.600 =0.7-0.8, which corresponds to growth for at least 2.5 generations in the presence of the inducer. The cells were suspended in 1 ml of Z buffer (Miller, 1972), and 2 drops of chloroform and 1 drop of 0.1% sodium dodecyl sulfate were added and mixed vigorously for 10 s on a tabletop vortex apparatus. The .beta.-Galactosidase activity was determined as described by Miller (1972) using the substrate o-nitrophenyl-.beta.-D-galactopyranoside (ONPG).
RNA preparation, northern blot and primer extension analysis
B. subtilis 151 cells or B. subtilis 168T+ were grown in C medium supplemented with 1% (w/v) casein hydrolysate in the presence and in the absence of L-arabinose at a final concentration of 0.4% (w/v). Cells were harvested during late logarithmic phase of growth. OD.sub.600 approximately 0.9, and RNA prepared essentially as described by Igo et al., J. Mol. Biol. 191:615-624 (1986). For Northern blot analysis, 2.5-10 .mu.g of total RNA was run in agarose/formaldehyde 1.0-1.2% (w/v) and transferred to positively-charge nylon membranes Hybond-N+ (Amersham International, UK) according to standard methods (Sambrook et al. 1989). A size determination was done by using an RNA ladder (9.5-0.24 kb; Gibco/BRL). The probes were labeled using the Multiprime random oligonucleotide DNA labeling system obtained from Amersham and [.alpha.-.sup.32 P]dATP (3,000 Ci/mmol). Primer extension analysis was performed essentially as described in Sambrook et al., (1989) using 25 .mu.g of total RNA. The two synthetic oligonucleotides used in primer extension experiments were: primer A (5'-GAAGCATGTAAACTGCCCC-3', SEQ ID NO:25) a 19-mer, complementary to a region of araA mRNA located between nucleotides 216 to 234 (FIG. 2) and primer B (5'-CCAGCGTCTCTTCCCCG-3', SEQ ID NO:26) a 17-mer, complementary to a region of the araABD mRNA located between nucleotides 283 to 300 (FIG. 2). The two oligonucleotides were used in separate experiments to rule out the possibility of primer-specific artifacts. A total of 10 ng of primer was used in the labeling reaction and mixed with 25 .mu.g of RNA, denatured by heating to 85.degree. C. for 10 min and annealed by incubation at 42.degree. C. for 3 h. The oligonucleotide primer was extended by using 15 units of avian myeloblastosis virus reverse transcriptase for 2 h at 37.degree. C., as described by Sambrook et al., (1989). Analysis of the extended products was carried out on 7.5% polyacrylamide urea gels.
Computer analysis
Amino acid sequences were deduced from the nucleotide sequence using DNASIS V2.0, Hitachi Software Engineering Co., Ltd., 1991. The GenBanK and EMBL databases were assessed using the Genetics Computer Group (GCG) package of sequence analysis software (Genetics Computer Group, Inc., Madison, Wis.).
Nucleotide sequence accession number
The DNA sequence reported here have been submitted to the GenBanK database and assigned numbers X89408 (araA, araB and araD genes) and X89810 (araL, araN, araP, araQ and abfA genes).
TABLE 1__________________________________________________________________________Percentage of amino acid identity between the predicted sequencesof the Ara proteins and their similar proteins AminoB. subtilis Percentage acidAra proteins Homologue (species).sup.(a) Function Identity overlap__________________________________________________________________________AraA AraA ( E. coli) L-Arabinose isomerase 52.9 495 AraA (S. typhimurium) L-Arabinose isomerase 52.9 495AraB AraB (E. coli) L-Ribulokinase 25.7 552 AraB (S. typhimurium) L-Ribulokinase 30.6 350AraD AraD (E. coli) L-ribulose-P 4-epimerase 57.1 231 AraD (S. typhimurium) L-ribulose-P 4-epimerase 58.0 205AraL NagD (E. coli) Unknown 25.5 251AraN LacE (A. radiobacter) Lactose-binding protein 26.2 302 MalX (S. pneumoniae) Maltose-binding protein 24.1 345 AmyE (T. thermosulfurigens) Starch-binding protein 21.7 369AraP LacF (A. radiobacter) Membrane protein 29.6 284 UgpA (E. coli) Membrane protein 26.2 286 AmyD (T. Membrane protein 25.4 284 thermosulfurigens) MalC (S. pneumoniae) Membrane protein 25.2 298AraQ LacG (A. radiobacter) Membrane protein 32.7 254 UgpE (E. coli) Membrane protein 22.9 279 AmyC (T. thermosulfurigens) Membrane protein 28.2 262 MalD (S. pneumoniae) Membrane protein 25.6 262AbfA AbfA (S. lividans) .alpha.-L-arabinofuranosidase 52.6 500__________________________________________________________________________ .sup.(a) AraA, AraB and AraD from E. coli [Lee et al., (1986)]; ArA, AraB and AraD from S. typhimurium [Lin et al., (1985a); Lin et al., (1985b); Lin et al., (1985c)]; LacE, LacF and LacG from Agrobacterium radiobacter [Williams et al., (1992)]; AmyE, AmyC and AmyD from Thermoanaerobacterium thermosulfurigens [Bahl et al., (1991); Sahm et al., 1996]; #UgpA and UgpE from E. coli [Overduin et al., (1988)]; MalX, MalC and MalD from Streptococcus pneumoniae [Puyet and Espinosa (1993)]; AbfA from Streptomyces lividans [Manin et al., (1994)]; NagD from E. coli [Plumbridge, (1988)].
TABLE 2__________________________________________________________________________B. subtilis strainsNumber Genotype Phenotype Source__________________________________________________________________________168T.sup.+ prototroph Ara.sup.+ F. E. YoungBR151 metB10 lys3 trpC2 Ara.sup.+ F. E. YoungIQB100 araB'::pSNL7(araB-cat lacZ) Cm.sup.r Ara.sup.- pSNL7 .fwdarw. 168T.sup.+IQB101 araB'::lacZerm LacZ.sup.+ MSL.sup.r Ara.sup.- pSNL11.sup.(a) .fwdarw. 168T.sup.+IQB102 araB'::erm lacZ LacZ.sup.- MSL.sup.r Ara.sup.. pSNL12.sup.(a) .fwdarw. 168T.sup.+IQB103 araA'::pSNL13 (araA-lacZ cat) LacZ.sup.+ Cm.sup.r Ara.sup.- pSNL13 .fwdarw. 168T.sup.+IQB104 araA'::pSNL14 (araA-cat lacZ) LacZ.sup.. Cm.sup.r Ara.sup.+ pSNL14 .fwdarw. 168T.sup.+IQB202 araL'::pSS2 (araL-amp cat) Cm.sup.r Ara.sup.+ pSS2 .fwdarw. 168T.sup.+IQB204 araN'::pTN10 (araN-cat amp) Cm.sup.r Ara.sup.+ pTN10 .fwdarw. 168T.sup.+IQB205 araQ'::pTN14 (araQ-lacZ `cat) LacZ-Cm.sup.r Ara.sup.+ pTN14 .fwdarw. 168T.sup.+IQB206 .DELTA.araL-abfA::spc Sp.sup.r Ara.sup.+ pSN22.sup.(a) .fwdarw. 168T.sup.+__________________________________________________________________________
All strains are derivatives of B. subtilis 168T.sup.+. The arrows indicate transformation and points from donor DNA to recipient strain. The DNA structure of the ara operon region in all strains is represented in FIG. 1. (a) indicate that the transformation was carried out with linearized plasmid DNA.
Example 2
Study of the Bacillus subtilis L-Arabonose Operon
Introduction
The primary sequence of the products of the genes L-arabinose isomerase, L-ribolukinase and L-ribulose 5-phosphate 4-epimerase respectively, showed strong similarity to the corresponding enzymes of Escherichia coli and Salmonella typhimurium. Transcription of this operon initiates from a .sigma.A-like promoter upstream from the araA gene and is inducible by L-arabinose and repressed by glucose.
Materials and Methods
Unless otherwise stated, the materials and methods used were those described in the Experimental procedure section of Example 1.
TABLE 3______________________________________Plasmids UsedPlasmids Genotypes Reference______________________________________pMK.sub.4 Amp.sup.R Cm.sup.R Sullivan et al., 1984pMC11 Amp.sup.R lacZerm Debarbouille et al., 1990pJM783 Amp.sup.R Cm.sup.R Perego and Hoch, 1988pSNL1 Amp.sup.R Cm.sup.R araA'araB araD Sa-Nogueira. and (insert fragment of 4.8Kb in pMK.sub.4) Lencastre, 1989______________________________________
Materials--Restriction endonucleases were obtained from Amersham, New England Biolabs Inc. and Bethesda Research Laboratories. T4 DNA ligase, the "Klenow fragment" of DNA polymerase I, and S1 Nuclease were from Amersham; Polynucleotide Kinase was from New England Biolabs Inc.; AMV Reverse Transcriptase was from Bethesda Research Laboratories. All the enzymes were used as specified by the manufacturers. .sup.32 P and .sup.35 S-labeled nucleotides were from Amersham. The SEQUENASE kit (T.sub.7 DNA polymerase; U.S. Biochemical Corp.) was used for DNA sequencing reactions. The method of Dale [Dale et al., Plasmid, 13:31-40 (1985)], using the Cyclone Biosystem Kit (International Biotechnologies Inc.), was applied to obtain overlapping deletions for DNA sequencing. Purified custom synthesized oligonucleotides were from SYMBIOCOM.
Transformation and Selection--B. subtilis and E. coli strains were transformed essentially as previously described [Yasbin et al, J. Bacteriol, 113:540-548 (1973); Ausubel et al., In Current Protocols in Molecular Biology, Ed. Green Publishing Associates and Wiley Interscience, (1987-1988)]. Selection of E. coli transformants was performed on Luria plates containing ampicillin 50 .mu.g/ml or chloratnphenicol 2.5 .mu.g/ml. B. subtilis chloramphenicol resistant transformants (Cm.sup.r) were selected on SP or Luria agar plates containing Cm 5 .mu.g/ml. When the marker to be selected in B. subtilis was MLS.sup.r (Macrolides, Lincosamides and Streptogramin B resistance), after DNA transformation, yeast extract (10 mg/ml) and casein hydrosolate (10 mg/ml) were added and incubation with shaking at 37.degree. C. was continued in the presence of erythromycin (0.1 .mu.g/ml) in order to induce the erm gene. Transformants were selected on SP or Luria plates containing lincomycin (25 .mu.g/ml) and erythromycin (1 .mu.g). The Lac+ phenotype of B. subtilis was scored on C agar plates supplemented with 1% (w/v) casein hydrolysate and 0.4% (w/v) L-arabinose or 0.4% (w/v) glucose, containing X-gal 200 .mu.g/ml (5-bromo-4-chloro-3-indolyl-.beta.-D-galactopyranoside).
DNA Manipulation--Plasmid DNA was extracted by the alkaline lysis method [Biarboim and Doly, Nucleic Acids Res., 7:1513-1523 (1979)] followed by ultracentrifugation in CsCl ethidium bromide gradient or Polyethyleneglycol precipitation as described [Sambrook et al., In Molecular cloning: a Laboratory Manual, 2nd edn., Cold Spring Harbor, N.Y.: Laboratory, Cold Spring Harbor Laboratory (1989)]. B. subtilis chromosomal DNA extraction was performed as previously described [Ferrari et al., J. Bacteriol., 152:782-785 (1982)].
Plasmids pSNL8 and pSNL9 were constructed as described by P. Youngman [Weinstein and Albersheim, Plant Physiol., 63:425-432 (1979)]. Chromosomal DNA of strain IQB100, resulting from the integration of pSNL7 into the chromosomal DNA of B. subtilis 168T.sup.+, was restricted by either Eco RI or Hind III and self ligated at low concentrations.
DNA Sequencing--The DNA sequence was determined by the dideoxy termination method [Perkins and Youngman, Proc Natl Acad Sci USA, 83:140-144 (1986)] with .alpha.[.sup.35 S] dATP (specific activity:>1000 Ci/nmol; Amersham). Several fragments from pSNL1, pSNL8 and pSNL9 were subcloned into the polycloning site of RFM13mp19 or RFM13mp18 and the DNA sequenced on both strands by the strategy of Dale et al. [Dale et al., 1985, supra]. Sequencing reactions were performed with modified T7 DNA polymerase (Sequenase) by using M13 templates and the M13 universal primer. The sequencing reaction products were resolved on 6%-8% polyacrylamide-8M urea gels and run at 1500-1700 V. Gels were exposed to Hyperfilm.TM.-.beta. max (Amersham).
Reverse Transcriptase Mapping of the 5'-End of ara mRNA--The method used was essentially as described by Sambrook et al. (Sambrook, J. et al., 1990) using 25 .mu.g RNA. The two synthetic oligonucleotides used in primer extension experiments were: primer A (5'-GAAGCATGTAAACTGCCCC-3') (SEQ ID NO:25) 19-mer, complementary to a region of araA mRNA located between nucleotides 216 to (FIG. 3) and primer B (5'-CCAGCGTCTCTTCCCCG-3') (SEQ ID NO:26) 17-mer, complementary to a region of the araA mRNA located between nucleotides 283 to 300 (FIG. 3). Both primers were .sup.32 P-labelled with polynucleotide kinase forward reaction as described (Sambrook, J. et al., 1990). The two oligonucleotides were used in separate experiments to role out the possibility of primer-specific artifacts. A total of 10 ng were used in the labelling reaction and mixed with 25 .mu.g of RNA, denaturated by heating to 85.degree. C. for 10 minutes and annealed by incubation at 42.degree. C. for 3 hours. The oligonucleotide primer was extended by using 15 units of avian myeloblastosis virus reverse transcriptase for 2 hours at 37.degree. C., as described (Sambrook, J. et al., 1990). Analysis of the extended products was carried out on 7.5% polyacrylamide urea gels.
Computer Analysis of DNA Sequences--Nucleotide sequences were analyzed by SEQNCE Program, Delaney Software Ltd., Vancouver, Canada. The alignments of araA, araB and araD predicted amino acid sequence were performed by the FASTA algorithm [Pearson and Lipman, Proc. Natl. Acad. Sci. USA, 85:2444-2448 (1988)].
Results
Nucleotide Sequence of the ara Genes
The B. subtilis araA gene could encode a 496 amino acid residue polypeptide with a predicted molecular mass, M.sub.r of 56,192 Da, which showed 52.5% identity, with a 495 amino acids overlap to AraA from E. coli (SEQ ID NO:16) and S. typhimurium (SEQ ID NO:17) (FIG. 9A). The araB gene could encode a 560 amino acid polypeptide with a predicted M.sub.r value of 60,973 Da and contiguous residues from 196 to 534 were 31.4% and 30.6% identical (350 a.a overlap) to E. coli AraB (SEQ ID NO:18) and S. typhimurium AraB (SEQ ID NO:19), respectively (FIG. 9B), B. subtilis araD gene could encode a 229 amino acid polypeptide with an M.sub.r of 25,669 Da which showed 58% identify in 231 overlap to E. coli AraD (SEQ ID NO:20) and 59% identity in 205 amino acid overlap to S. typhimurium AraD (SEQ ID NO:21) (FIG. 9C). The most significant divergency between amino acid sequences was observed at the N Terminal sequence of araB (170 amino acids). The B. subtilis AraA, AraB and AraD proteins were shown to be moderately hydrophilic according to Kyte and Doolittle [Kyte and Doolittle, J Mol. Biol., 157:105-132 (1982)].
5'-End Mapping of ara mRNA. A promoter-like region was found upstream from the araA gene. The -35 and -10 region are identical to the consensus sequence (TTGACA and TATAAT) of the promoters recognized by B. subtilis .sigma.-A form of RNA polymerase and show a spacing of 17 bp between -35 and -10 sequences as observed on many other B. subtilis promoters [Moran et al., In: Bacillus subtilis and other Gram-positive bacteria: biochemistry, physiology, and molecular genetics., American Society for Microbiology, Washington, D.C., pp. 653-667 (1993)].
To determine the transcriptional start site and if inducibility is at the transcriptional level, RNA extracted from exponentially grown cells, in the presence and in the absence of L-arabinose, was analyzed by primer extension.
Reverse-transcripts were obtained using a 19-mer (primer A) and a 17-mer (primer B) complementary to part of the mRNA, 83 and 153 bases, respectively, from the presumed start site of transcription, as described in Materials and Methods. Fragments corresponding to the transcription start site at a T residue in the non-transcribed strand were obtained with both primers only with mRNA from the induced culture.
Expression of araB-lacZ Transcriptional Fusions--The araA, araB and araD genes are adjacent. The direction of transcription is from araA to araD and no obvious transcription termination sequence is present between the three genes, suggesting that they are organized in an operon. To facilitate the study of the regulation of expression of the araA, araB and araD genes, a transcriptional araA, araB-lacZ fusion was constructed. Plasmids pSNL11 and PSNL12 were obtained by inserting a DNA fragment containing the lacZ.sup.+ and erm genes from pTV32 [Perkins and Youngman, 1986, supra] into the araB gene in opposite orientations (see Materials and Methods). The two plasmids were linearized by Bgl II, used to transform B. subtilis 168T.sup.+ and selection was made for Em.sup.r Cm.sup.s transformants. The use of linear DNA ensured a double crossover event leading to the integration of the araB-lacZ and the erm marker into the chromosome, which was confirmed by Southern hybridization (results not shown). The resulting strains IQB101 and IQB102 showed an Ara.sup.- phenotype, and their structure is presented in FIG. 10.
In strain IQB101 and araB-lacZ transcriptional fusion was obtained by fusion lacZ to the araB gene in the appropriate orientation of transcription. In strain IQB102, the lacZ gene was fused in the opposite orientation. The .beta.-galactosidase activity of the resulting strains was tested on MMCH-X-gal plates. Upon addition of L-arabinose to the medium, colonies of IQB101 presented a dark blue phenotype whereas those of IQB102 remained white, confirming that the direction of transcription is from araB to araD. Strain IQB101 was grown on plates MMCH-X-gal 0.04% L-arabinose, MMCH-X-gal 0.04% glucose, MMCH-X-gal 0.2% Glucose+0.2% L-arabinose and .beta.-galactosidase activity was tested. Only the colonies grown on MMCH-X-gal L-arabinose plates showed a dark blue phenotype. Thus, L-arabinose is the physiological inducer which stimulates the expression of the araB-lacZ fusion at the transcriptional level and araB transcription is subjected to catabolite repression.
Discussion
Using recombinant strains of B. subtilis bearing araB-lacZ fusions, the expression of the ara genes was studied. It was shown that the transcription of ara gene is inducible by L-arabinose, using an araB-lacZ fusion. These results were also consistent with the ones obtained by primer extension analysis. Using the same lacZ fusion, it was demonstrated that the expression of ara genes is repressed by glucose.
The 5' end of araABD operon was precisely determined by reverse transcriptase mapping and the promoter region identified. The 5' terminus of araABD transcript was located at a T residue (FIG. 1). The -35 and -10 regions are identical to the consensus sequence for the (A promoters in B. subtilis [TTGACA(17 bp)-TATAAT(18)] (SEQ ID NO:38).
In previous work [(Sa-Nogueira et al., J. Bacteriol., 170:2855-2857 (1988)], the existence of constitutive mutants for L-arabinose utilization was reported. Although these mutations are clustered in a different region of the chromosome, they influence the expression of the genes araA, araB and araD. Therefore, a regulatory role for the affected locus araC seemed plausible. Expression of araABD operon is inducible by L-arabinose. So, it can be assumed that the product(s) of a regulatory gene(s) interacts with the promoter region of the operon. Six regions possibly involved in transcription regulation were identified near the promoter (FIG. 11) (SEQ ID NO: 1). The first two were found upstream from the -35 region: an inverted repeat of ten nucleotides (IR1) located upstream from the -35 region (position -49 to -77, FIG. 11 (SEQ ID NO:2) and two direct repeats (comprise between position -66 to -113, FIG. 11). Downstream from IR1, three other inverted repeats were found: the first, IR2, located in the -35 region (SEQ ID NO:3); the second, IR3, located in the -10 region; and the third (SEQ ID NO:4); IR4, in the +4-+20 region (SEQ ID NO:5) (FIG. 11). All these sequences may be putative operator-like regions, and IR1 might also be a putative transcription terminator of a gene located upstream from the cloned fragment. Downstream from the transcription start site, the DNA sequence, +20-ATAGGTTTATTTTCTATCATTAGT ACGT-+47 (SEQ ID NO:6) (FIG. 11) show some similarity to the sequence recognized by the product of the regulatory gene, araC, at the E. coli araBAD promoter ATAGCATTTTTATCCATAAGATTAGCGG (SEQ ID NO:7) [Brunell and Schleif, J. Mol. Biol., 209:607-622 (1989)].
Expression of the ara genes is repressed by glucose as demonstrated by using the ara-lacZ fusion integrated into the ara region. In a previous work [Sa-Nogueira et al., 1988, supra], it was observed that strains carrying constitutive mutations at the araC locus still retained catabolite repression of the L-arabinose isomerase expression. Thus, it appears that inducer exclusion does not play a major role in carbon regulation of isomerase expression. Although the regulatory system mediating catabolite repression in B. subtilis is unknown, there is some evidence that it is accomplished by a negative regulatory mechanism [Chambliss, In: Bacillus subtilis and other Gram-positive bacteria: biochemistry, physiology, and molecular genetics, American Society for Microbiology, Washington, D.C., pp. 213-219 (1993)]. This evidence is based on the location and sequences of cis-acting sites responsible for catabolite repression of several B. subtilis genes and operons [Chambliss, 1993, supra]; these sequences are similar to the B. subtilis catabolite repression consensus sequence (TGWNANCGNTNWCA) (SEQ ID NO:8) deduced from mutagenesis studies of the amyE catabolite repression operator site [Weickert and Chambliss, Proc. Natl. Acad. Sci. USA, 87:6238-6242 (1990)]. Moreover, a trans-acting gene product CcpA which is involved in catabolite repression of the amyE gene was identified [Henkin et al., Mol. Microbiol., 5:575-584 (1991)]. Sequence analysis suggests that CcpA is a DNA-binding protein, but it is not known whether CcpA is directly involved in the mechanism of catabolite repression [Chambliss, 1993, supra; Fujita and Miwa, J. Bacteriol., 176:511-513 (1994)]. The promoter region of the araABD operon contains a sequence, +60 TGAAAGCGTTTTAT +73 (SEQ ID NO:9) (FIG. 11) very similar to the catabolite repression consensus sequence. A second sequence, which shows a weak similarity with the catabolite repression consensus sequence, was found within the araA gene, +160 TGTGACAGGAAGCC +173 (SEQ ID NO:10) (FIG. 11). In this work, it is shown that the catabolite repression of the ara operon acts at the transcriptional level; thus, these sequences might be putative cis-acting sites responsible for catabolite repression of the ara genes.
This invention may be embodied in other forms or carried out in other ways without departing from the spirit or essential characteristics thereof. The present disclosure is therefore to be considered as in all respects illustrative and not restrictive, the scope of the invention being indicated by the appended claims, and all changes which come within the meaning and range of equivalency are intended to be embraced therein.
The following is a list of documents related to the above disclosure and particularly to the experimental procedures and discussions.
Ausubel, F. M.; Bren, R.; Kingston, R.; Moore, D. D.; Smith, J. A.; Seidman, J. G.; and Struttl, K. (1987-1988). In Current Protocols in Molecular Biology. Ed. Green Publishing Associates and Wiley-Interscience.
Biarboim, H. C. and Doly, J. (1979). A rapid alkaline extraction procedure for screening recombinant plasmid DNA. Nucleic Acids Res. 7: 1513-1523.
Brunelle, A. and Schleif, R. 1989. Determining residue base interactions between araC protein and araI DNA. J. Mol. Biol. Biol. 209: 607-622.
Ferrari, F. A.; Ferrari, E.; and Hoch, J. 1982. Chromosomal location of a Bacillus subtilis DNA fragment uniquely transcribed by Sigma-28 containing RNA polymerase. J. Bacteriol. 152:782-785.
Pearson, W. R. and Lipman, D. J. 1988. Improved tools for biological sequence comparison. Proc. Natl. Acad. Sci. USA. 85:2444-2448.
Perego, M. and Hoch, J. 1988. Molecular cloning of the transcription inhibitor abrB of Bacillus subtilis. p. 129-134. In Genetics and Biotechnology of Bacilli. Vol. 2, Academic Press.
Yasbin, R.; Wilson, G.; and Young, F. 1973. Transformation and transfection in lysogenic strains of Bacillus subtilis 168. J. Bacteriol. 113:540-548.
Youngman, P. 1985. Plasmid vectors for recovering and exploiting Tn917 transpositions in Bacillus and other gram-positives. In Plasmids: a practical approach. Kitardy (Ed.). IRL Press, Oxford.
Zalkin, H. and Ebbole, D. J. 1988. Organization and regulation of genes encoding Biosynthetic enzymes in Bacillus subtilis. J. Biol. Chem. 263:1595-1598.
__________________________________________________________________________# SEQUENCE LISTING- (1) GENERAL INFORMATION:- (iii) NUMBER OF SEQUENCES: 64- (2) INFORMATION FOR SEQ ID NO:1:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 281 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: DNA (genomic)- (iii) HYPOTHETICAL: NO- (iv) ANTI-SENSE: NO- (vi) ORIGINAL SOURCE:#subtilis (A) ORGANISM: Bacillus- (ix) FEATURE:10 signa - #l NAME/KEY: (B) LOCATION: 119..124- (ix) FEATURE:35 signa - #l NAME/KEY: (B) LOCATION: 96..101- (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 228..281- (ix) FEATURE: (A) NAME/KEY: RBS (B) LOCATION: 211..219- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:- AAGCTTCTCA TCAATGATTT GAATTGGAGC TCGGGCTGGC CGTCCTATTG AA - #TTAAAAAG 60- CCGGCTCTGC CCCCGGCTTT TTTTAAAAGA AAAGATTGAC AGTATAATAG TC - #AATTACTA 120- TAATAAAATT GTTCGTACAA ATATTTATTT ATAGGTTTAT TTTCTATCAT TA - #GTACGTAT 180#CTT CAG 236AGCGTT TTATTTTATG AGAAAGGGGC AGTTTAC ATG#Leu Gln Met#1- ACA AAG GAT TAT GAA TTC TGG TTT GTG ACA GG - #A AGC CAG CAC CTA 28 - #1Thr Lys Asp Tyr Glu Phe Trp Phe Val Thr Gl - #y Ser Gln His Leu# 15- (2) INFORMATION FOR SEQ ID NO:2:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 28 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: DNA (genomic)- (iii) HYPOTHETICAL: NO- (iv) ANTI-SENSE: NO- (vi) ORIGINAL SOURCE:#subtilis (A) ORGANISM: Bacillus- (ix) FEATURE: (A) NAME/KEY: misc.sub.-- - #feature (B) LOCATION: 1..28- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:# 28 CCCC GGCTTTTT- (2) INFORMATION FOR SEQ ID NO:3:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 30 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: DNA (genomic)- (iii) HYPOTHETICAL: NO- (iv) ANTI-SENSE: NO- (vi) ORIGINAL SOURCE:#subtilis (A) ORGANISM: Bacillus- (ix) FEATURE: (A) NAME/KEY: misc.sub.-- - #feature (B) LOCATION: 1..30- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:# 30 TCAA TTACTATAAT- (2) INFORMATION FOR SEQ ID NO:4:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 23 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: DNA (genomic)- (iii) HYPOTHETICAL: NO- (iv) ANTI-SENSE: NO- (vi) ORIGINAL SOURCE:#subtilis (A) ORGANISM: Bacillus- (ix) FEATURE: (A) NAME/KEY: misc.sub.-- - #feature (B) LOCATION: 1..23- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:# 23TATA ATA- (2) INFORMATION FOR SEQ ID NO:5:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 22 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: DNA (genomic)- (iii) HYPOTHETICAL: NO- (iv) ANTI-SENSE: NO- (vi) ORIGINAL SOURCE:#subtilis (A) ORGANISM: Bacillus- (ix) FEATURE: (A) NAME/KEY: misc.sub.-- - #feature (B) LOCATION: 1..22- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:# 22ATA GG- (2) INFORMATION FOR SEQ ID NO:6:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 28 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: DNA (genomic)- (iii) HYPOTHETICAL: NO- (iv) ANTI-SENSE: NO- (vi) ORIGINAL SOURCE:#subtilis (A) ORGANISM: Bacillus- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:# 28 TCAT TAGTACGT- (2) INFORMATION FOR SEQ ID NO:7:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 28 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: DNA (genomic)- (iii) HYPOTHETICAL: NO- (iv) ANTI-SENSE: NO- (vi) ORIGINAL SOURCE:#subtilis (A) ORGANISM: Bacillus- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:7:# 28 TAAG ATTAGCGG- (2) INFORMATION FOR SEQ ID NO:8:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 14 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: unknown- (ii) MOLECULE TYPE:- (iii) HYPOTHETICAL: NO- (iv) ANTI-SENSE: NO- (v) FRAGMENT TYPE: internal- (vi) ORIGINAL SOURCE:#subtilis (A) ORGANISM: Bacillus- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:8:# 14- (2) INFORMATION FOR SEQ ID NO:9:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 14 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: DNA (genomic)- (iii) HYPOTHETICAL: NO- (iv) ANTI-SENSE: NO- (vi) ORIGINAL SOURCE:#subtilis (A) ORGANISM: Bacillus- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:9:# 14- (2) INFORMATION FOR SEQ ID NO:10:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 14 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: DNA (genomic)- (iii) HYPOTHETICAL: NO- (iv) ANTI-SENSE: NO- (vi) ORIGINAL SOURCE:#subtilis (A) ORGANISM: Bacillus- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:10:# 14- (2) INFORMATION FOR SEQ ID NO:11:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 10917 base (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: DNA (genomic)- (iii) HYPOTHETICAL: NO- (vi) ORIGINAL SOURCE:#subtilis (A) ORGANISM: Bacillus- (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 228..1718#/product= "araA"ER INFORMATION:- (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 1732..3417#/product= "araB"ER INFORMATION:- (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 3431..4120#/product= "araD"ER INFORMATION:- (ix) FEATURE: (A) NAME/KEY: misc.sub.-- - #feature (B) LOCATION: 4107..4916#/product= "araL"ER INFORMATION:- (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 4913..6097#/product= "araM"ER INFORMATION:- (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 6128..7429#/product= "araN"ER INFORMATION:- (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 7465..8406#/product= "araP"ER INFORMATION:- (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 8407..9255#/product= "araQ"ER INFORMATION:- (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 9271..10773#/product= "abfA"ER INFORMATION:- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:11:- AAGCTTCTCA TCAATGATTT GAATTGGAGC TCGGGCTGGC CGTCCTATTG AA - #TTAAAAAG 60- CCGGCTCTGC CCCCGGCTTT TTTTAAAAGA AAAGATTGAC AGTATAATAG TC - #AATTACTA 120- TAATAAAATT GTTCGTACAA ATATTTATTT ATAGGTTTAT TTTCTATCAT TA - #GTACGTAT 180#CTT CAG 236AGCGTT TTATTTTATG AGAAAGGGGC AGTTTAC ATG#Leu Gln Met#1- ACA AAG GAT TAT GAA TTC TGG TTT GTG ACA GG - #A AGC CAG CAC CTA TAC 284Thr Lys Asp Tyr Glu Phe Trp Phe Val Thr Gl - #y Ser Gln His Leu Tyr# 15- GGG GAA GAG ACG CTG GAA CTC GTA GAT CAG CA - #T GCT AAA AGC ATT TGT 332Gly Glu Glu Thr Leu Glu Leu Val Asp Gln Hi - #s Ala Lys Ser Ile Cys# 35- GAG GGG CTC AGC GGG ATT TCT TCC AGA TAT AA - #A ATC ACT CAT AAG CCC 380Glu Gly Leu Ser Gly Ile Ser Ser Arg Tyr Ly - #s Ile Thr His Lys Pro# 50- GTC GTC ACT TCA CCG GAA ACC ATT AGA GAG CT - #G TTA AGA GAA GCG GAG 428Val Val Thr Ser Pro Glu Thr Ile Arg Glu Le - #u Leu Arg Glu Ala Glu# 65- TAC AGT GAG ACA TGT GCT GGC ATC ATT ACA TG - #G ATG CAC ACA TTT TCC 476Tyr Ser Glu Thr Cys Ala Gly Ile Ile Thr Tr - #p Met His Thr Phe Ser# 80- CCT GCA AAA ATG TGG ATA GAA GGC CTT TCC TC - #T TAT CAA AAA CCG CTT 524Pro Ala Lys Met Trp Ile Glu Gly Leu Ser Se - #r Tyr Gln Lys Pro Leu# 95- ATG CAT TTG CAT ACC CAA TAT AAT CGC GAT AT - #C CCG TGG GGT ACG ATT 572Met His Leu His Thr Gln Tyr Asn Arg Asp Il - #e Pro Trp Gly Thr Ile100 1 - #05 1 - #10 1 -#15- GAC ATG GAT TTT ATG AAC AGC AAC CAA TCC GC - #G CAT GGC GAT CGA GAG 620Asp Met Asp Phe Met Asn Ser Asn Gln Ser Al - #a His Gly Asp Arg Glu# 130- TAC GGT TAC ATC AAC TCG AGA ATG GGG CTT AG - #C CGA AAA GTC ATT GCC 668Tyr Gly Tyr Ile Asn Ser Arg Met Gly Leu Se - #r Arg Lys Val Ile Ala# 145- GGC TAT TGG GAT GAT GAA GAA GTG AAA AAA GA - #A ATG TCC CAG TGG ATG 716Gly Tyr Trp Asp Asp Glu Glu Val Lys Lys Gl - #u Met Ser Gln Trp Met# 160- GAT ACG GCG GCT GCA TTA AAT GAA AGC AGA CA - #T ATT AAG GTT GCC AGA 764Asp Thr Ala Ala Ala Leu Asn Glu Ser Arg Hi - #s Ile Lys Val Ala Arg# 175- TTT GGA GAT AAC ATG CGT CAT GTC GCG GTA AC - #G GAC GGA GAC AAG GTG 812Phe Gly Asp Asn Met Arg His Val Ala Val Th - #r Asp Gly Asp Lys Val180 1 - #85 1 - #90 1 -#95- GGA GCG CAT ATT CAA TTT GGC TGG CAG GTT GA - #C GGA TAT GGC ATC GGG 860Gly Ala His Ile Gln Phe Gly Trp Gln Val As - #p Gly Tyr Gly Ile Gly# 210- GAT CTC GTT GAA GTG ATG GAT CGC ATT ACG GA - #C GAC GAG GTT GAC ACG 908Asp Leu Val Glu Val Met Asp Arg Ile Thr As - #p Asp Glu Val Asp Thr# 225- CTT TAT GCC GAG TAT GAC AGA CTA TAT GTG AT - #C AGT GAG GAA ACA AAA 956Leu Tyr Ala Glu Tyr Asp Arg Leu Tyr Val Il - #e Ser Glu Glu Thr Lys# 240- CGT GAC GAA GCA AAG GTA GCG TCC ATT AAA GA - #A CAG GCG AAA ATT GAA1004Arg Asp Glu Ala Lys Val Ala Ser Ile Lys Gl - #u Gln Ala Lys Ile Glu# 255- CTT GGA TTA ACC GCT TTT CTT GAG CAA GGC GG - #A TAC ACA GCG TTT ACG1052Leu Gly Leu Thr Ala Phe Leu Glu Gln Gly Gl - #y Tyr Thr Ala Phe Thr260 2 - #65 2 - #70 2 -#75- ACA TCG TTT GAA GTG CTG CAC GGA ATG AAA CA - #G CTG CCG GGA CTT GCC1100Thr Ser Phe Glu Val Leu His Gly Met Lys Gl - #n Leu Pro Gly Leu Ala# 290- GTT CAG CGC CTG ATG GAG AAA GGC TAT GGG TT - #T GCC GGT GAA GGA GAT1148Val Gln Arg Leu Met Glu Lys Gly Tyr Gly Ph - #e Ala Gly Glu Gly Asp# 305- TGG AAG ACA GCG GCC CTT GTA CGG ATG ATG AA - #A ATC ATG GCT AAA GGA1196Trp Lys Thr Ala Ala Leu Val Arg Met Met Ly - #s Ile Met Ala Lys Gly# 320- AAA AGA ACT TCC TTC ATG GAA GAT TAC ACG TA - #C CAT TTT GAA CCG GGA1244Lys Arg Thr Ser Phe Met Glu Asp Tyr Thr Ty - #r His Phe Glu Pro Gly# 335- AAT GAA ATG ATT CTG GGC TCT CAC ATG CTT GA - #A GTG TGT CCG ACT GTC1292Asn Glu Met Ile Leu Gly Ser His Met Leu Gl - #u Val Cys Pro Thr Val340 3 - #45 3 - #50 3 -#55- GCT TTG GAT CAG CCG AAA ATC GAG GTT CAT TC - #G CTT TCG ATT GGC GGC1340Ala Leu Asp Gln Pro Lys Ile Glu Val His Se - #r Leu Ser Ile Gly Gly# 370- AAA GAG GAC CCT GCG CGT TTG GTA TTT AAC GG - #C ATC AGC GGT TCT GCC1388Lys Glu Asp Pro Ala Arg Leu Val Phe Asn Gl - #y Ile Ser Gly Ser Ala# 385- ATT CAA GCT AGC ATT GTT GAT ATT GGC GGG CG - #T TTC CGC CTT GTG CTG1436Ile Gln Ala Ser Ile Val Asp Ile Gly Gly Ar - #g Phe Arg Leu Val Leu# 400- AAT GAA GTC AAC GGC CAG GAA ATT GAA AAA GA - #C ATG CCG AAT TTA CCG1484Asn Glu Val Asn Gly Gln Glu Ile Glu Lys As - #p Met Pro Asn Leu Pro# 415- GTT GCC CGT GTT CTC TGG AAG CCG GAG CCG TC - #A TTG AAA ACA GCA GCG1532Val Ala Arg Val Leu Trp Lys Pro Glu Pro Se - #r Leu Lys Thr Ala Ala420 4 - #25 4 - #30 4 -#35- GAG GCA TGG ATT TTA GCC GGC GGT GCA CAC CA - #T ACC TGC CTG TCT TAT1580Glu Ala Trp Ile Leu Ala Gly Gly Ala His Hi - #s Thr Cys Leu Ser Tyr# 450- GAA CTG ACA GCG GAG CAA ATG CTT GAT TGG GC - #G GAA ATG GCG GGA ATC1628Glu Leu Thr Ala Glu Gln Met Leu Asp Trp Al - #a Glu Met Ala Gly Ile# 465- GAA AGT GTT CTC ATT TCC CGT GAT ACG ACA AT - #T CAT AAA CTG AAA CAC1676Glu Ser Val Leu Ile Ser Arg Asp Thr Thr Il - #e His Lys Leu Lys His# 480- GAG TTA AAA TGG AAC GAG GCG CTT TAC CGG CT - #T CAA AAG TAG#1718Glu Leu Lys Trp Asn Glu Ala Leu Tyr Arg Le - #u Gln Lys *# 495- AGGGGGATGT CAC ATG GCT TAC ACA ATA GGG GTT GA - #T TTT GGA ACT TTA1767#Tyr Thr Ile Gly Val Asp Phe Gly Thr Leu# 10- TCA GGA AGA GCA GTG CTC GTT CAT GTC CAA AC - #A GGG GAG GAA CTT GCG1815Ser Gly Arg Ala Val Leu Val His Val Gln Th - #r Gly Glu Glu Leu Ala# 25- GCT GCT GTA AAA GAA TAC AGG CAT GCT GTC AT - #T GAT ACC GTC CTT CCA1863Ala Ala Val Lys Glu Tyr Arg His Ala Val Il - #e Asp Thr Val Leu Pro# 40- AAA ACG GGT CAA AAG CTG CCG CGT GAC TGG GC - #G CTG CAG CAC CCT GCT1911Lys Thr Gly Gln Lys Leu Pro Arg Asp Trp Al - #a Leu Gln His Pro Ala# 60- GAT TAC CTC GAA GTC TTG GAA ACA ACC ATT CC - #G TCT TTA CTC GAA CAG1959Asp Tyr Leu Glu Val Leu Glu Thr Thr Ile Pr - #o Ser Leu Leu Glu Gln# 75- ACG GGC GTT GAC CCG AAA GAC ATT ATC GGG AT - #T GGA ATT GAT TTC ACG2007Thr Gly Val Asp Pro Lys Asp Ile Ile Gly Il - #e Gly Ile Asp Phe Thr# 90- GCA TGT ACG ATC CTT CCT ATT GAC AGC AGC GG - #G CAG CCG TTA TGC ATG2055Ala Cys Thr Ile Leu Pro Ile Asp Ser Ser Gl - #y Gln Pro Leu Cys Met# 105- CTG CCT GAA TAT GAA GAG GAG CCG CAC AGC TA - #T GTG AAG CTC TGG AAG2103Leu Pro Glu Tyr Glu Glu Glu Pro His Ser Ty - #r Val Lys Leu Trp Lys# 120- CAT CAT GCG GCC CAA AAA CAT GCT GAT CGG CT - #C AAT CAA ATC GCG GAA2151His His Ala Ala Gln Lys His Ala Asp Arg Le - #u Asn Gln Ile Ala Glu125 1 - #30 1 - #35 1 -#40- GAA GAA GGA GAG GCT TTT TTA CAG CGG TAC GG - #A GGA AAA ATT TCA TCA2199Glu Glu Gly Glu Ala Phe Leu Gln Arg Tyr Gl - #y Gly Lys Ile Ser Ser# 155- GAA TGG ATG ATT CCA AAG GTC ATG CAA ATT GC - #C GAG GAA GCG CCT CAC2247Glu Trp Met Ile Pro Lys Val Met Gln Ile Al - #a Glu Glu Ala Pro His# 170- ATT TAT GAA GCG GCT GAC CGG ATC ATC GAG GC - #T GCG GAC TGG ATC GTG2295Ile Tyr Glu Ala Ala Asp Arg Ile Ile Glu Al - #a Ala Asp Trp Ile Val# 185- TAC CAG CTG TGC GGC TCG CTC AAG CGA AGC AA - #T TGT ACC GCA GGG TAT2343Tyr Gln Leu Cys Gly Ser Leu Lys Arg Ser As - #n Cys Thr Ala Gly Tyr# 200- AAA GCG ATG TGG AGT GAA AAA GCG GGG TAT CC - #G TCA GAT GAT TTC TTT2391Lys Ala Met Trp Ser Glu Lys Ala Gly Tyr Pr - #o Ser Asp Asp Phe Phe205 2 - #10 2 - #15 2 -#20- GAG AAA TTA AAT CCT TCA ATG AAA ACG ATT AC - #A AAG GAC AAA TTG TCA2439Glu Lys Leu Asn Pro Ser Met Lys Thr Ile Th - #r Lys Asp Lys Leu Ser# 235- GGT TCT ATT CAT TCA GTA GGA GAA AAA GCC GG - #C AGT CTG ACT GAA AAA2487Gly Ser Ile His Ser Val Gly Glu Lys Ala Gl - #y Ser Leu Thr Glu Lys# 250- ATG GCA AAG CTG ACA GGG CTT CTC CCG GGA AC - #G GCT GTT GCG GTT GCC2535Met Ala Lys Leu Thr Gly Leu Leu Pro Gly Th - #r Ala Val Ala Val Ala# 265- AAT GTG GAC GCT CAT GTT TCG GTA CCG GCG GT - #C GGC ATT ACA GAG CCA2583Asn Val Asp Ala His Val Ser Val Pro Ala Va - #l Gly Ile Thr Glu Pro# 280- GGG AAA ATG CTG ATG ATT ATG GGA ACC TCG AC - #G TGC CAT GTT CTA CTT2631Gly Lys Met Leu Met Ile Met Gly Thr Ser Th - #r Cys His Val Leu Leu285 2 - #90 2 - #95 3 -#00- GGT GAA GAG GTG CAT ATC GTT CCA GGA ATG TG - #C GGC GTT GTG GAC AAC2679Gly Glu Glu Val His Ile Val Pro Gly Met Cy - #s Gly Val Val Asp Asn# 315- GGA ATT CTC CCG GGC TAT GCG GGA TAT GAA GC - #C GGG CAG TCC TGT GTC2727Gly Ile Leu Pro Gly Tyr Ala Gly Tyr Glu Al - #a Gly Gln Ser Cys Val# 330- GGC GAT CAT TTT GAC TGG TTT GTG AAA ACA TG - #T GTC CCG CCA GCT TAT2775Gly Asp His Phe Asp Trp Phe Val Lys Thr Cy - #s Val Pro Pro Ala Tyr# 345- CAA GAG GAA GCA AAG GAA AAA AAC ATT GGC GT - #T CAT GAG CTG CTG AGT2823Gln Glu Glu Ala Lys Glu Lys Asn Ile Gly Va - #l His Glu Leu Leu Ser# 360- GAG AAA GCA AAC CAT CAA GCG CCT GGT GAA AG - #C GGC TTG CTT GCT TTA2871Glu Lys Ala Asn His Gln Ala Pro Gly Glu Se - #r Gly Leu Leu Ala Leu365 3 - #70 3 - #75 3 -#80- GAT TGG TGG AAT GGA AAC CGT TCA ACT CTT GT - #T GAT GCA GAT TTA ACA2919Asp Trp Trp Asn Gly Asn Arg Ser Thr Leu Va - #l Asp Ala Asp Leu Thr# 395- GGG ATG CTG CTT GGC ATG ACA CTG CTG ACG AA - #G CCT GAA GAG ATT TAT2967Gly Met Leu Leu Gly Met Thr Leu Leu Thr Ly - #s Pro Glu Glu Ile Tyr# 410- AGA GCG TTA GTT GAA GCG ACA GCT TAC GGA AC - #C CGG ATG ATT ATC GAA3015Arg Ala Leu Val Glu Ala Thr Ala Tyr Gly Th - #r Arg Met Ile Ile Glu# 425- ACA TTC AAA GAA AGC GGT GTT CCG ATT GAG GA - #A CTG TTC GCA GCC GGC3063Thr Phe Lys Glu Ser Gly Val Pro Ile Glu Gl - #u Leu Phe Ala Ala Gly# 440- GGA ATA GCT GAG AAA AAC CCG TTT GTC ATG CA - #G ATT TAT GCG GAT GTG3111Gly Ile Ala Glu Lys Asn Pro Phe Val Met Gl - #n Ile Tyr Ala Asp Val445 4 - #50 4 - #55 4 -#60- ACA AAC ATG GAC ATT AAA ATC TCT GGT TCA CC - #G CAA GCC CCA GCC TTA3159Thr Asn Met Asp Ile Lys Ile Ser Gly Ser Pr - #o Gln Ala Pro Ala Leu# 475- GGA TCT GCC ATT TTC GGC GCG CTT GCA GCA GG - #C AAA GAA AAA GGC GGC3207Gly Ser Ala Ile Phe Gly Ala Leu Ala Ala Gl - #y Lys Glu Lys Gly Gly# 490- TAC GAT GAT ATC AAA AAG GCA GCG GCG AAC AT - #G GGA AAA CTG AAA GAT3255Tyr Asp Asp Ile Lys Lys Ala Ala Ala Asn Me - #t Gly Lys Leu Lys Asp# 505- ATA ACT TAT ACG CCA AAT GCC GAA AAC GCC GC - #G GTT TAT GAA AAA TTG3303Ile Thr Tyr Thr Pro Asn Ala Glu Asn Ala Al - #a Val Tyr Glu Lys Leu# 520- TAC GCT GAA TAT AAA GAG CTG GTT CAT TAT TT - #C GGA AAA GAA AAC CAT3351Tyr Ala Glu Tyr Lys Glu Leu Val His Tyr Ph - #e Gly Lys Glu Asn His525 5 - #30 5 - #35 5 -#40- GTC ATG AAG CGT CTG AAA ACG ATC AAA AAT CT - #T CAA TTT TCA TCT GCC3399Val Met Lys Arg Leu Lys Thr Ile Lys Asn Le - #u Gln Phe Ser Ser Ala# 555- GCC AAA AAG AAT TGA TAA AGGGTGATGG AGC ATG CT - #T GAA ACA TTA AAA3448# Met Leu Glu Thr Leu - # Lys# 1 5- AAA GAA GTG CTG GCT GCC AAC CTG AAG CTT CA - #A GAG CAT CAG CTG GTA3496Lys Glu Val Leu Ala Ala Asn Leu Lys Leu Gl - #n Glu His Gln Leu Val# 20- ACC TTT ACG TGG GGA AAT GTC AGC GGC ATT GA - #C CGT GAA AAA GAA AGA3544Thr Phe Thr Trp Gly Asn Val Ser Gly Ile As - #p Arg Glu Lys Glu Arg# 35- ATT GTC ATC AAA CTA GCG GAG TCG AAT ACC AG - #C GAC CTG ACA GCC GAT3592Ile Val Ile Lys Leu Ala Glu Ser Asn Thr Se - #r Asp Leu Thr Ala Asp# 50- GAC TTG GTT GTT TTG AAC CTT GAT GGA GAG GT - #C GTC GAA GGC TCG CTT3640Asp Leu Val Val Leu Asn Leu Asp Gly Glu Va - #l Val Glu Gly Ser Leu# 70- AAA CCT TCT TCA GAT ACA CCT ACC CAT GTT TA - #T CTA TAT AAA GCC TTT3688Lys Pro Ser Ser Asp Thr Pro Thr His Val Ty - #r Leu Tyr Lys Ala Phe# 85- CCG AAT ATC GGG GGA ATT GTC CAT ACC CAT TC - #T CAA TGG GCG ACA AGC3736Pro Asn Ile Gly Gly Ile Val His Thr His Se - #r Gln Trp Ala Thr Ser# 100- TGG GCG CAA TCG GGC AGA GAC ATC CCT CCG TT - #A GGC ACG ACC CAT GCT3784Trp Ala Gln Ser Gly Arg Asp Ile Pro Pro Le - #u Gly Thr Thr His Ala# 115- GAT TAT TTT GAC AGT GCG ATT CCA TGT ACT CG - #A GAA ATG TAC GAT GAA3832Asp Tyr Phe Asp Ser Ala Ile Pro Cys Thr Ar - #g Glu Met Tyr Asp Glu# 130- GAA ATC ATT CAT GAC TAC GAA CTG AAT ACA GG - #A AAA GTC ATA GCG GAA3880Glu Ile Ile His Asp Tyr Glu Leu Asn Thr Gl - #y Lys Val Ile Ala Glu135 1 - #40 1 - #45 1 -#50- ACC TTT CAG CAT CAT AAT TAC GAA CAG GTG CC - #G GGT GTG CTC GTG AAT3928Thr Phe Gln His His Asn Tyr Glu Gln Val Pr - #o Gly Val Leu Val Asn# 165- AAT CAC GGA CCG TTC TGC TGG GGC ACT GAC GC - #C TTA AAT GCC ATT CAT3976Asn His Gly Pro Phe Cys Trp Gly Thr Asp Al - #a Leu Asn Ala Ile His# 180- AAC GCA GTT GTA TTA GAA ACG GTT GCC GAA AT - #G GCC TAT CAC TCC ATT4024Asn Ala Val Val Leu Glu Thr Val Ala Glu Me - #t Ala Tyr His Ser Ile# 195- ATG CTG AAC AAG GAT GTA ACC CCA ATC AAT AC - #A GTC CTG CAT GAA AAG4072Met Leu Asn Lys Asp Val Thr Pro Ile Asn Th - #r Val Leu His Glu Lys# 210- CAT TTT TAT CGA AAA CAC GGA GCA AAT GCG TA - #T TAT GGC CAG TCA TGA4120His Phe Tyr Arg Lys His Gly Ala Asn Ala Ty - #r Tyr Gly Gln Ser *215 2 - #20 2 - #25 2 -#30- TACGCCTGTG TCACCGGCTG GCATTCTGAT TGACTTGGAC GGTACTGTAT TC - #AGAGGAAA4180- TGAGTTGATC GAAGGAGCAA GAGAAGCGAT CAAAACGCTT AGGAGAATGG GA - #AAGAAAAT4240- CGTCTTTTTA AGCAACCGGG GGAATATCTC CCGTGCCATG TGCAGAAAAA AA - #CTTCTTGG4300- CGCGGGGATT GAAACGGACG TAAACGACAT TGTTCTGTCA TCAAGCGTGA CA - #GCGGCTTT4360- TCTGAAAAAA CATTATCGTT TTTCAAAGGT ATGGGTGCTT GGGGAGCAAG GC - #TTGGTTGA4420- CGAGCTGAGG CTGGCCGGTG TGCAGAACGC GAGCGAACCG AAGGAAGCGG AT - #TGGCTCGT4480- GATCTCCCTT CATGAAACGC TCACGTACGA CGATTTAAAT CAAGCCTTTC AA - #GCGGCTGC4540- CGGCGGCGCT CGTATTATCG CTACAAACAA AGACCGCTCT TTTCCGAACG AA - #GACGGAAA4600- TGCCATTGAT GTGGCCGGAA TGATCGGGGC AATTGAGACT TCTGCACAAG CG - #AAGACTGA4660- ACTTGTTGTC GGAAAACCGT CATGGCTGAT GGCGGAGGCT GCCTGTACGG CA - #ATGGGGCT4720- GTCCGCACAT GAATGCATGA TTATAGGAGA CAGCATTGAA TCTGACATTG CG - #ATGGGGAA4780- GCTTTATGGC ATGAAAAGCG CCTTAGTGCT AACTGGTTCT GCGAAACAGG GT - #GAACAGCG4840- TTTGTACACG CCGGATTATG TGCTGGATTC TATTAAGGAT GTAACCAAAT TG - #GCTGAGGA4900- GGGGATTCTG AT ATG AAT CGT ATC GCA GCT GAC GTT - # CAG CGT GCT TTT4948 Met Asn Ar - #g Ile Ala Ala Asp Val Gln Arg Ala Phe# 10- GAA AAC GCC GGA GAA AAG ACG TTG CCT ATA AA - #A GTT GAA GAA ATT GTT4996Glu Asn Ala Gly Glu Lys Thr Leu Pro Ile Ly - #s Val Glu Glu Ile Val# 25- CTC GGT AAG CAA GCA GCT GAT TCG CTT TTG GA - #T TAT GTA AAA CGA AAA5044Leu Gly Lys Gln Ala Ala Asp Ser Leu Leu As - #p Tyr Val Lys Arg Lys# 40- AAC AAT CAA CAT ATT GTC CTT GTC TGC GAC GC - #G AAT ACA CAC CGC ATT5092Asn Asn Gln His Ile Val Leu Val Cys Asp Al - #a Asn Thr His Arg Ile# 60- GCA GGA ATT GAT TTA GAA AAC CGA CTG AAT CA - #A GAA GGA TTT CAG GCC5140Ala Gly Ile Asp Leu Glu Asn Arg Leu Asn Gl - #n Glu Gly Phe Gln Ala# 75- GAG TGC CTG ATC ATT CCA GAA AAT GAA GCC GG - #A GAT GTG ACA GCT GAT5188Glu Cys Leu Ile Ile Pro Glu Asn Glu Ala Gl - #y Asp Val Thr Ala Asp# 90- GAA CGA TCG CTC ATT CAT GTG CTG ATC CAT AC - #G AAA CAA CCA ACG GAT5236Glu Arg Ser Leu Ile His Val Leu Ile His Th - #r Lys Gln Pro Thr Asp# 105- GTC ATG ATC GCA GTC GGT TCG GGC ACG ATT CA - #T GAT ATC GTC CGC TTT5284Val Met Ile Ala Val Gly Ser Gly Thr Ile Hi - #s Asp Ile Val Arg Phe# 120- GCG GCG TTT CAA AGA GAT TTG CCG TTT ATT TC - #T TAT CCG ACT GCT CCA5332Ala Ala Phe Gln Arg Asp Leu Pro Phe Ile Se - #r Tyr Pro Thr Ala Pro125 1 - #30 1 - #35 1 -#40- TCT GTA GAC GGT TTT ACA TCA GCC GGT GCG CC - #G ATT ATT TTA TAC GGC5380Ser Val Asp Gly Phe Thr Ser Ala Gly Ala Pr - #o Ile Ile Leu Tyr Gly# 155- ACG AAA ACA ACC ATT CAA ACG AAG GCC CCA TC - #T GCG CTG TTC GCT GAT5428Thr Lys Thr Thr Ile Gln Thr Lys Ala Pro Se - #r Ala Leu Phe Ala Asp# 170- CTG GAT CTA TTA AAA GCG GCA CCG CAG TCA AT - #G GTG GCG GCT GGC TTT5476Leu Asp Leu Leu Lys Ala Ala Pro Gln Ser Me - #t Val Ala Ala Gly Phe# 185- GGT GAC ATG CTC GGT AAA ATC ACG TCT TTA GC - #A GAT TGG GAA ATA TCC5524Gly Asp Met Leu Gly Lys Ile Thr Ser Leu Al - #a Asp Trp Glu Ile Ser# 200- CGG CAT CTT GCC GGT GAG CCT TAT TCG CCT GC - #A GGA GCT AAG ATC GTT5572Arg His Leu Ala Gly Glu Pro Tyr Ser Pro Al - #a Gly Ala Lys Ile Val205 2 - #10 2 - #15 2 -#20- CAG GAG GCG CTT GCT GCC TGC ATT GAA CAC AC - #A GAA GAC ATT GCG ATG5620Gln Glu Ala Leu Ala Ala Cys Ile Glu His Th - #r Glu Asp Ile Ala Met# 235- AAA ACG GAA ACT GGC ATA CGG GTT TTG ATG GA - #G TCT TTA CTT GTA TCG5668Lys Thr Glu Thr Gly Ile Arg Val Leu Met Gl - #u Ser Leu Leu Val Ser# 250- GGG CTT GTC ATG CTG GCT TTA GAT CAT TCC CG - #A CCG GCA TCA GGC GGC5716Gly Leu Val Met Leu Ala Leu Asp His Ser Ar - #g Pro Ala Ser Gly Gly# 265- GAG CAT CAT ATT TCA CAT TGG ATT GAA ATG GA - #G TTA ATG GAG AAA AAA5764Glu His His Ile Ser His Trp Ile Glu Met Gl - #u Leu Met Glu Lys Lys# 280- CGG CCT CAG ATT CTT CAT GGG GCA AAG GTG GG - #C TGT GCC GCT GTT TTA5812Arg Pro Gln Ile Leu His Gly Ala Lys Val Gl - #y Cys Ala Ala Val Leu285 2 - #90 2 - #95 3 -#00- TTA ACT GAC ACA TAC AGA AAG CTC GCT CAG GA - #T GAC GGG CTG AAC GAA5860Leu Thr Asp Thr Tyr Arg Lys Leu Ala Gln As - #p Asp Gly Leu Asn Glu# 315- TTT TCA CCA AGC CGC CGG GAA GCC ATC CAA TC - #G GCT TAT CAA ACA CTC5908Phe Ser Pro Ser Arg Arg Glu Ala Ile Gln Se - #r Ala Tyr Gln Thr Leu# 330- CCG AGA GGA GAA GTG CTG GCT GAT TGG CTG AG - #A TCA GCC GGA GGC CCT5956Pro Arg Gly Glu Val Leu Ala Asp Trp Leu Ar - #g Ser Ala Gly Gly Pro# 345- GCT GAT TTT GAC GAA ATC GGT GTC GGG CAG GA - #T TCC GTC AAA AAT GCC6004Ala Asp Phe Asp Glu Ile Gly Val Gly Gln As - #p Ser Val Lys Asn Ala# 360- TTC AGA CAC GCG CAC ACC TTA AGA GAC CGA TG - #C ACC GGA TTA AGA ATC6052Phe Arg His Ala His Thr Leu Arg Asp Arg Cy - #s Thr Gly Leu Arg Ile365 3 - #70 3 - #75 3 -#80- ATC AAT GAA AAC AAA ACG CTG ATC AAC CAT GG - #T CTA TAT GAA TAG6097Ile Asn Glu Asn Lys Thr Leu Ile Asn His Gl - #y Leu Tyr Glu *# 395- CCCGCACCTC GAATGGAAGG GGTAACGCAG ATG AAA AAA ATG AC - #T GTC TGT TTT6151#Lys Met Thr Val Cys Phe# 5 1- CTT GTG CTC ATG ATG TTG CTG ACA TTA GTC AT - #T GCC GGG TGT TCA GCA6199Leu Val Leu Met Met Leu Leu Thr Leu Val Il - #e Ala Gly Cys Ser Ala# 20- GAA AAA TCA TCC GGC AAA TCG GGT GAA ACT GA - #G CTG ACC TTT TGG ACA6247Glu Lys Ser Ser Gly Lys Ser Gly Glu Thr Gl - #u Leu Thr Phe Trp Thr# 40- TTT AAC GGG CTT CAT GAG CAG TTC TAT GTG GA - #A ATG GTG AAG GAA TGG6295Phe Asn Gly Leu His Glu Gln Phe Tyr Val Gl - #u Met Val Lys Glu Trp# 55- AAC AAA AAA TAT CCT GAC CGC AAA ATT AAG CT - #G AAT ACG GTC GTT TAT6343Asn Lys Lys Tyr Pro Asp Arg Lys Ile Lys Le - #u Asn Thr Val Val Tyr# 70- CCA TAT GGA CAA ATG CAC GAT AAC TTA TCT AT - #C TCC CTA ATA GCG GGA6391Pro Tyr Gly Gln Met His Asp Asn Leu Ser Il - #e Ser Leu Ile Ala Gly# 85- GAA GGC GTT CCT GAT ATT GCA GAT GTC GAA TT - #G GCC CGT TTT TCA AAC6439Glu Gly Val Pro Asp Ile Ala Asp Val Glu Le - #u Ala Arg Phe Ser Asn# 100- TTT TTG AAG GGC TCT GAC ATA CCG CTT GCC GA - #C TTG ACT CCG CTG ATT6487Phe Leu Lys Gly Ser Asp Ile Pro Leu Ala As - #p Leu Thr Pro Leu Ile105 1 - #10 1 - #15 1 -#20- GAA AAG GAT CGC GAT AAA TTC GTT GAG GCG CG - #G CTG ACA TTG TAC AGC6535Glu Lys Asp Arg Asp Lys Phe Val Glu Ala Ar - #g Leu Thr Leu Tyr Ser# 135- AAA AAC GGA AAG CTT TAC GGA CTC GAT ACA CA - #T GTA GGG ACA ACG GTC6583Lys Asn Gly Lys Leu Tyr Gly Leu Asp Thr Hi - #s Val Gly Thr Thr Val# 150- ATG TTT TAT AAC ATG GAT GTG ATG AAA AAA GC - #C GGC GTC AAT CCT GAC6631Met Phe Tyr Asn Met Asp Val Met Lys Lys Al - #a Gly Val Asn Pro Asp# 165- GAT ATT AAA ACA TGG GAT GAT TAC CAT AAA GC - #C GGA CAG AAA GTG CGC6679Asp Ile Lys Thr Trp Asp Asp Tyr His Lys Al - #a Gly Gln Lys Val Arg# 180- AAA GTG ACC GGG AAG CCG ATG GGA ACG GTG GA - #A ACA AAT GAT TCC GCA6727Lys Val Thr Gly Lys Pro Met Gly Thr Val Gl - #u Thr Asn Asp Ser Ala185 1 - #90 1 - #95 2 -#00- ACG TTC TTA TCT ATG ATT TCA CAG CAA AAC TC - #A GGC TAT TTT GAT AAA6775Thr Phe Leu Ser Met Ile Ser Gln Gln Asn Se - #r Gly Tyr Phe Asp Lys# 215- AAC GGC AAG CTG ATC CTC AAT AAT GAC ACC AA - #C GTA AAA ACA CTT CAA6823Asn Gly Lys Leu Ile Leu Asn Asn Asp Thr As - #n Val Lys Thr Leu Gln# 230- TAT TTA AAA GAC ATG ATC AAT GAT AAA ACG AT - #G ATT CCT GCG CCG GGC6871Tyr Leu Lys Asp Met Ile Asn Asp Lys Thr Me - #t Ile Pro Ala Pro Gly# 245- GGC GGG CAT CAC AGT GAA GAA TAC TAC GGC TT - #T ATG AAC CAA GGA GGA6919Gly Gly His His Ser Glu Glu Tyr Tyr Gly Ph - #e Met Asn Gln Gly Gly# 260- GCT GCT TCA GTT CTC ATG CCG ATT TGG TAT AT - #G GGA AGA TTT ATC GAT6967Ala Ala Ser Val Leu Met Pro Ile Trp Tyr Me - #t Gly Arg Phe Ile Asp265 2 - #70 2 - #75 2 -#80- TAT ATG CCT GAT CTG AAA GGG AAG ATT GCC AT - #C AGA CCG CTC CCG GCA7015Tyr Met Pro Asp Leu Lys Gly Lys Ile Ala Il - #e Arg Pro Leu Pro Ala# 295- TGG AAA GAG GGG GGC GAC CGC TCG GCA GGT TT - #G GGC GGT ACG GCA ACT7063Trp Lys Glu Gly Gly Asp Arg Ser Ala Gly Le - #u Gly Gly Thr Ala Thr# 310- GTT GTA CCG AAG CAA TCC AAG CAT GTT GAG TT - #A GCA AAA GAG TTT TTG7111Val Val Pro Lys Gln Ser Lys His Val Glu Le - #u Ala Lys Glu Phe Leu# 325- GCC TTT GCG AAG GGC TCT GAA GAA GGA AAT AA - #A AAA CTC TGG AGC GTA7159Ala Phe Ala Lys Gly Ser Glu Glu Gly Asn Ly - #s Lys Leu Trp Ser Val# 340- CTC GGC TTT GAC CCG CTT CGC TGG GAT GTT TG - #G AGC TCC AAG GAA TTG7207Leu Gly Phe Asp Pro Leu Arg Trp Asp Val Tr - #p Ser Ser Lys Glu Leu345 3 - #50 3 - #55 3 -#60- AAA GAG AAA AAC AAA TAC ACG GAT TAC TTC CA - #A AAC GGA ACA GGC ATT7255Lys Glu Lys Asn Lys Tyr Thr Asp Tyr Phe Gl - #n Asn Gly Thr Gly Ile# 375- TTT TCT GTG CTG CTC GAT ATC AAG GAT GAA AT - #C AAT CCA ATT TAT TTA7303Phe Ser Val Leu Leu Asp Ile Lys Asp Glu Il - #e Asn Pro Ile Tyr Leu# 390- CAT GAG GAT TTT GCC AAG GCT TCA GAC CTT GT - #C AAC AGA AGC GTA TTG7351His Glu Asp Phe Ala Lys Ala Ser Asp Leu Va - #l Asn Arg Ser Val Leu# 405- TTC GAC GCG CTT AAA TCT CAG CAA AAA ACG CC - #T AAA CAA GCC TTG GAC7399Phe Asp Ala Leu Lys Ser Gln Gln Lys Thr Pr - #o Lys Gln Ala Leu Asp# 420- AGA GCG GCA GGT GAA CTG AAA CAG AAA TAG AA - #TCCCATTC AAAAAGTGAA7449Arg Ala Ala Gly Glu Leu Lys Gln Lys *425 4 - #30#ACG GTT CAT CCC GTT 7500CT GTG AAA ACG GGA#Lys Pro Val Lys Thr Gly Thr Val His Pro V - #al# 10- CCT TCA GCT GCG AAA CAA TCA GGC TGG CGA GA - #T CTG TTT TAT TCA AAA7548Pro Ser Ala Ala Lys Gln Ser Gly Trp Arg As - #p Leu Phe Tyr Ser Lys# 25- AAA GCG GCG CCC TAT CTG TTT ACA GCG CCA TT - #C GTT TTA TCC TTT CTC7596Lys Ala Ala Pro Tyr Leu Phe Thr Ala Pro Ph - #e Val Leu Ser Phe Leu# 40- GTA TTT TTT CTA TAC CCC ATC ATT AGT GTC TT - #C ATC ATG AGC TTC CAA7644Val Phe Phe Leu Tyr Pro Ile Ile Ser Val Ph - #e Ile Met Ser Phe Gln# 60- AGA ATT TTG CCG GGA GAG GTG TCC TTT GTC GG - #A TTG TCT AAT TAT ACA7692Arg Ile Leu Pro Gly Glu Val Ser Phe Val Gl - #y Leu Ser Asn Tyr Thr# 75- GCG CTA AAC AAC CCG ACG TTC TAT ACC GCC CT - #T TGG AAT ACG CTG GAA7740Ala Leu Asn Asn Pro Thr Phe Tyr Thr Ala Le - #u Trp Asn Thr Leu Glu# 90- TAC ACC TTT TGG ACG CTG ATC GTG CTG ATT CC - #T GTT CCA TTG CTT CTG7788Tyr Thr Phe Trp Thr Leu Ile Val Leu Ile Pr - #o Val Pro Leu Leu Leu# 105- GCC ATA TTC CTG AAT TCA AAG CTG GTC AAA TT - #T AGA AAT ATA TTT AAA7836Ala Ile Phe Leu Asn Ser Lys Leu Val Lys Ph - #e Arg Asn Ile Phe Lys# 120- TCA GCA TTA TTT ATC CCG GCA TTG ACC TCA AC - #C ATT GTC GCG GGG ATC7884Ser Ala Leu Phe Ile Pro Ala Leu Thr Ser Th - #r Ile Val Ala Gly Ile125 1 - #30 1 - #35 1 -#40- ATT TTT CGG CTG ATC TTC GGA GAA ATG GAA AC - #G TCT CTG GCC AAT TCC7932Ile Phe Arg Leu Ile Phe Gly Glu Met Glu Th - #r Ser Leu Ala Asn Ser# 155- ATC CTA CTT AAA CTC GGC TTT TCA CCT CAG AA - #C TGG ATG AAC AAT GAA7980Ile Leu Leu Lys Leu Gly Phe Ser Pro Gln As - #n Trp Met Asn Asn Glu# 170- CAT ACC GGC ATG TTT TTG ATG GTG CTG CTT GC - #T TCA TGG AAA TGG ATG8028His Thr Gly Met Phe Leu Met Val Leu Leu Al - #a Ser Trp Lys Trp Met# 185- GGA ATC AAC ATC CTT TAC TTT TTA GCA GGT TT - #G CAA AAT GTG CCG AAA8076Gly Ile Asn Ile Leu Tyr Phe Leu Ala Gly Le - #u Gln Asn Val Pro Lys# 200- GAG CTG TAC GAA GCC GCT GAT ATA GAC GGC GC - #G AAT ACA ATG AAA AAA8124Glu Leu Tyr Glu Ala Ala Asp Ile Asp Gly Al - #a Asn Thr Met Lys Lys205 2 - #10 2 - #15 2 -#20- TTT CTG CAC ATC ACG CTG CCG TTT CTC AAG CC - #T GTA ACC GTA TAT GTG8172Phe Leu His Ile Thr Leu Pro Phe Leu Lys Pr - #o Val Thr Val Tyr Val# 235- CTG ACC ATC AGC ATC ATC GGC GGC TTC AGG AT - #G TTT GAG GAA AGC TAC8220Leu Thr Ile Ser Ile Ile Gly Gly Phe Arg Me - #t Phe Glu Glu Ser Tyr# 250- GTC CTT TGG CAG AAT AAT TCC CCG GGT AAT AT - #T GGT CTG ACG CTT GTC8268Val Leu Trp Gln Asn Asn Ser Pro Gly Asn Il - #e Gly Leu Thr Leu Val# 265- GGA TAT TTG TAT CAG CAG GGA CTT GCC TAC AA - #T GAA ATG GGA TAC GGA8316Gly Tyr Leu Tyr Gln Gln Gly Leu Ala Tyr As - #n Glu Met Gly Tyr Gly# 280- GCG GCC ATC GGC ATT GTG CTT TTG ATT GTG AT - #C CTT GTT GTC AGC CTG8364Ala Ala Ile Gly Ile Val Leu Leu Ile Val Il - #e Leu Val Val Ser Leu285 2 - #90 2 - #95 3 -#00- ATT TCA TTA AAG CTG TCA GGC TCG TTT AAG GG - #G GAG GGA TAA ATG TTG8412Ile Ser Leu Lys Leu Ser Gly Ser Phe Lys Gl - #y Glu Gly * Met Leu# 1- CGG CAC AGT CCT CAG TTT AGC GTT TAT AGA AT - #T GCG CTG ACC CTG TTT8460Arg His Ser Pro Gln Phe Ser Val Tyr Arg Il - #e Ala Leu Thr Leu Phe# 15- TTT ATG ATG CTG AGC CTA TTG TAT CTT TTT CC - #G ATT TTC TGT TTG CTT8508Phe Met Met Leu Ser Leu Leu Tyr Leu Phe Pr - #o Ile Phe Cys Leu Leu# 30- TTA GGA TCA TTA AAG CCG TCA TCT GAG CTT TT - #G CGT GTG GGG CTG AAT8556Leu Gly Ser Leu Lys Pro Ser Ser Glu Leu Le - #u Arg Val Gly Leu Asn# 50- CTT GAT ATT GAT CCA AAA GTG ATG AGT TTT GA - #T AAC TAC ACA TTT CTG8604Leu Asp Ile Asp Pro Lys Val Met Ser Phe As - #p Asn Tyr Thr Phe Leu# 65- TTT AAT GGC GGC AGC ATT TAT TTC AAA TGG TT - #T TTT AAC AGT CTT GTA8652Phe Asn Gly Gly Ser Ile Tyr Phe Lys Trp Ph - #e Phe Asn Ser Leu Val# 80- CTC GGA CTT TTT ACG ACT GTG CTC ACT CTG TT - #T TTT TCT TCG ATG ATC8700Leu Gly Leu Phe Thr Thr Val Leu Thr Leu Ph - #e Phe Ser Ser Met Ile# 95- GGG TAC GGG CTT GCG GTT TAT GAT TTT AAG GG - #C AGA AAT ATC ATC TTT8748Gly Tyr Gly Leu Ala Val Tyr Asp Phe Lys Gl - #y Arg Asn Ile Ile Phe# 110- GTT CTT GTG CTG ATT ATT ATG ATG GTT CCG CT - #G GAA GTG ATG ATG CTT8796Val Leu Val Leu Ile Ile Met Met Val Pro Le - #u Glu Val Met Met Leu115 1 - #20 1 - #25 1 -#30- CCT CTG TTT AAA CTT ACT GTC GGA CTG CAC TT - #G ATC GAT TCA TAT ACG8844Pro Leu Phe Lys Leu Thr Val Gly Leu His Le - #u Ile Asp Ser Tyr Thr# 145- GGT GTC ATA TTG CCG TTT ATC GTT TCA CCT GT - #T GCT GTT TTC TTT TTC8892Gly Val Ile Leu Pro Phe Ile Val Ser Pro Va - #l Ala Val Phe Phe Phe# 160- AGG CAA TAT GCT CTT GGC CTT CCA AGA GAT CT - #G CTG GAC TCT GCA AGG8940Arg Gln Tyr Ala Leu Gly Leu Pro Arg Asp Le - #u Leu Asp Ser Ala Arg# 175- ATG GAC GGC TGT ACG GAA TTC GGC ATC TTT TT - #C AGG ATT ATG GCA CCG8988Met Asp Gly Cys Thr Glu Phe Gly Ile Phe Ph - #e Arg Ile Met Ala Pro# 190- CTG ATG AAA CCG GCT TTC GGT GCG ATG ATT AT - #C CTT CAG TCC TTA AAC9036Leu Met Lys Pro Ala Phe Gly Ala Met Ile Il - #e Leu Gln Ser Leu Asn195 2 - #00 2 - #05 2 -#10- AGC TGG AAC AAC TTC TTG TGG CCG CTG ATT GT - #G CTT CGG TCG AAA GAA9084Ser Trp Asn Asn Phe Leu Trp Pro Leu Ile Va - #l Leu Arg Ser Lys Glu# 225- ATG TTT ACG CTT CCA ATA GGG CTG TCC AGC TT - #G CTG AGC CCT TAT GGA9132Met Phe Thr Leu Pro Ile Gly Leu Ser Ser Le - #u Leu Ser Pro Tyr Gly# 240- AAT AAT TAC GAC ATG CTT ATA TCC GGC TCA GT - #A TTT GCG ATT TTG CCG9180Asn Asn Tyr Asp Met Leu Ile Ser Gly Ser Va - #l Phe Ala Ile Leu Pro# 255- GTG ATT ATC ATT TTC TTG TTT TTC CAA AAG TA - #C TTT ATC TCC GGC CTG9228Val Ile Ile Ile Phe Leu Phe Phe Gln Lys Ty - #r Phe Ile Ser Gly Leu# 270- ACG GTA GGG GGA GTC AAA GGT TAA TGA AGGAGGAAA - #C GTGTG ATG AAA AAA9279# Met - # Lys Lys*# 1 2 - #80- GCG CGA ATG ATT GTA GAC AAA GAA TAT AAA AT - #C GGT GAA GTA GAT AAA9327Ala Arg Met Ile Val Asp Lys Glu Tyr Lys Il - #e Gly Glu Val Asp Lys# 15- CGG ATT TAT GGC TCG TTT ATC GAA CAT ATG GG - #T CGT GCG GTA TAT GAA9375Arg Ile Tyr Gly Ser Phe Ile Glu His Met Gl - #y Arg Ala Val Tyr Glu# 35- GGC ATA TAC GAG CCT GAT CAC CCT GAA GCG GA - #T GAA GAT GGA TTT AGA9423Gly Ile Tyr Glu Pro Asp His Pro Glu Ala As - #p Glu Asp Gly Phe Arg# 50- AAA GAT GTC CAG TCG CTG ATC AAA GAA TTA CA - #G GTT CCC ATC ATC CGC9471Lys Asp Val Gln Ser Leu Ile Lys Glu Leu Gl - #n Val Pro Ile Ile Arg# 65- TAT CCG GGC GGA AAC TTT TTA TCC GGA TAC AA - #C TGG GAG GAC GGT GTC9519Tyr Pro Gly Gly Asn Phe Leu Ser Gly Tyr As - #n Trp Glu Asp Gly Val# 80- GGA CCA GTC GAA AAC CGC CCG AGA CGG CTT GA - #C TTG GCA TGG CAA ACG9567Gly Pro Val Glu Asn Arg Pro Arg Arg Leu As - #p Leu Ala Trp Gln Thr# 95- ACA GAA ACC AAT GAA GTG GGA ACA AAT GAA TT - #T TTA TCT TGG GCA AAA9615Thr Glu Thr Asn Glu Val Gly Thr Asn Glu Ph - #e Leu Ser Trp Ala Lys100 1 - #05 1 - #10 1 -#15- AAG GTG AAC ACT GAG GTC AAT ATG GCC GTC AA - #C CTT GGC ACA AGA GGC9663Lys Val Asn Thr Glu Val Asn Met Ala Val As - #n Leu Gly Thr Arg Gly# 130- ATA GAT GCC GCC CGT AAT CTC GTT GAA TAT TG - #C AAC CAT CCG AAA GGC9711Ile Asp Ala Ala Arg Asn Leu Val Glu Tyr Cy - #s Asn His Pro Lys Gly# 145- TCT TAC TGG AGT GAT TTA AGA AGA TCG CAT GG - #C TAT GAA CAG CCG TAT9759Ser Tyr Trp Ser Asp Leu Arg Arg Ser His Gl - #y Tyr Glu Gln Pro Tyr# 160- GGC ATC AAA ACA TGG TGC TTA GGA AAC GAA AT - #G GAT GGA CCA TGG CAG9807Gly Ile Lys Thr Trp Cys Leu Gly Asn Glu Me - #t Asp Gly Pro Trp Gln# 175- ATC GGC CAC AAA ACA GCT GAT GAA TAC GGA CG - #G CTT GCC GCA GAG ACA9855Ile Gly His Lys Thr Ala Asp Glu Tyr Gly Ar - #g Leu Ala Ala Glu Thr180 1 - #85 1 - #90 1 -#95- GCA AAG GTC ATG AAG TGG GTT GAC CCA TCA AT - #T GAA CTC GTT GCC TGC9903Ala Lys Val Met Lys Trp Val Asp Pro Ser Il - #e Glu Leu Val Ala Cys# 210- GGC AGC TCA AAC AGC GGT ATG CCG ACC TTT AT - #C GAT TGG GAA GCG AAG9951Gly Ser Ser Asn Ser Gly Met Pro Thr Phe Il - #e Asp Trp Glu Ala Lys# 225- GTG CTT GAG CAT ACG TAT GAG CAT GTC GAC TA - #T ATC TCT CTT CAC ACT9999Val Leu Glu His Thr Tyr Glu His Val Asp Ty - #r Ile Ser Leu His Thr# 240- TAC TAC GGA AAC CGG GAT AAC AAT CTG CCA AA - #C TAC TTG GCA CGT TCT10047Tyr Tyr Gly Asn Arg Asp Asn Asn Leu Pro As - #n Tyr Leu Ala Arg Ser# 255- ATG GAT TTG GAT CAT TTT ATC AAA TCA GTC GC - #T GCG ACC TGT GAC TAT10095Met Asp Leu Asp His Phe Ile Lys Ser Val Al - #a Ala Thr Cys Asp Tyr260 2 - #65 2 - #70 2 -#75- GTA AAA GCA AAA ACA CGC AGC AAG AAA ACT AT - #C AAT CTC TCT CTG GAT10143Val Lys Ala Lys Thr Arg Ser Lys Lys Thr Il - #e Asn Leu Ser Leu Asp# 290- GAA TGG AAC GTC TGG TAC CAC TCA AAT GAG GC - #T GAT AAA AAA GTC GAG10191Glu Trp Asn Val Trp Tyr His Ser Asn Glu Al - #a Asp Lys Lys Val Glu# 305- CCG TGG ATC ACT GCG CGT CCG ATT TTA GAG GA - #T ATT TAC AAT TTT GAA10239Pro Trp Ile Thr Ala Arg Pro Ile Leu Glu As - #p Ile Tyr Asn Phe Glu# 320- GAT GCC TTA TTA GTC GGC TCT CTG CTC ATT AC - #G ATG CTG CAG CAC GCA10287Asp Ala Leu Leu Val Gly Ser Leu Leu Ile Th - #r Met Leu Gln His Ala# 335- GAC CGT GTG AAA ATT GCG TGT CTT GCA CAG CT - #T GTT AAT GTC ATC GCG10335Asp Arg Val Lys Ile Ala Cys Leu Ala Gln Le - #u Val Asn Val Ile Ala340 3 - #45 3 - #50 3 -#55- CCG ATC ATG ACG GAA AAA GGC GGA GAA GCA TG - #G AGA CAG CCG ATT TTC10383Pro Ile Met Thr Glu Lys Gly Gly Glu Ala Tr - #p Arg Gln Pro Ile Phe# 370- TAT CCA TAC ATG CAT GCT TCT GTT TAC GGA AG - #G GGC GAG TCA CTG AAA10431Tyr Pro Tyr Met His Ala Ser Val Tyr Gly Ar - #g Gly Glu Ser Leu Lys# 385- CCG CTT ATT TCT TCT CCT AAG TAC GAT TGT TC - #T GAT TTC ACT GAT GTG10479Pro Leu Ile Ser Ser Pro Lys Tyr Asp Cys Se - #r Asp Phe Thr Asp Val# 400- CCA TAT GTT GAT GCT GCT GTT GTG TAC TCT GA - #A GAG GAA GAA ACA CTC10527Pro Tyr Val Asp Ala Ala Val Val Tyr Ser Gl - #u Glu Glu Glu Thr Leu# 415- ACT ATT TTT GCG GTA AAC AAG GCT GAG GAT CA - #G ATG GAG ACG GAG ATT10575Thr Ile Phe Ala Val Asn Lys Ala Glu Asp Gl - #n Met Glu Thr Glu Ile420 4 - #25 4 - #30 4 -#35- TCG CTC AGA GGC TTT GAA TCC TAC CAA ATC GC - #A GAG CAC ATC GTA CTT10623Ser Leu Arg Gly Phe Glu Ser Tyr Gln Ile Al - #a Glu His Ile Val Leu# 450- GAG CAT CAG GAT ATC AAA GCA ACA AAC CAG CA - #T AAC AGA AAA AAT GTC10671Glu His Gln Asp Ile Lys Ala Thr Asn Gln Hi - #s Asn Arg Lys Asn Val# 465- GTT CCG CAT TCC AAC GGA TCA TCG TCT GTC AG - #C GAA AAC GGC TTA ACT10719Val Pro His Ser Asn Gly Ser Ser Ser Val Se - #r Glu Asn Gly Leu Thr# 480- GCT CAT TTC ACG CCG CTT TCC TGG AAT GTG AT - #C CGC CTG AAA AAA CAG10767Ala His Phe Thr Pro Leu Ser Trp Asn Val Il - #e Arg Leu Lys Lys Gln# 495- TCA TAA GAATAGCAAA GCCGGAGATT TCTCTCCGGC TTGTCTTTCA AC - #TGCCACGA10823Ser *500- GCCGGCCCAT TCCAGCCGGC TTTTTGTATA GGAAAAAATG ACCGCTTTTC AC - #CATGAAAT10883# 10917 AAAA CAGAAAAGGG GATG- (2) INFORMATION FOR SEQ ID NO:12:- (i) SEQUENCE CHARACTERISTICS:#acids (A) LENGTH: 496 amino (B) TYPE: amino acid (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: protein- (vi) ORIGINAL SOURCE:#subtilis (A) ORGANISM: Bacillus- (ix) FEATURE:#/product= "araA"ER INFORMATION:- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:12:- Met Leu Gln Thr Lys Asp Tyr Glu Phe Trp Ph - #e Val Thr Gly Ser Gln# 15- His Leu Tyr Gly Glu Glu Thr Leu Glu Leu Va - #l Asp Gln His Ala Lys# 30- Ser Ile Cys Glu Gly Leu Ser Gly Ile Ser Se - #r Arg Tyr Lys Ile Thr# 45- His Lys Pro Val Val Thr Ser Pro Glu Thr Il - #e Arg Glu Leu Leu Arg# 60- Glu Ala Glu Tyr Ser Glu Thr Cys Ala Gly Il - #e Ile Thr Trp Met His# 80- Thr Phe Ser Pro Ala Lys Met Trp Ile Glu Gl - #y Leu Ser Ser Tyr Gln# 95- Lys Pro Leu Met His Leu His Thr Gln Tyr As - #n Arg Asp Ile Pro Trp# 110- Gly Thr Ile Asp Met Asp Phe Met Asn Ser As - #n Gln Ser Ala His Gly# 125- Asp Arg Glu Tyr Gly Tyr Ile Asn Ser Arg Me - #t Gly Leu Ser Arg Lys# 140- Val Ile Ala Gly Tyr Trp Asp Asp Glu Glu Va - #l Lys Lys Glu Met Ser145 1 - #50 1 - #55 1 -#60- Gln Trp Met Asp Thr Ala Ala Ala Leu Asn Gl - #u Ser Arg His Ile Lys# 175- Val Ala Arg Phe Gly Asp Asn Met Arg His Va - #l Ala Val Thr Asp Gly# 190- Asp Lys Val Gly Ala His Ile Gln Phe Gly Tr - #p Gln Val Asp Gly Tyr# 205- Gly Ile Gly Asp Leu Val Glu Val Met Asp Ar - #g Ile Thr Asp Asp Glu# 220- Val Asp Thr Leu Tyr Ala Glu Tyr Asp Arg Le - #u Tyr Val Ile Ser Glu225 2 - #30 2 - #35 2 -#40- Glu Thr Lys Arg Asp Glu Ala Lys Val Ala Se - #r Ile Lys Glu Gln Ala# 255- Lys Ile Glu Leu Gly Leu Thr Ala Phe Leu Gl - #u Gln Gly Gly Tyr Thr# 270- Ala Phe Thr Thr Ser Phe Glu Val Leu His Gl - #y Met Lys Gln Leu Pro# 285- Gly Leu Ala Val Gln Arg Leu Met Glu Lys Gl - #y Tyr Gly Phe Ala Gly# 300- Glu Gly Asp Trp Lys Thr Ala Ala Leu Val Ar - #g Met Met Lys Ile Met305 3 - #10 3 - #15 3 -#20- Ala Lys Gly Lys Arg Thr Ser Phe Met Glu As - #p Tyr Thr Tyr His Phe# 335- Glu Pro Gly Asn Glu Met Ile Leu Gly Ser Hi - #s Met Leu Glu Val Cys# 350- Pro Thr Val Ala Leu Asp Gln Pro Lys Ile Gl - #u Val His Ser Leu Ser# 365- Ile Gly Gly Lys Glu Asp Pro Ala Arg Leu Va - #l Phe Asn Gly Ile Ser# 380- Gly Ser Ala Ile Gln Ala Ser Ile Val Asp Il - #e Gly Gly Arg Phe Arg385 3 - #90 3 - #95 4 -#00- Leu Val Leu Asn Glu Val Asn Gly Gln Glu Il - #e Glu Lys Asp Met Pro# 415- Asn Leu Pro Val Ala Arg Val Leu Trp Lys Pr - #o Glu Pro Ser Leu Lys# 430- Thr Ala Ala Glu Ala Trp Ile Leu Ala Gly Gl - #y Ala His His Thr Cys# 445- Leu Ser Tyr Glu Leu Thr Ala Glu Gln Met Le - #u Asp Trp Ala Glu Met# 460- Ala Gly Ile Glu Ser Val Leu Ile Ser Arg As - #p Thr Thr Ile His Lys465 4 - #70 4 - #75 4 -#80- Leu Lys His Glu Leu Lys Trp Asn Glu Ala Le - #u Tyr Arg Leu Gln Lys# 495- (2) INFORMATION FOR SEQ ID NO:13:- (i) SEQUENCE CHARACTERISTICS:#acids (A) LENGTH: 560 amino (B) TYPE: amino acid (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: protein- (vi) ORIGINAL SOURCE:#subtilis (A) ORGANISM: Bacillus- (ix) FEATURE:#/product= "araB"ER INFORMATION:- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:13:- Met Ala Tyr Thr Ile Gly Val Asp Phe Gly Th - #r Leu Ser Gly Arg Ala# 15- Val Leu Val His Val Gln Thr Gly Glu Glu Le - #u Ala Ala Ala Val Lys# 30- Glu Tyr Arg His Ala Val Ile Asp Thr Val Le - #u Pro Lys Thr Gly Gln# 45- Lys Leu Pro Arg Asp Trp Ala Leu Gln His Pr - #o Ala Asp Tyr Leu Glu# 60- Val Leu Glu Thr Thr Ile Pro Ser Leu Leu Gl - #u Gln Thr Gly Val Asp# 80- Pro Lys Asp Ile Ile Gly Ile Gly Ile Asp Ph - #e Thr Ala Cys Thr Ile# 95- Leu Pro Ile Asp Ser Ser Gly Gln Pro Leu Cy - #s Met Leu Pro Glu Tyr# 110- Glu Glu Glu Pro His Ser Tyr Val Lys Leu Tr - #p Lys His His Ala Ala# 125- Gln Lys His Ala Asp Arg Leu Asn Gln Ile Al - #a Glu Glu Glu Gly Glu# 140- Ala Phe Leu Gln Arg Tyr Gly Gly Lys Ile Se - #r Ser Glu Trp Met Ile145 1 - #50 1 - #55 1 -#60- Pro Lys Val Met Gln Ile Ala Glu Glu Ala Pr - #o His Ile Tyr Glu Ala# 175- Ala Asp Arg Ile Ile Glu Ala Ala Asp Trp Il - #e Val Tyr Gln Leu Cys# 190- Gly Ser Leu Lys Arg Ser Asn Cys Thr Ala Gl - #y Tyr Lys Ala Met Trp# 205- Ser Glu Lys Ala Gly Tyr Pro Ser Asp Asp Ph - #e Phe Glu Lys Leu Asn# 220- Pro Ser Met Lys Thr Ile Thr Lys Asp Lys Le - #u Ser Gly Ser Ile His225 2 - #30 2 - #35 2 -#40- Ser Val Gly Glu Lys Ala Gly Ser Leu Thr Gl - #u Lys Met Ala Lys Leu# 255- Thr Gly Leu Leu Pro Gly Thr Ala Val Ala Va - #l Ala Asn Val Asp Ala# 270- His Val Ser Val Pro Ala Val Gly Ile Thr Gl - #u Pro Gly Lys Met Leu# 285- Met Ile Met Gly Thr Ser Thr Cys His Val Le - #u Leu Gly Glu Glu Val# 300- His Ile Val Pro Gly Met Cys Gly Val Val As - #p Asn Gly Ile Leu Pro305 3 - #10 3 - #15 3 -#20- Gly Tyr Ala Gly Tyr Glu Ala Gly Gln Ser Cy - #s Val Gly Asp His Phe# 335- Asp Trp Phe Val Lys Thr Cys Val Pro Pro Al - #a Tyr Gln Glu Glu Ala# 350- Lys Glu Lys Asn Ile Gly Val His Glu Leu Le - #u Ser Glu Lys Ala Asn# 365- His Gln Ala Pro Gly Glu Ser Gly Leu Leu Al - #a Leu Asp Trp Trp Asn# 380- Gly Asn Arg Ser Thr Leu Val Asp Ala Asp Le - #u Thr Gly Met Leu Leu385 3 - #90 3 - #95 4 -#00- Gly Met Thr Leu Leu Thr Lys Pro Glu Glu Il - #e Tyr Arg Ala Leu Val# 415- Glu Ala Thr Ala Tyr Gly Thr Arg Met Ile Il - #e Glu Thr Phe Lys Glu# 430- Ser Gly Val Pro Ile Glu Glu Leu Phe Ala Al - #a Gly Gly Ile Ala Glu# 445- Lys Asn Pro Phe Val Met Gln Ile Tyr Ala As - #p Val Thr Asn Met Asp# 460- Ile Lys Ile Ser Gly Ser Pro Gln Ala Pro Al - #a Leu Gly Ser Ala Ile465 4 - #70 4 - #75 4 -#80- Phe Gly Ala Leu Ala Ala Gly Lys Glu Lys Gl - #y Gly Tyr Asp Asp Ile# 495- Lys Lys Ala Ala Ala Asn Met Gly Lys Leu Ly - #s Asp Ile Thr Tyr Thr# 510- Pro Asn Ala Glu Asn Ala Ala Val Tyr Glu Ly - #s Leu Tyr Ala Glu Tyr# 525- Lys Glu Leu Val His Tyr Phe Gly Lys Glu As - #n His Val Met Lys Arg# 540- Leu Lys Thr Ile Lys Asn Leu Gln Phe Ser Se - #r Ala Ala Lys Lys Asn545 5 - #50 5 - #55 5 -#60- (2) INFORMATION FOR SEQ ID NO:14:- (i) SEQUENCE CHARACTERISTICS:#acids (A) LENGTH: 229 amino (B) TYPE: amino acid (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: protein- (vi) ORIGINAL SOURCE:#subtilis (A) ORGANISM: Bacillus- (ix) FEATURE:#/product= "araD"ER INFORMATION:- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:14:- Met Leu Glu Thr Leu Lys Lys Glu Val Leu Al - #a Ala Asn Leu Lys Leu# 15- Gln Glu His Gln Leu Val Thr Phe Thr Trp Gl - #y Asn Val Ser Gly Ile# 30- Asp Arg Glu Lys Glu Arg Ile Val Ile Lys Le - #u Ala Glu Ser Asn Thr# 45- Ser Asp Leu Thr Ala Asp Asp Leu Val Val Le - #u Asn Leu Asp Gly Glu# 60- Val Val Glu Gly Ser Leu Lys Pro Ser Ser As - #p Thr Pro Thr His Val# 80- Tyr Leu Tyr Lys Ala Phe Pro Asn Ile Gly Gl - #y Ile Val His Thr His# 95- Ser Gln Trp Ala Thr Ser Trp Ala Gln Ser Gl - #y Arg Asp Ile Pro Pro# 110- Leu Gly Thr Thr His Ala Asp Tyr Phe Asp Se - #r Ala Ile Pro Cys Thr# 125- Arg Glu Met Tyr Asp Glu Glu Ile Ile His As - #p Tyr Glu Leu Asn Thr# 140- Gly Lys Val Ile Ala Glu Thr Phe Gln His Hi - #s Asn Tyr Glu Gln Val145 1 - #50 1 - #55 1 -#60- Pro Gly Val Leu Val Asn Asn His Gly Pro Ph - #e Cys Trp Gly Thr Asp# 175- Ala Leu Asn Ala Ile His Asn Ala Val Val Le - #u Glu Thr Val Ala Glu# 190- Met Ala Tyr His Ser Ile Met Leu Asn Lys As - #p Val Thr Pro Ile Asn# 205- Thr Val Leu His Glu Lys His Phe Tyr Arg Ly - #s His Gly Ala Asn Ala# 220- Tyr Tyr Gly Gln Ser225- (2) INFORMATION FOR SEQ ID NO:15:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 690 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: cDNA- (iii) HYPOTHETICAL: NO- (iv) ANTI-SENSE: NO- (vi) ORIGINAL SOURCE:#subtilis (A) ORGANISM: Bacillus- (ix) FEATURE: (A) NAME/KEY: mat.sub.-- - #peptide (B) LOCATION: 1..690- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:15:- ATGCTTGAAA CATTAAAAAA AGAAGTGCTG GCTGCCAACC TGAAGCTTCA AG - #AGCATCAG 60- CTGGTAACCT TTACGTGGGG AAATGTCAGC GGCATTGACC GTGAAAAAGA AA - #GAATTGTC 120- ATCAAACTAG CGGAGTCGAA TACCAGCGAC CTGACAGCCG ATGACTTGGT TG - #TTTTGAAC 180- CTTGATGGAG AGGTCGTCGA AGGCTCGCTT AAACCTTCTT CAGATACACC TA - #CCCATGTT 240- TATCTATATA AAGCCTTTCC GAATATCGGG GGAATTGTCC ATACCCATTC TC - #AATGGGCG 300- ACAAGCTGGG CGCAATCGGG CAGAGACATC CCTCCGTTAG GCACGACCCA TG - #CTGATTAT 360- TTTGACAGTG CGATTCCATG TACTCGAGAA ATGTACGATG AAGAAATCAT TC - #ATGACTAC 420- GAACTGAATA CAGGAAAAGT CATAGCGGAA ACCTTTCAGC ATCATAATTA CG - #AACAGGTG 480- CCGGGTGTGC TCGTGAATAA TCACGGACCG TTCTGCTGGG GCACTGACGC CT - #TAAATGCC 540- ATTCATAACG CAGTTGTATT AGAAACGGTT GCCGAAATGG CCTATCACTC CA - #TTATGCTG 600- AACAAGGATG TAACCCCAAT CAATACAGTC CTGCATGAAA AGCATTTTTA TC - #GAAAACAC 660# 690 ATGG CCAGTCATGA- (2) INFORMATION FOR SEQ ID NO:16:- (i) SEQUENCE CHARACTERISTICS:#acids (A) LENGTH: 500 amino (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: protein- (iii) HYPOTHETICAL: NO- (vi) ORIGINAL SOURCE:#coli (A) ORGANISM: Escherichia- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:16:- Met Thr Ile Phe Asp Asn Tyr Glu Val Trp Ph - #e Val Ile Gly Ser Gln# 15- His Leu Tyr Gly Pro Glu Thr Leu Arg Gln Va - #l Thr Gln His Ala Glu# 30- His Val Val Asn Ala Leu Asn Thr Glu Ala Ly - #s Leu Pro Cys Lys Leu# 45- Val Leu Lys Pro Leu Gly Thr Thr Pro Asp Gl - #u Ile Thr Ala Ile Cys# 60- Arg Asp Ala Asn Tyr Asp Asp Arg Cys Ala Gl - #y Leu Val Val Trp Leu#80- His Thr Phe Ser Pro Ala Lys Met Trp Ile As - #n Gly Leu Thr Met Leu# 95- Asn Lys Pro Leu Leu Gln Phe His Thr Gln Ph - #e Asn Ala Ala Leu Pro# 110- Trp Asp Ser Ile Asp Met Asp Phe Met Asn Le - #u Asn Gln Thr Ala His# 125- Gly Gly Arg Glu Phe Gly Phe Ile Gly Ala Ar - #g Met Arg Gln Gln His# 140- Ala Val Val Thr Gly His Trp Gln Asp Lys Gl - #n Ala His Glu Arg Ile145 1 - #50 1 - #55 1 -#60- Gly Ser Trp Met Arg Gln Ala Val Ser Lys Gl - #n Asp Thr Arg His Leu# 175- Lys Val Cys Arg Phe Gly Asp Asn Met Arg Gl - #u Val Ala Val Thr Asp# 190- Gly Asp Lys Val Ala Ala Gln Ile Lys Phe Gl - #y Phe Ser Val Asn Thr# 205- Trp Ala Val Gly Asp Leu Val Gln Val Val As - #n Ser Ile Ser Asp Gly# 220- Asp Val Asn Ala Leu Val Asp Glu Tyr Glu Se - #r Cys Tyr Thr Met Thr225 2 - #30 2 - #35 2 -#40- Pro Ala Thr Gln Ile His Gly Glu Lys Arg Gl - #n Asn Val Leu Glu Ala# 255- Ala Arg Ile Glu Leu Gly Met Lys Arg Phe Le - #u Glu Gln Gly Gly Phe# 270- His Ala Phe Thr Thr Thr Phe Glu Asp Leu Hi - #s Gly Leu Lys Gln Leu# 285- Pro Gly Leu Ala Val Gln Arg Leu Met Gln Gl - #n Gly Tyr Gly Phe Ala# 300- Gly Glu Gly Asp Trp Lys Thr Ala Ala Leu Le - #u Arg Ile Met Lys Val305 3 - #10 3 - #15 3 -#20- Met Ser Thr Gly Leu Gln Gly Gly Thr Ser Ph - #e Met Glu Asp Tyr Thr# 335- Tyr His Phe Glu Lys Gly Asn Asp Leu Val Le - #u Gly Ser His Met Leu# 350- Glu Val Cys Pro Ser Ile Ala Val Glu Glu Ly - #s Pro Ile Leu Asp Val# 365- Gln His Leu Gly Ile Gly Gly Lys Asp Asp Pr - #o Ala Arg Leu Ile Phe# 380- Asn Thr Gln Thr Gly Pro Ala Ile Val Ala Se - #r Leu Ile Asp Leu Gly385 3 - #90 3 - #95 4 -#00- Asp Arg Tyr Arg Leu Leu Val Asn Cys Ile As - #p Thr Val Lys Thr Pro# 415- His Ser Leu Pro Lys Leu Pro Val Ala Asn Al - #a Leu Trp Lys Ala Gln# 430- Pro Asp Leu Pro Thr Ala Ser Glu Ala Trp Il - #e Leu Ala Gly Gly Ala# 445- His His Thr Val Phe Ser His Ala Leu Asn Le - #u Asn Asp Met Arg Gln# 460- Phe Ala Glu Met His Asp Ile Glu Ile Thr Va - #l Ile Asp Asn Asp Thr465 4 - #70 4 - #75 4 -#80- Arg Leu Pro Ala Phe Lys Asp Ala Leu Arg Tr - #p Asn Glu Val Tyr Tyr# 495- Gly Phe Arg Arg 500- (2) INFORMATION FOR SEQ ID NO:17:- (i) SEQUENCE CHARACTERISTICS:#acids (A) LENGTH: 500 amino (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: protein- (iii) HYPOTHETICAL: NO- (vi) ORIGINAL SOURCE:#typhimurium) ORGANISM: Salmonella- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:17:- Met Thr Ile Phe Asp Asn Tyr Glu Val Trp Ph - #e Val Ile Gly Ser Gln# 15- His Leu Tyr Gly Ala Glu Thr Leu Arg Gln Va - #l Thr Gln His Ala Glu# 30- His Val Val Asn Ala Leu Asn Thr Glu Ala Ly - #s Leu Pro Cys Lys Leu# 45- Val Leu Lys Pro Leu Gly Thr Ser Pro Asp Gl - #u Ile Thr Ala Ile Cys# 60- Arg Asp Ala Asn Tyr Asp Asp Arg Cys Ala Gl - #y Leu Val Val Trp Leu#80- His Thr Phe Ser Pro Ala Lys Met Trp Ile As - #n Gly Leu Ser Ile Leu# 95- Asn Lys Pro Leu Leu Gln Phe His Thr Gln Ph - #e Asn Ala Ala Leu Pro# 110- Trp Asp Ser Ile Asp Met Asp Phe Met Asn Le - #u Asn Gln Thr Ala His# 125- Gly Gly Arg Glu Phe Gly Phe Ile Gly Ala Ar - #g Met Arg Gln Gln His# 140- Ala Val Val Thr Gly His Trp Gln Asp Lys Gl - #u Ala His Thr Arg Ile145 1 - #50 1 - #55 1 -#60- Gly Ala Trp Met Arg Gln Ala Val Ser Lys Gl - #n Asp Thr Arg Gln Leu# 175- Lys Val Cys Arg Phe Gly Asp Asn Met Arg Gl - #u Val Ala Val Thr Asp# 190- Gly Asp Lys Val Ala Ala Gln Ile Lys Phe Gl - #y Phe Ser Val Asn Thr# 205- Trp Ala Val Gly Asp Leu Val Gln Val Val As - #n Ser Ile Gly Asp Gly# 220- Asp Ile Asn Ala Leu Ile Asp Glu Tyr Glu Se - #r Ser Tyr Thr Leu Thr225 2 - #30 2 - #35 2 -#40- Pro Ala Thr Gln Ile His Gly Asp Lys Arg Gl - #n Asn Val Arg Glu Ala# 255- Ala Gly Ile Glu Leu Gly Met Lys Arg Phe Le - #u Glu Gln Gly Gly Phe# 270- His Ala Phe Thr Thr Thr Phe Glu Asp Leu Hi - #s Gly Leu Lys Gln Leu# 285- Pro Gly Leu Ala Val Gln Arg Leu Met Gln Gl - #n Gly Tyr Gly Phe Ala# 300- Gly Glu Gly Asp Trp Lys Thr Ala Ala Leu Le - #u Arg Ile Met Lys Val305 3 - #10 3 - #15 3 -#20- Met Ser Thr Gly Leu Gln Gly Gly Thr Ser Ph - #e Met Glu Asp Tyr Thr# 335- Tyr His Phe Glu Lys Gly Asn Asp Leu Val Le - #u Gly Ser His Met Leu# 350- Glu Val Cys Pro Ser Ile Ala Val Glu Glu Ly - #s Pro Ile Leu Asp Val# 365- Gln His Leu Gly Ile Gly Gly Lys Glu Asp Pr - #o Ala Arg Leu Ile Phe# 380- Asn Thr Gln Thr Gly Pro Ala Ile Val Ala Se - #r Leu Ile Asp Leu Gly385 3 - #90 3 - #95 4 -#00- Asp Arg Tyr Arg Leu Leu Val Asn Cys Ile As - #p Thr Val Lys Thr Pro# 415- His Ser Leu Pro Lys Leu Pro Val Arg Asn Al - #a Leu Trp Lys Ala Gln# 430- Pro Asp Leu Pro Thr Ala Ser Glu Ala Trp Il - #e Leu Ala Gly Gly Ala# 445- His His Thr Val Phe Ser His Ala Leu Asp Le - #u Asn Asp Met Arg Gln# 460- Phe Ala Glu Ile His Asp Ile Glu Ile Ala Va - #l Ile Asp Asn Asp Thr465 4 - #70 4 - #75 4 -#80- His Leu Pro Ala Phe Lys Asp Ala Leu Arg Tr - #p Asn Glu Val Tyr Tyr# 495- Gly Phe Lys Arg 500- (2) INFORMATION FOR SEQ ID NO:18:- (i) SEQUENCE CHARACTERISTICS:#acids (A) LENGTH: 566 amino (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: protein- (iii) HYPOTHETICAL: NO- (vi) ORIGINAL SOURCE:#coli (A) ORGANISM: Escherichia- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:18:- Met Ala Ile Ala Ile Gly Leu Asp Phe Gly Se - #r Asp Ser Val Arg Ala# 15- Leu Ala Val Asp Cys Ala Ser Gly Glu Glu Il - #e Ala Thr Ser Val Glu# 30- Trp Tyr Pro Arg Trp Gln Lys Gly Gln Phe Cy - #s Asp Ala Pro Asn Asn# 45- Gln Phe Arg His His Pro Arg Asp Tyr Ile Gl - #u Ser Met Glu Ala Ala# 60- Leu Lys Thr Val Leu Ala Glu Leu Ser Val Gl - #u Gln Arg Ala Ala Val#80- Val Gly Ile Gly Val Asp Ser Thr Gly Ser Th - #r Pro Ala Pro Ile Asp# 95- Ala Asp Gly Asn Val Leu Ala Leu Arg Pro Gl - #u Phe Ala Glu Asn Pro# 110- Asn Ala Met Phe Val Leu Trp Lys Asp His Th - #r Ala Val Glu Arg Ser# 125- Glu Glu Ile Thr Arg Leu Cys His Ala Pro Gl - #y Asn Val Asp Tyr Ser# 140- Arg Tyr Ile Gly Gly Ile Tyr Ser Ser Glu Tr - #p Phe Trp Ala Lys Ile145 1 - #50 1 - #55 1 -#60- Leu His Val Thr Arg Gln Asp Ser Ala Val Al - #a Gln Ser Ala Ala Ser# 175- Trp Ile Glu Leu Cys Asp Trp Val Pro Ala Le - #u Leu Ser Gly Thr Thr# 190- Arg Pro Gln Asp Ile Arg Arg Gly Arg Cys Se - #r Ala Gly His Lys Ser# 205- Leu Trp His Glu Ser Trp Gly Gly Leu Pro Pr - #o Ala Ser Phe Phe Asp# 220- Glu Leu Asp Pro Ile Leu Asn Arg His Leu Pr - #o Ser Pro Leu Phe Thr225 2 - #30 2 - #35 2 -#40- Asp Thr Trp Thr Ala Asp Ile Pro Val Gly Th - #r Leu Cys Pro Glu Trp# 255- Ala Gln Arg Leu Gly Leu Pro Glu Ser Val Va - #l Ile Ser Gly Gly Ala# 270- Phe Asp Cys His Met Gly Ala Val Gly Ala Gl - #y Ala Gln Pro Asn Ala# 285- Leu Val Lys Val Ile Gly Thr Ser Thr Cys As - #p Ile Leu Ile Ala Asp# 300- Lys Gln Ser Val Gly Glu Arg Ala Val Lys Gl - #y Ile Cys Gly Gln Val305 3 - #10 3 - #15 3 -#20- Asp Gly Ser Val Val Pro Gly Phe Ile Gly Le - #u Glu Ala Gly Gln Ser# 335- Ala Phe Gly Asp Ile Tyr Ala Trp Phe Gly Ar - #g Val Leu Ser Trp Pro# 350- Leu Glu Gln Leu Ala Ala Gln His Pro Glu Le - #u Lys Ala Gln Ile Asn# 365- Ala Ser Gln Lys Gln Leu Leu Pro Ala Leu Th - #r Glu Ala Trp Ala Lys# 380- Asn Pro Ser Leu Asp His Leu Pro Val Val Le - #u Asp Trp Phe Asn Gly385 3 - #90 3 - #95 4 -#00- Arg Arg Ser Pro Asn Ala Asn Gln Arg Leu Ly - #s Gly Val Ile Thr Asp# 415- Leu Asn Leu Ala Thr Asp Ala Pro Leu Leu Ph - #e Gly Gly Leu Ile Ala# 430- Ala Thr Ala Phe Gly Ala Arg Ala Ile Met Gl - #u Cys Phe Thr Asp Gln# 445- Gly Ile Ala Val Asn Asn Val Met Ala Leu Gl - #y Gly Ile Ala Arg Lys# 460- Asn Gln Val Ile Met Gln Ala Cys Cys Asp Va - #l Leu Asn Arg Pro Leu465 4 - #70 4 - #75 4 -#80- Gln Ile Val Ala Ser Asp Gln Cys Cys Ala Le - #u Gly Ala Ala Ile Phe# 495- Ala Ala Val Ala Ala Lys Val His Ala Asp Il - #e Pro Ser Ala Gln Gln# 510- Lys Met Ala Ser Ala Val Glu Lys Thr Leu Gl - #n Pro Arg Ser Glu Gln# 525- Ala Gln Arg Phe Glu Gln Leu Tyr Arg Arg Ty - #r Gln Gln Trp Ala Met# 540- Ser Ala Glu Gln His Tyr Leu Pro Thr Ser Al - #a Pro Ala Gln Ala Ala545 5 - #50 5 - #55 5 -#60- Gln Ala Val Ala Thr Leu 565- (2) INFORMATION FOR SEQ ID NO:19:- (i) SEQUENCE CHARACTERISTICS:#acids (A) LENGTH: 569 amino (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: protein- (iii) HYPOTHETICAL: NO- (vi) ORIGINAL SOURCE:#typhimurium) ORGANISM: Salmonella- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:19:- Met Ala Ile Ala Ile Gly Leu Asp Phe Gly Se - #r Asp Ser Val Arg Ala# 15- Leu Ala Val Asp Cys Ala Thr Gly Asp Glu Il - #e Ala Thr Ser Val Glu# 30- Trp Tyr Pro Arg Trp Gln Glu Gly Arg Tyr Cy - #s Asp Gly Pro Asn Asn# 45- Gln Phe Arg His His Pro Arg Asp Tyr Met Gl - #u Ser Met Glu Ala Ala# 60- Leu Lys Ala Val Leu Ala Gln Leu Ser Ala Al - #a Gln Arg Ala Asn Val#80- Val Gly Ile Gly Val Asp Ser Thr Gly Ser Th - #r Pro Ala Pro Ile Asp# 95- Ala Asp Gly Asn Val Leu Ala Leu Arg Pro Gl - #u Phe Ala Glu Asn Pro# 110- Asn Ala Met Phe Val Leu Trp Lys Asp His Th - #r Ala Val Glu Glu Ala# 125- Asp Glu Ile Thr Arg Leu Cys His Lys Pro Gl - #y Lys Val Asp Tyr Ser# 140- Arg Tyr Ile Gly Gly Ile Tyr Ser Ser Glu Tr - #p Phe Trp Ala Lys Ile145 1 - #50 1 - #55 1 -#60- Leu His Val Thr Arg Gln Asp Ser Ala Val Al - #a Gln Ala Ala Val Ser# 175- Trp Ile Glu Leu Cys Asp Trp Val Pro Ala Le - #u Leu Ser Gly Thr Thr# 190- Arg Pro Gln Asp Ile Arg Arg Gly Arg Cys Se - #r Ala Gly His Lys Thr# 205- Leu Trp His Glu Ser Trp Gly Gly Leu Pro Pr - #o Ala Ser Phe Phe Asp# 220- Glu Leu Asp Pro Cys Ile Asn Arg His Leu Ar - #g Tyr Pro Leu Phe Ser225 2 - #30 2 - #35 2 -#40- Glu Thr Phe Thr Ala Asp Leu Pro Val Gly Th - #r Leu Cys Ala Glu Trp# 255- Ala Gln Arg Leu Asp Leu Pro Glu Ser Val Va - #l Ile Ser Gly Gly Ala# 270- Phe Asp Cys His Met Gly Ala Val Gly Ala Gl - #y Ala Gln Pro Asn Thr# 285- Leu Val Lys Val Ile Gly Thr Ser Thr Cys As - #p Ile Leu Ile Ala Asp# 300- Lys Gln Ser Val Gly Asp Arg Ala Val Lys Gl - #y Ile Cys Gly Gln Val305 3 - #10 3 - #15 3 -#20- Asp Gly Ser Val Val Pro Asn Phe Ile Gly Le - #u Glu Ala Gly Gln Ser# 335- Ala Phe Gly Asp Ile Tyr Ala Trp Phe Ser Ar - #g Val Leu Ser Trp Pro# 350- Leu Glu Gln Leu Ala Ala Gln His Pro Glu Le - #u Lys Pro Gln Ile Asn# 365- Ala Ser Gln Lys Gln Leu Leu Pro Ala Leu Th - #r Asp Ala Trp Ala Lys# 380- Asn Pro Ser Leu Asp His Leu Pro Val Val Le - #u Asp Trp Phe Asn Gly385 3 - #90 3 - #95 4 -#00- Arg Arg Thr Pro Asn Ala Asn Gln Arg Leu Ly - #s Gly Val Ile Thr Asp# 415- Leu Asn Leu Ala Thr Asp Ala Pro Ala Leu Ph - #e Gly Gly Leu Val Ala# 430- Ser Thr Ala Phe Gly Ala Arg Ala Ile Gln Gl - #u Cys Phe Thr Asp Gln# 445- Gly Ile Ala Val Asn Asn Val Met Ala Leu Gl - #y Gly Ile Ala Arg Lys# 460- Asn Gln Val Ile Met Gln Val Cys Cys Asp Va - #l Leu Asn Arg Pro Leu465 4 - #70 4 - #75 4 -#80- Gln Ile Val Ala Ser Asp Gln Cys Cys Ala Le - #u Gly Ala Ala Ile Phe# 495- Ala Ala Val Ala Ala Lys Val His Ala Asp Il - #e Pro Ala Ala Gln Gln# 510- Ser Met Ala Ser Ala Val Glu Arg Thr Leu Ar - #g Pro His Pro Glu Gln# 525- Ala Gln Arg Phe Glu Gln Leu Tyr Arg Arg Ty - #r Gln Gln Trp Ala Leu# 540- Ser Ala Glu Gln His Tyr Leu Pro Thr Ala Al - #a Pro Ala Pro Thr Thr545 5 - #50 5 - #55 5 -#60- Pro Ala Asn Gln Ala Ile Leu Thr His 565- (2) INFORMATION FOR SEQ ID NO:20:- (i) SEQUENCE CHARACTERISTICS:#acids (A) LENGTH: 231 amino (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: protein- (iii) HYPOTHETICAL: NO- (vi) ORIGINAL SOURCE:#coli (A) ORGANISM: Escherichia- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:20:- Met Leu Glu Asp Leu Lys Arg Gln Val Leu Gl - #u Ala Asn Leu Ala Leu# 15- Pro Lys His Asn Leu Val Thr Leu Thr Trp Gl - #y Asn Val Ser Ala Val# 30- Asp Arg Glu Arg Gly Val Phe Val Ile Lys Pr - #o Ser Gly Val Asp Tyr# 45- Ser Ile Met Thr Ala Asp Asp Met Val Val Va - #l Ser Ile Glu Thr Gly# 60- Glu Val Val Glu Gly Ala Lys Lys Pro Ser Se - #r Asp Thr Pro Thr His#80- Arg Leu Leu Tyr Gln Ala Phe Pro Ser Ile Gl - #y Gly Ile Val His Thr# 95- His Ser Arg His Ala Thr Ile Trp Ala Gln Al - #a Gly Gln Ser Ile Pro# 110- Ala Thr Gly Thr Thr His Ala Asp Tyr Phe Ty - #r Gly Thr Ile Pro Cys# 125- Thr Arg Lys Met Thr Asp Ala Glu Ile Asn Gl - #y Glu Tyr Glu Trp Glu# 140- Thr Gly Asn Val Ile Val Glu Thr Phe Glu Ly - #s Gln Gly Ile Asp Ala145 1 - #50 1 - #55 1 -#60- Ala Gln Met Pro Gly Val Leu Val His Ser Hi - #s Gly Pro Phe Ala Trp# 175- Gly Lys Asn Ala Glu Asp Ala Val His Asn Al - #a Ile Val Leu Glu Glu# 190- Val Ala Tyr Met Gly Ile Phe Cys Arg Gln Le - #u Ala Pro Gln Leu Pro# 205- Asp Met Gln Gln Thr Leu Leu Asn Lys His Ty - #r Leu Arg Lys His Gly# 220- Ala Lys Ala Tyr Tyr Gly Gln225 2 - #30- (2) INFORMATION FOR SEQ ID NO:21:- (i) SEQUENCE CHARACTERISTICS:#acids (A) LENGTH: 240 amino (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (iii) HYPOTHETICAL: NO- (iv) ANTI-SENSE: NO- (vi) ORIGINAL SOURCE:#typhimurium) ORGANISM: Salmonella- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:21:- Met Leu Glu Asp Leu Lys Arg Gln Val Leu Gl - #u Ala Asn Leu Ala Leu# 15- Pro Lys His Asn Leu Val Thr Leu Thr Trp Gl - #y Asn Val Ser Ala Val# 30- Asp Arg Glu Arg Gly Val Leu Val Ile Lys Pr - #o Ser Gly Val Asp Tyr# 45- Ser Val Met Thr Ala Asp Asp Met Val Val Va - #l Ser Leu Glu Ser Gly# 60- Glu Val Val Glu Gly His Lys Lys Pro Ser Se - #r Asp Thr Pro Thr His#80- Arg Leu Leu Tyr Gln Ala Phe Pro Thr Ile Gl - #y Gly Ile Val His Thr# 95- His Ser Arg His Ala Thr Ile Trp Ala Gln Al - #a Gly Gln Pro Ile Pro# 110- Ala Thr Gly Thr Thr His Ala Asp Tyr Phe Ty - #r Gly Thr Ile Pro Cys# 125- Thr Arg Lys Met Thr Glu Ala Glu Ile Asn Gl - #y Glu Tyr Glu Trp Glu# 140- Thr Gly Asn Val Ile Val Glu Thr Phe Glu Ly - #s Gln Gly Ile Asp Ala145 1 - #50 1 - #55 1 -#60- Ala Gln Met Pro Gly Val Leu Val His Ser Hi - #s Gly Pro Phe Ala Trp# 175- Gly Lys Asn Ala Glu Asp Ala Val His Asn Al - #a Ile Val Leu Glu Glu# 190- Val Ala Tyr Met Gly Ile Phe Cys Arg His Le - #u Arg Arg Ser Cys Pro# 205- Thr Cys Ser Asn Pro Cys Trp Ile Asn Thr Il - #e Tyr Ala Asn Thr Ala# 220- Gln Lys Pro Ile Thr Gly Ser Asn Ala Ser Ly - #s Asn Ala Ser His Gly225 2 - #30 2 - #35 2 -#40- (2) INFORMATION FOR SEQ ID NO:22:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 27 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: DNA (genomic)- (iii) HYPOTHETICAL: NO- (iv) ANTI-SENSE: NO- (vi) ORIGINAL SOURCE:#subtilis (A) ORGANISM: Bacillus- (ix) FEATURE:--> "araB"(D) OTHER INFORMATION:- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:22:# 27 TCAC ATGGCTT- (2) INFORMATION FOR SEQ ID NO:23:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 28 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: DNA (genomic)- (iii) HYPOTHETICAL: NO- (iv) ANTI-SENSE: NO- (vi) ORIGINAL SOURCE:#subtilis (A) ORGANISM: Bacillus- (ix) FEATURE:--> "araD"(D) OTHER INFORMATION:- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:23:# 28 TGGA GCATGCTT- (2) INFORMATION FOR SEQ ID NO:24:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 12 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: DNA (genomic)- (iii) HYPOTHETICAL: NO- (iv) ANTI-SENSE: NO- (vi) ORIGINAL SOURCE:#subtilis (A) ORGANISM: Bacillus- (ix) FEATURE: (A) NAME/KEY: misc.sub.-- - #feature (B) LOCATION: 1..23- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:24:# 12- (2) INFORMATION FOR SEQ ID NO:25:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 19 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: DNA (genomic)- (iii) HYPOTHETICAL: NO- (iv) ANTI-SENSE: NO- (vi) ORIGINAL SOURCE:#subtilis (A) ORGANISM: Bacillus- (ix) FEATURE: (A) NAME/KEY: misc.sub.-- - #feature (B) LOCATION: 1..23- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:25:# 19 CCC- (2) INFORMATION FOR SEQ ID NO:26:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 17 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: DNA (genomic)- (iii) HYPOTHETICAL: NO- (iv) ANTI-SENSE: NO- (vi) ORIGINAL SOURCE:#subtilis (A) ORGANISM: Bacillus- (ix) FEATURE: (A) NAME/KEY: misc.sub.-- - #feature (B) LOCATION: 1..23- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:26:# 17 G- (2) INFORMATION FOR SEQ ID NO:27:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 40 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: DNA (genomic)- (iii) HYPOTHETICAL: NO- (iv) ANTI-SENSE: NO- (vi) ORIGINAL SOURCE:#subtilis (A) ORGANISM: Bacillus- (ix) FEATURE:--> "araD"(D) OTHER INFORMATION:- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:27:# 40 GCGT ATTATGGCCA AGTCATGATA- (2) INFORMATION FOR SEQ ID NO:28:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 12 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: RNA (genomic)- (iii) HYPOTHETICAL: NO- (iv) ANTI-SENSE: NO- (vi) ORIGINAL SOURCE:#subtilis (A) ORGANISM: Bacillus- (ix) FEATURE: (A) NAME/KEY: rRNA (B) LOCATION: 1..15- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:28:# 12- (2) INFORMATION FOR SEQ ID NO:29:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 28 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: DNA (genomic)- (iii) HYPOTHETICAL: NO- (iv) ANTI-SENSE: NO- (vi) ORIGINAL SOURCE:#subtilis (A) ORGANISM: Bacillus- (ix) FEATURE:#"araA" (D) OTHER INFORMATION:- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:29:# 28 AGTT TACATGCT- (2) INFORMATION FOR SEQ ID NO:30:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 29 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: DNA (genomic)- (iii) HYPOTHETICAL: NO- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:30:# 29 CTGA TATGAATCG- (2) INFORMATION FOR SEQ ID NO:31:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 37 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: DNA (genomic)- (iii) HYPOTHETICAL: NO- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:31:# 37 AATG GAAGGGGTAA CGCGATG- (2) INFORMATION FOR SEQ ID NO:32:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 11 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: RNA (genomic)- (iii) HYPOTHETICAL: NO- (iv) ANTI-SENSE: NO- (vi) ORIGINAL SOURCE:#subtilis (A) ORGANISM: Bacillus- (ix) FEATURE: (A) NAME/KEY: rRNA (B) LOCATION: 1..15- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:32:# 11- (2) INFORMATION FOR SEQ ID NO:33:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 41 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: DNA (genomic)- (iii) HYPOTHETICAL: NO- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:33:# 41 AAGT GAAAGAGGGG AGGTTCTCAT G- (2) INFORMATION FOR SEQ ID NO:34:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 13 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: RNA (genomic)- (iii) HYPOTHETICAL: NO- (iv) ANTI-SENSE: NO- (vi) ORIGINAL SOURCE:#subtilis (A) ORGANISM: Bacillus- (ix) FEATURE: (A) NAME/KEY: rRNA (B) LOCATION: 1..15- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:34:# 13- (2) INFORMATION FOR SEQ ID NO:35:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 1491 base (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: cDNA- (iii) HYPOTHETICAL: NO- (vi) ORIGINAL SOURCE:#subtilis (A) ORGANISM: Bacillus- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:35:- ATGCTTCAGA CAAAGGATTA TGAATTCTGG TTTGTGACAG GAAGCCAGCA CC - #TATACGGG 60- GAAGAGACGC TGGAACTCGT AGATCAGCAT GCTAAAAGCA TTTGTGAGGG GC - #TCAGCGGG 120- ATTTCTTCCA GATATAAAAT CACTCATAAG CCCGTCGTCA CTTCACCGGA AA - #CCATTAGA 180- GAGCTGTTAA GAGAAGCGGA GTACAGTGAG ACATGTGCTG GCATCATTAC AT - #GGATGCAC 240- ACATTTTCCC CTGCAAAAAT GTGGATAGAA GGCCTTTCCT CTTATCAAAA AC - #CGCTTATG 300- CATTTGCATA CCCAATATAA TCGCGATATC CCGTGGGGTA CGATTGACAT GG - #ATTTTATG 360- AACAGCAACC AATCCGCGCA TGGCGATCGA GAGTACGGTT ACATCAACTC GA - #GAATGGGG 420- CTTAGCCGAA AAGTCATTGC CGGCTATTGG GATGATGAAG AAGTGAAAAA AG - #AAATGTCC 480- CAGTGGATGG ATACGGCGGC TGCATTAAAT GAAAGCAGAC ATATTAAGGT TG - #CCAGATTT 540- GGAGATAACA TGCGTCATGT CGCGGTAACG GACGGAGACA AGGTGGGAGC GC - #ATATTCAA 600- TTTGGCTGGC AGGTTGACGG ATATGGCATC GGGGATCTCG TTGAAGTGAT GG - #ATCGCATT 660- ACGGACGACG AGGTTGACAC GCTTTATGCC GAGTATGACA GACTATATGT GA - #TCAGTGAG 720- GAAACAAAAC GTGACGAAGC AAAGGTAGCG TCCATTAAAG AACAGGCGAA AA - #TTGAACTT 780- GGATTAACCG CTTTTCTTGA GCAAGGCGGA TACACAGCGT TTACGACATC GT - #TTGAAGTG 840- CTGCACGGAA TGAAACAGCT GCCGGGACTT GCCGTTCAGC GCCTGATGGA GA - #AAGGCTAT 900- GGGTTTGCCG GTGAAGGAGA TTGGAAGACA GCGGCCCTTG TACGGATGAT GA - #AAATCATG 960- GCTAAAGGAA AAAGAACTTC CTTCATGGAA GATTACACGT ACCATTTTGA AC - #CGGGAAAT1020- GAAATGATTC TGGGCTCTCA CATGCTTGAA GTGTGTCCGA CTGTCGCTTT GG - #ATCAGCCG1080- AAAATCGAGG TTCATTCGCT TTCGATTGGC GGCAAAGAGG ACCCTGCGCG TT - #TGGTATTT1140- AACGGCATCA GCGGTTCTGC CATTCAAGCT AGCATTGTTG ATATTGGCGG GC - #GTTTCCGC1200- CTTGTGCTGA ATGAAGTCAA CGGCCAGGAA ATTGAAAAAG ACATGCCGAA TT - #TACCGGTT1260- GCCCGTGTTC TCTGGAAGCC GGAGCCGTCA TTGAAAACAG CAGCGGAGGC AT - #GGATTTTA1320- GCCGGCGGTG CACACCATAC CTGCCTGTCT TATGAACTGA CAGCGGAGCA AA - #TGCTTGAT1380- TGGGCGGAAA TGGCGGGAAT CGAAAGTGTT CTCATTTCCC GTGATACGAC AA - #TTCATAAA1440# 1491TAAAATG GAACGAGGCG CTTTACCGGC TTCAAAAGTA G- (2) INFORMATION FOR SEQ ID NO:36:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 1683 base (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: cDNA- (iii) HYPOTHETICAL: NO- (vi) ORIGINAL SOURCE:#subtilis (A) ORGANISM: Bacillus- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:36:- ATGGCTTACA CAATAGGGGT TGATTTTGGA ACTTTATCAG GAAGAGCAGT GC - #TCGTTCAT 60- GTCCAAACAG GGGAGGAACT TGCGGCTGCT GTAAAAGAAT ACAGGCATGC TG - #TCATTGAT 120- ACCGTCCTTC CAAAAACGGG TCAAAAGCTG CCGCGTGACT GGGCGCTGCA GC - #ACCCTGCT 180- GATTACCTCG AAGTCTTGGA AACAACCATT CCGTCTTTAC TCGAACAGAC GG - #GCGTTGAC 240- CCGAAAGACA TTATCGGGAT TGGAATTGAT TTCACGGCAT GTACGATCCT TC - #CTATTGAC 300- AGCAGCGGGC AGCCGTTATG CATGCTGCCT GAATATGAAG AGGAGCCGCA CA - #GCTATGTG 360- AAGCTCTGGA AGCATCATGC GGCCCAAAAA CATGCTGATC GGCTCAATCA AA - #TCGCGGAA 420- GAAGAAGGAG AGGCTTTTTT ACAGCGGTAC GGAGGAAAAA TTTCATCAGA AT - #GGATGATT 480- CCAAAGGTCA TGCAAATTGC CGAGGAAGCG CCTCACATTT ATGAAGCGGC TG - #ACCGGATC 540- ATCGAGGCTG CGGACTGGAT CGTGTACCAG CTGTGCGGCT CGCTCAAGCG AA - #GCAATTGT 600- ACCGCAGGGT ATAAAGCGAT GTGGAGTGAA AAAGCGGGGT ATCCGTCAGA TG - #ATTTCTTT 660- GAGAAATTAA ATCCTTCAAT GAAAACGATT ACAAAGGACA AATTGTCAGG TT - #CTATTCAT 720- TCAGTAGGAG AAAAAGCCGG CAGTCTGACT GAAAAAATGG CAAAGCTGAC AG - #GGCTTCTC 780- CCGGGAACGG CTGTTGCGGT TGCCAATGTG GACGCTCATG TTTCGGTACC GG - #CGGTCGGC 840- ATTACAGAGC CAGGGAAAAT GCTGATGATT ATGGGAACCT CGACGTGCCA TG - #TTCTACTT 900- GGTGAAGAGG TGCATATCGT TCCAGGAATG TGCGGCGTTG TGGACAACGG AA - #TTCTCCCG 960- GGCTATGCGG GATATGAAGC CGGGCAGTCC TGTGTCGGCG ATCATTTTGA CT - #GGTTTGTG1020- AAAACATGTG TCCCGCCAGC TTATCAAGAG GAAGCAAAGG AAAAAAACAT TG - #GCGTTCAT1080- GAGCTGCTGA GTGAGAAAGC AAACCATCAA GCGCCTGGTG AAAGCGGCTT GC - #TTGCTTTA1140- GATTGGTGGA ATGGAAACCG TTCAACTCTT GTTGATGCAG ATTTAACAGG GA - #TGCTGCTT1200- GGCATGACAC TGCTGACGAA GCCTGAAGAG ATTTATAGAG CGTTAGTTGA AG - #CGACAGCT1260- TACGGAACCC GGATGATTAT CGAAACATTC AAAGAAAGCG GTGTTCCGAT TG - #AGGAACTG1320- TTCGCAGCCG GCGGAATAGC TGAGAAAAAC CCGTTTGTCA TGCAGATTTA TG - #CGGATGTG1380- ACAAACATGG ACATTAAAAT CTCTGGTTCA CCGCAAGCCC CAGCCTTAGG AT - #CTGCCATT1440- TTCGGCGCGC TTGCAGCAGG CAAAGAAAAA GGCGGCTACG ATGATATCAA AA - #AGGCAGCG1500- GCGAACATGG GAAAACTGAA AGATATAACT TATACGCCAA ATGCCGAAAA CG - #CCGCGGTT1560- TATGAAAAAT TGTACGCTGA ATATAAAGAG CTGGTTCATT ATTTCGGAAA AG - #AAAACCAT1620- GTCATGAAGC GTCTGAAAAC GATCAAAAAT CTTCAATTTT CATCTGCCGC CA - #AAAAGAAT1680# 1683- (2) INFORMATION FOR SEQ ID NO:37:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 690 base (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: cDNA- (iii) HYPOTHETICAL: NO- (vi) ORIGINAL SOURCE:#subtilis (A) ORGANISM: Bacillus- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:37:- ATGCTTGAAA CATTAAAAAA AGAAGTGCTG GCTGCCAACC TGAAGCTTCA AG - #AGCATCAG 60- CTGGTAACCT TTACGTGGGG AAATGTCAGC GGCATTGACC GTGAAAAAGA AA - #GAATTGTC 120- ATCAAACTAG CGGAGTCGAA TACCAGCGAC CTGACAGCCG ATGACTTGGT TG - #TTTTGAAC 180- CTTGATGGAG AGGTCGTCGA AGGCTCGCTT AAACCTTCTT CAGATACACC TA - #CCCATGTT 240- TATCTATATA AAGCCTTTCC GAATATCGGG GGAATTGTCC ATACCCATTC TC - #AATGGGCG 300- ACAAGCTGGG CGCAATCGGG CAGAGACATC CCTCCGTTAG GCACGACCCA TG - #CTGATTAT 360- TTTGACAGTG CGATTCCATG TACTCGAGAA ATGTACGATG AAGAAATCAT TC - #ATGACTAC 420- GAACTGAATA CAGGAAAAGT CATAGCGGAA ACCTTTCAGC ATCATAATTA CG - #AACAGGTG 480- CCGGGTGTGC TCGTGAATAA TCACGGACCG TTCTGCTGGG GCACTGACGC CT - #TAAATGCC 540- ATTCATAACG CAGTTGTATT AGAAACGGTT GCCGAAATGG CCTATCACTC CA - #TTATGCTG 600- AACAAGGATG TAACCCCAAT CAATACAGTC CTGCATGAAA AGCATTTTTA TC - #GAAAACAC 660# 690 ATGG CCAGTCATGA- (2) INFORMATION FOR SEQ ID NO:38:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 29 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: DNA (genomic)- (iii) HYPOTHETICAL: NO- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:38:# 29 NNNN NNNTATAAT- (2) INFORMATION FOR SEQ ID NO:39:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 27 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: DNA (genomic)- (iii) HYPOTHETICAL: NO- (iv) ANTI-SENSE: NO- (vi) ORIGINAL SOURCE:#subtilis (A) ORGANISM: Bacillus- (ix) FEATURE:--> "abfA"(D) OTHER INFORMATION:- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:39:# 27 ACGT GTGATGA- (2) INFORMATION FOR SEQ ID NO:40:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 85 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: DNA (genomic)- (iii) HYPOTHETICAL: NO- (iv) ANTI-SENSE: NO- (vi) ORIGINAL SOURCE:#subtilis (A) ORGANISM: Bacillus- (ix) FEATURE:# "abfA" (D) OTHER INFORMATION:- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:40:- TCAATAAGAA TAGCAAAGCC GGAGATTTCT CTCCGGCTTG TCTTTCAACT GC - #CACGAGCC 60# 85 CTTT TTGTA- (2) INFORMATION FOR SEQ ID NO:41:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 11 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: RNA (genomic)- (iii) HYPOTHETICAL: NO- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:41:# 11- (2) INFORMATION FOR SEQ ID NO:42:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 13 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: RNA (genomic)- (iii) HYPOTHETICAL: NO- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:42:# 13- (2) INFORMATION FOR SEQ ID NO:43:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 12 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: RNA (genomic)- (iii) HYPOTHETICAL: NO- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:43:# 12- (2) INFORMATION FOR SEQ ID NO:44:- (i) SEQUENCE CHARACTERISTICS:#acids (A) LENGTH: 17 amino (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: peptide- (iii) HYPOTHETICAL: NO- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:44:- Glu Ala Ala Xaa Xaa Xaa Gly Xaa Xaa Xaa Xa - #a Xaa Xaa Ile Xaa Leu# 15- Pro- (2) INFORMATION FOR SEQ ID NO:45:- (i) SEQUENCE CHARACTERISTICS:#acids (A) LENGTH: 6 amino (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: peptide- (iii) HYPOTHETICAL: NO- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:45:- Ile Ala Gly Cys Ser Ala1 5- (2) INFORMATION FOR SEQ ID NO:46:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 17 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: other nucleic acid#= "PRIMER"A) DESCRIPTION: /desc- (iii) HYPOTHETICAL: NO- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:46:# 17 C- (2) INFORMATION FOR SEQ ID NO:47:- (i) SEQUENCE CHARACTERISTICS:#acids (A) LENGTH: 19 amino (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: peptide- (iii) HYPOTHETICAL: NO- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:47:- Leu Xaa Xaa Leu Gly Lys Xaa Phe Glu Xaa As - #p Xaa Xaa Gly Ile Lys# 15- Val Xaa Val- (2) INFORMATION FOR SEQ ID NO:48:- (i) SEQUENCE CHARACTERISTICS:#acids (A) LENGTH: 26 amino (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: peptide- (iii) HYPOTHETICAL: NO- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:48:- Tyr Val Glu Met Val Lys Glu Trp Asn Lys Ly - #s Tyr Pro Asp Arg Lys# 15- Ile Lys Leu Asn Thr Val Val Tyr Pro Tyr# 25- (2) INFORMATION FOR SEQ ID NO:49:- (i) SEQUENCE CHARACTERISTICS:#acids (A) LENGTH: 49 amino (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: peptide- (iii) HYPOTHETICAL: NO- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:49:- Met Lys Lys Ala Arg Met Ile Val Asp Lys Gl - #u Tyr Lys Ile Gly Glu# 15- Val Asp Lys Arg Ile Tyr Gly Ser Phe Ile Gl - #u His Met Gly Arg Ala# 30- Val Tyr Glu Gly Ile Tyr Glu Pro Asp His Pr - #o Glu Ala Asp Glu Asp# 45- Gly- (2) INFORMATION FOR SEQ ID NO:50:- (i) SEQUENCE CHARACTERISTICS:#acids (A) LENGTH: 50 amino (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: peptide- (iii) HYPOTHETICAL: NO- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:50:- Ala Thr Lys Lys Ala Thr Met Ile Ile Glu Ly - #s Asp Phe Lys Ile Ala# 15- Glu Ile Asp Lys Arg Ile Tyr Gly Ser Phe Il - #e Glu His Leu Gly Arg# 30- Ala Val Tyr Gly Gly Ile Tyr Glu Pro Gly Hi - #s Pro Gln Ala Asp Glu# 45- Asn Gly 50- (2) INFORMATION FOR SEQ ID NO:51:- (i) SEQUENCE CHARACTERISTICS:#acids (A) LENGTH: 40 amino (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: peptide- (iii) HYPOTHETICAL: NO- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:51:- Gly Leu Gln Asn Val Pro Lys Glu Leu Tyr Gl - #u Ala Ala Asp Ile Asp# 15- Gly Ala Asn Thr Met Lys Lys Phe Leu His Il - #e Thr Leu Pro Phe Leu# 30- Lys Pro Val Thr Val Tyr Val Leu# 40- (2) INFORMATION FOR SEQ ID NO:52:- (i) SEQUENCE CHARACTERISTICS:#acids (A) LENGTH: 40 amino (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: peptide- (iii) HYPOTHETICAL: NO- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:52:- Ala Leu Gln Ser Ile Pro Asp Ser Leu Ile Gl - #u Ala Ala Lys Ile Asp# 15- Gly Ala Gly Pro Phe Gln Arg Phe Trp Asn Il - #e Val Leu Pro Leu Leu# 30- Lys Pro Val Leu Ala Val Leu Leu# 40- (2) INFORMATION FOR SEQ ID NO:53:- (i) SEQUENCE CHARACTERISTICS:#acids (A) LENGTH: 40 amino (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: peptide- (iii) HYPOTHETICAL: NO- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:53:- Tyr Ala Leu Gly Leu Pro Arg Asp Leu Leu As - #p Ser Ala Arg Met Asp# 15- Gly Cys Thr Glu Arg Gly Ile Phe Phe Arg Il - #e Met Ala Pro Leu Met# 30- Lys Pro Ala Phe Gly Ala Met Ile# 40- (2) INFORMATION FOR SEQ ID NO:54:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 23 base (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: DNA (genomic)- (iii) HYPOTHETICAL: NO- (vi) ORIGINAL SOURCE:#subtilis (A) ORGANISM: Bacillus- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:54:# 23GTAC AAA- (2) INFORMATION FOR SEQ ID NO:55:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 20 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: DNA (genomic)- (iii) HYPOTHETICAL: NO- (iv) ANTI-SENSE: NO- (vi) ORIGINAL SOURCE:#subtilis (A) ORGANISM: Bacillus- (ix) FEATURE:--> "araQ"(D) OTHER INFORMATION:- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:55:# 20 AATG- (2) INFORMATION FOR SEQ ID NO:56:- (i) SEQUENCE CHARACTERISTICS:#acids (A) LENGTH: 18 amino (B) TYPE: amino acid (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: protein- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:56:- Met Leu Gln Thr Lys Asp Tyr Glu Phe Trp Ph - #e Val Thr Gly Ser Gln# 15- His Leu- (2) INFORMATION FOR SEQ ID NO:57:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 94 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: cDNA- (iii) HYPOTHETICAL: NO- (iv) ANTI-SENSE: NO- (vi) ORIGINAL SOURCE:#subtilis (A) ORGANISM: Bacillus- (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 1..94- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:57:- ATG GCC AGT CAT GAT ACG CCT GTG TCA CCG GC - #T GGC ATT CTG ATT GAC 48Met Ala Ser His Asp Thr Pro Val Ser Pro Al - #a Gly Ile Leu Ile Asp# 15- TTG GAC GGT ACT GTA TTC AGA GGA AAT GAG TT - #G ATC GAA GGA GCA A 9 - #4Leu Asp Gly Thr Val Phe Arg Gly Asn Glu Le - #u Ile Glu Gly Ala# 30- (2) INFORMATION FOR SEQ ID NO:58:- (i) SEQUENCE CHARACTERISTICS:#acids (A) LENGTH: 31 amino (B) TYPE: amino acid (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: protein- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:58:- Met Ala Ser His Asp Thr Pro Val Ser Pro Al - #a Gly Ile Leu Ile Asp# 15- Leu Asp Gly Thr Val Phe Arg Gly Asn Glu Le - #u Ile Glu Gly Ala# 30- (2) INFORMATION FOR SEQ ID NO:59:- (i) SEQUENCE CHARACTERISTICS:#acids (A) LENGTH: 269 amino (B) TYPE: amino acid (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: protein- (vi) ORIGINAL SOURCE:#subtilis (A) ORGANISM: Bacillus- (ix) FEATURE:#/product= "araL"ER INFORMATION:- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:59:- Met Ala Ser His Asp Thr Pro Val Ser Pro Al - #a Gly Ile Leu Ile Asp# 15- Leu Asp Gly Thr Val Phe Arg Gly Asn Glu Le - #u Ile Glu Gly Ala Arg# 30- Glu Ala Ile Lys Thr Leu Arg Arg Met Gly Ly - #s Lys Ile Val Phe Leu# 45- Ser Asn Arg Gly Asn Ile Ser Arg Ala Met Cy - #s Arg Lys Lys Leu Leu# 60- Gly Ala Gly Ile Glu Thr Asp Val Asn Asp Il - #e Val Leu Ser Ser Ser# 80- Val Thr Ala Ala Phe Leu Lys Lys His Tyr Ar - #g Phe Ser Lys Val Trp# 95- Val Leu Gly Glu Gln Gly Leu Val Asp Glu Le - #u Arg Leu Ala Gly Val# 110- Gln Asn Ala Ser Glu Pro Lys Glu Ala Asp Tr - #p Leu Val Ile Ser Leu# 125- His Glu Thr Leu Thr Tyr Asp Asp Leu Asn Gl - #n Ala Phe Gln Ala Ala# 140- Ala Gly Gly Ala Arg Ile Ile Ala Thr Asn Ly - #s Asp Arg Ser Phe Pro145 1 - #50 1 - #55 1 -#60- Asn Glu Asp Gly Asn Ala Ile Asp Val Ala Gl - #y Met Ile Gly Ala Ile# 175- Glu Thr Ser Ala Gln Ala Lys Thr Glu Leu Va - #l Val Gly Lys Pro Ser# 190- Trp Leu Met Ala Glu Ala Ala Cys Thr Ala Me - #t Gly Leu Ser Ala His# 205- Glu Cys Met Ile Ile Gly Asp Ser Ile Glu Se - #r Asp Ile Ala Met Gly# 220- Lys Leu Tyr Gly Met Lys Ser Ala Leu Val Le - #u Thr Gly Ser Ala Lys225 2 - #30 2 - #35 2 -#40- Gln Gly Glu Gln Arg Leu Tyr Thr Pro Asp Ty - #r Val Leu Asp Ser Ile# 255- Lys Asp Val Thr Lys Leu Ala Glu Glu Gly Il - #e Leu Ile# 265- (2) INFORMATION FOR SEQ ID NO:60:- (i) SEQUENCE CHARACTERISTICS:#acids (A) LENGTH: 394 amino (B) TYPE: amino acid (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: protein- (vi) ORIGINAL SOURCE:#subtilis (A) ORGANISM: Bacillus- (ix) FEATURE:#/product= "araM"ER INFORMATION:- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:60:- Met Asn Arg Ile Ala Ala Asp Val Gln Arg Al - #a Phe Glu Asn Ala Gly# 15- Glu Lys Thr Leu Pro Ile Lys Val Glu Glu Il - #e Val Leu Gly Lys Gln# 30- Ala Ala Asp Ser Leu Leu Asp Tyr Val Lys Ar - #g Lys Asn Asn Gln His# 45- Ile Val Leu Val Cys Asp Ala Asn Thr His Ar - #g Ile Ala Gly Ile Asp# 60- Leu Glu Asn Arg Leu Asn Gln Glu Gly Phe Gl - #n Ala Glu Cys Leu Ile# 80- Ile Pro Glu Asn Glu Ala Gly Asp Val Thr Al - #a Asp Glu Arg Ser Leu# 95- Ile His Val Leu Ile His Thr Lys Gln Pro Th - #r Asp Val Met Ile Ala# 110- Val Gly Ser Gly Thr Ile His Asp Ile Val Ar - #g Phe Ala Ala Phe Gln# 125- Arg Asp Leu Pro Phe Ile Ser Tyr Pro Thr Al - #a Pro Ser Val Asp Gly# 140- Phe Thr Ser Ala Gly Ala Pro Ile Ile Leu Ty - #r Gly Thr Lys Thr Thr145 1 - #50 1 - #55 1 -#60- Ile Gln Thr Lys Ala Pro Ser Ala Leu Phe Al - #a Asp Leu Asp Leu Leu# 175- Lys Ala Ala Pro Gln Ser Met Val Ala Ala Gl - #y Phe Gly Asp Met Leu# 190- Gly Lys Ile Thr Ser Leu Ala Asp Trp Glu Il - #e Ser Arg His Leu Ala# 205- Gly Glu Pro Tyr Ser Pro Ala Gly Ala Lys Il - #e Val Gln Glu Ala Leu# 220- Ala Ala Cys Ile Glu His Thr Glu Asp Ile Al - #a Met Lys Thr Glu Thr225 2 - #30 2 - #35 2 -#40- Gly Ile Arg Val Leu Met Glu Ser Leu Leu Va - #l Ser Gly Leu Val Met# 255- Leu Ala Leu Asp His Ser Arg Pro Ala Ser Gl - #y Gly Glu His His Ile# 270- Ser His Trp Ile Glu Met Glu Leu Met Glu Ly - #s Lys Arg Pro Gln Ile# 285- Leu His Gly Ala Lys Val Gly Cys Ala Ala Va - #l Leu Leu Thr Asp Thr# 300- Tyr Arg Lys Leu Ala Gln Asp Asp Gly Leu As - #n Glu Phe Ser Pro Ser305 3 - #10 3 - #15 3 -#20- Arg Arg Glu Ala Ile Gln Ser Ala Tyr Gln Th - #r Leu Pro Arg Gly Glu# 335- Val Leu Ala Asp Trp Leu Arg Ser Ala Gly Gl - #y Pro Ala Asp Phe Asp# 350- Glu Ile Gly Val Gly Gln Asp Ser Val Lys As - #n Ala Phe Arg His Ala# 365- His Thr Leu Arg Asp Arg Cys Thr Gly Leu Ar - #g Ile Ile Asn Glu Asn# 380- Lys Thr Leu Ile Asn His Gly Leu Tyr Glu385 3 - #90- (2) INFORMATION FOR SEQ ID NO:61:- (i) SEQUENCE CHARACTERISTICS:#acids (A) LENGTH: 433 amino (B) TYPE: amino acid (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: protein- (vi) ORIGINAL SOURCE:#subtilis (A) ORGANISM: Bacillus- (ix) FEATURE:#/product= "araN"ER INFORMATION:- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:61:- Met Lys Lys Met Thr Val Cys Phe Leu Val Le - #u Met Met Leu Leu Thr# 15- Leu Val Ile Ala Gly Cys Ser Ala Glu Lys Se - #r Ser Gly Lys Ser Gly# 30- Glu Thr Glu Leu Thr Phe Trp Thr Phe Asn Gl - #y Leu His Glu Gln Phe# 45- Tyr Val Glu Met Val Lys Glu Trp Asn Lys Ly - #s Tyr Pro Asp Arg Lys# 60- Ile Lys Leu Asn Thr Val Val Tyr Pro Tyr Gl - #y Gln Met His Asp Asn# 80- Leu Ser Ile Ser Leu Ile Ala Gly Glu Gly Va - #l Pro Asp Ile Ala Asp# 95- Val Glu Leu Ala Arg Phe Ser Asn Phe Leu Ly - #s Gly Ser Asp Ile Pro# 110- Leu Ala Asp Leu Thr Pro Leu Ile Glu Lys As - #p Arg Asp Lys Phe Val# 125- Glu Ala Arg Leu Thr Leu Tyr Ser Lys Asn Gl - #y Lys Leu Tyr Gly Leu# 140- Asp Thr His Val Gly Thr Thr Val Met Phe Ty - #r Asn Met Asp Val Met145 1 - #50 1 - #55 1 -#60- Lys Lys Ala Gly Val Asn Pro Asp Asp Ile Ly - #s Thr Trp Asp Asp Tyr# 175- His Lys Ala Gly Gln Lys Val Arg Lys Val Th - #r Gly Lys Pro Met Gly# 190- Thr Val Glu Thr Asn Asp Ser Ala Thr Phe Le - #u Ser Met Ile Ser Gln# 205- Gln Asn Ser Gly Tyr Phe Asp Lys Asn Gly Ly - #s Leu Ile Leu Asn Asn# 220- Asp Thr Asn Val Lys Thr Leu Gln Tyr Leu Ly - #s Asp Met Ile Asn Asp225 2 - #30 2 - #35 2 -#40- Lys Thr Met Ile Pro Ala Pro Gly Gly Gly Hi - #s His Ser Glu Glu Tyr# 255- Tyr Gly Phe Met Asn Gln Gly Gly Ala Ala Se - #r Val Leu Met Pro Ile# 270- Trp Tyr Met Gly Arg Phe Ile Asp Tyr Met Pr - #o Asp Leu Lys Gly Lys# 285- Ile Ala Ile Arg Pro Leu Pro Ala Trp Lys Gl - #u Gly Gly Asp Arg Ser# 300- Ala Gly Leu Gly Gly Thr Ala Thr Val Val Pr - #o Lys Gln Ser Lys His305 3 - #10 3 - #15 3 -#20- Val Glu Leu Ala Lys Glu Phe Leu Ala Phe Al - #a Lys Gly Ser Glu Glu# 335- Gly Asn Lys Lys Leu Trp Ser Val Leu Gly Ph - #e Asp Pro Leu Arg Trp# 350- Asp Val Trp Ser Ser Lys Glu Leu Lys Glu Ly - #s Asn Lys Tyr Thr Asp# 365- Tyr Phe Gln Asn Gly Thr Gly Ile Phe Ser Va - #l Leu Leu Asp Ile Lys# 380- Asp Glu Ile Asn Pro Ile Tyr Leu His Glu As - #p Phe Ala Lys Ala Ser385 3 - #90 3 - #95 4 -#00- Asp Leu Val Asn Arg Ser Val Leu Phe Asp Al - #a Leu Lys Ser Gln Gln# 415- Lys Thr Pro Lys Gln Ala Leu Asp Arg Ala Al - #a Gly Glu Leu Lys Gln# 430- Lys- (2) INFORMATION FOR SEQ ID NO:62:- (i) SEQUENCE CHARACTERISTICS:#acids (A) LENGTH: 313 amino (B) TYPE: amino acid (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: protein- (vi) ORIGINAL SOURCE:#subtilis (A) ORGANISM: Bacillus- (ix) FEATURE:#/product= "araP"ER INFORMATION:- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:62:- Met Lys Pro Val Lys Thr Gly Thr Val His Pr - #o Val Pro Ser Ala Ala# 15- Lys Gln Ser Gly Trp Arg Asp Leu Phe Tyr Se - #r Lys Lys Ala Ala Pro# 30- Tyr Leu Phe Thr Ala Pro Phe Val Leu Ser Ph - #e Leu Val Phe Phe Leu# 45- Tyr Pro Ile Ile Ser Val Phe Ile Met Ser Ph - #e Gln Arg Ile Leu Pro# 60- Gly Glu Val Ser Phe Val Gly Leu Ser Asn Ty - #r Thr Ala Leu Asn Asn# 80- Pro Thr Phe Tyr Thr Ala Leu Trp Asn Thr Le - #u Glu Tyr Thr Phe Trp# 95- Thr Leu Ile Val Leu Ile Pro Val Pro Leu Le - #u Leu Ala Ile Phe Leu# 110- Asn Ser Lys Leu Val Lys Phe Arg Asn Ile Ph - #e Lys Ser Ala Leu Phe# 125- Ile Pro Ala Leu Thr Ser Thr Ile Val Ala Gl - #y Ile Ile Phe Arg Leu# 140- Ile Phe Gly Glu Met Glu Thr Ser Leu Ala As - #n Ser Ile Leu Leu Lys145 1 - #50 1 - #55 1 -#60- Leu Gly Phe Ser Pro Gln Asn Trp Met Asn As - #n Glu His Thr Gly Met# 175- Phe Leu Met Val Leu Leu Ala Ser Trp Lys Tr - #p Met Gly Ile Asn Ile# 190- Leu Tyr Phe Leu Ala Gly Leu Gln Asn Val Pr - #o Lys Glu Leu Tyr Glu# 205- Ala Ala Asp Ile Asp Gly Ala Asn Thr Met Ly - #s Lys Phe Leu His Ile# 220- Thr Leu Pro Phe Leu Lys Pro Val Thr Val Ty - #r Val Leu Thr Ile Ser225 2 - #30 2 - #35 2 -#40- Ile Ile Gly Gly Phe Arg Met Phe Glu Glu Se - #r Tyr Val Leu Trp Gln# 255- Asn Asn Ser Pro Gly Asn Ile Gly Leu Thr Le - #u Val Gly Tyr Leu Tyr# 270- Gln Gln Gly Leu Ala Tyr Asn Glu Met Gly Ty - #r Gly Ala Ala Ile Gly# 285- Ile Val Leu Leu Ile Val Ile Leu Val Val Se - #r Leu Ile Ser Leu Lys# 300- Leu Ser Gly Ser Phe Lys Gly Glu Gly305 3 - #10- (2) INFORMATION FOR SEQ ID NO:63:- (i) SEQUENCE CHARACTERISTICS:#acids (A) LENGTH: 281 amino (B) TYPE: amino acid (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: protein- (vi) ORIGINAL SOURCE:#subtilis (A) ORGANISM: Bacillus- (ix) FEATURE:#/product= "araQ"ER INFORMATION:- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:63:- Met Leu Arg His Ser Pro Gln Phe Ser Val Ty - #r Arg Ile Ala Leu Thr# 15- Leu Phe Phe Met Met Leu Ser Leu Leu Tyr Le - #u Phe Pro Ile Phe Cys# 30- Leu Leu Leu Gly Ser Leu Lys Pro Ser Ser Gl - #u Leu Leu Arg Val Gly# 45- Leu Asn Leu Asp Ile Asp Pro Lys Val Met Se - #r Phe Asp Asn Tyr Thr# 60- Phe Leu Phe Asn Gly Gly Ser Ile Tyr Phe Ly - #s Trp Phe Phe Asn Ser# 80- Leu Val Leu Gly Leu Phe Thr Thr Val Leu Th - #r Leu Phe Phe Ser Ser# 95- Met Ile Gly Tyr Gly Leu Ala Val Tyr Asp Ph - #e Lys Gly Arg Asn Ile# 110- Ile Phe Val Leu Val Leu Ile Ile Met Met Va - #l Pro Leu Glu Val Met# 125- Met Leu Pro Leu Phe Lys Leu Thr Val Gly Le - #u His Leu Ile Asp Ser# 140- Tyr Thr Gly Val Ile Leu Pro Phe Ile Val Se - #r Pro Val Ala Val Phe145 1 - #50 1 - #55 1 -#60- Phe Phe Arg Gln Tyr Ala Leu Gly Leu Pro Ar - #g Asp Leu Leu Asp Ser# 175- Ala Arg Met Asp Gly Cys Thr Glu Phe Gly Il - #e Phe Phe Arg Ile Met# 190- Ala Pro Leu Met Lys Pro Ala Phe Gly Ala Me - #t Ile Ile Leu Gln Ser# 205- Leu Asn Ser Trp Asn Asn Phe Leu Trp Pro Le - #u Ile Val Leu Arg Ser# 220- Lys Glu Met Phe Thr Leu Pro Ile Gly Leu Se - #r Ser Leu Leu Ser Pro225 2 - #30 2 - #35 2 -#40- Tyr Gly Asn Asn Tyr Asp Met Leu Ile Ser Gl - #y Ser Val Phe Ala Ile# 255- Leu Pro Val Ile Ile Ile Phe Leu Phe Phe Gl - #n Lys Tyr Phe Ile Ser# 270- Gly Leu Thr Val Gly Gly Val Lys Gly# 280- (2) INFORMATION FOR SEQ ID NO:64:- (i) SEQUENCE CHARACTERISTICS:#acids (A) LENGTH: 500 amino (B) TYPE: amino acid (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: protein- (vi) ORIGINAL SOURCE:#subtilis (A) ORGANISM: Bacillus- (ix) FEATURE:#/product= "abfA"ER INFORMATION:- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:64:- Met Lys Lys Ala Arg Met Ile Val Asp Lys Gl - #u Tyr Lys Ile Gly Glu# 15- Val Asp Lys Arg Ile Tyr Gly Ser Phe Ile Gl - #u His Met Gly Arg Ala# 30- Val Tyr Glu Gly Ile Tyr Glu Pro Asp His Pr - #o Glu Ala Asp Glu Asp# 45- Gly Phe Arg Lys Asp Val Gln Ser Leu Ile Ly - #s Glu Leu Gln Val Pro# 60- Ile Ile Arg Tyr Pro Gly Gly Asn Phe Leu Se - #r Gly Tyr Asn Trp Glu# 80- Asp Gly Val Gly Pro Val Glu Asn Arg Pro Ar - #g Arg Leu Asp Leu Ala# 95- Trp Gln Thr Thr Glu Thr Asn Glu Val Gly Th - #r Asn Glu Phe Leu Ser# 110- Trp Ala Lys Lys Val Asn Thr Glu Val Asn Me - #t Ala Val Asn Leu Gly# 125- Thr Arg Gly Ile Asp Ala Ala Arg Asn Leu Va - #l Glu Tyr Cys Asn His# 140- Pro Lys Gly Ser Tyr Trp Ser Asp Leu Arg Ar - #g Ser His Gly Tyr Glu145 1 - #50 1 - #55 1 -#60- Gln Pro Tyr Gly Ile Lys Thr Trp Cys Leu Gl - #y Asn Glu Met Asp Gly# 175- Pro Trp Gln Ile Gly His Lys Thr Ala Asp Gl - #u Tyr Gly Arg Leu Ala# 190- Ala Glu Thr Ala Lys Val Met Lys Trp Val As - #p Pro Ser Ile Glu Leu# 205- Val Ala Cys Gly Ser Ser Asn Ser Gly Met Pr - #o Thr Phe Ile Asp Trp# 220- Glu Ala Lys Val Leu Glu His Thr Tyr Glu Hi - #s Val Asp Tyr Ile Ser225 2 - #30 2 - #35 2 -#40- Leu His Thr Tyr Tyr Gly Asn Arg Asp Asn As - #n Leu Pro Asn Tyr Leu# 255- Ala Arg Ser Met Asp Leu Asp His Phe Ile Ly - #s Ser Val Ala Ala Thr# 270- Cys Asp Tyr Val Lys Ala Lys Thr Arg Ser Ly - #s Lys Thr Ile Asn Leu# 285- Ser Leu Asp Glu Trp Asn Val Trp Tyr His Se - #r Asn Glu Ala Asp Lys# 300- Lys Val Glu Pro Trp Ile Thr Ala Arg Pro Il - #e Leu Glu Asp Ile Tyr305 3 - #10 3 - #15 3 -#20- Asn Phe Glu Asp Ala Leu Leu Val Gly Ser Le - #u Leu Ile Thr Met Leu# 335- Gln His Ala Asp Arg Val Lys Ile Ala Cys Le - #u Ala Gln Leu Val Asn# 350- Val Ile Ala Pro Ile Met Thr Glu Lys Gly Gl - #y Glu Ala Trp Arg Gln# 365- Pro Ile Phe Tyr Pro Tyr Met His Ala Ser Va - #l Tyr Gly Arg Gly Glu# 380- Ser Leu Lys Pro Leu Ile Ser Ser Pro Lys Ty - #r Asp Cys Ser Asp Phe385 3 - #90 3 - #95 4 -#00- Thr Asp Val Pro Tyr Val Asp Ala Ala Val Va - #l Tyr Ser Glu Glu Glu# 415- Glu Thr Leu Thr Ile Phe Ala Val Asn Lys Al - #a Glu Asp Gln Met Glu# 430- Thr Glu Ile Ser Leu Arg Gly Phe Glu Ser Ty - #r Gln Ile Ala Glu His# 445- Ile Val Leu Glu His Gln Asp Ile Lys Ala Th - #r Asn Gln His Asn Arg# 460- Lys Asn Val Val Pro His Ser Asn Gly Ser Se - #r Ser Val Ser Glu Asn465 4 - #70 4 - #75 4 -#80- Gly Leu Thr Ala His Phe Thr Pro Leu Ser Tr - #p Asn Val Ile Arg Leu# 495- Lys Lys Gln Ser 500__________________________________________________________________________

Highly regulable promoter for heterologous gene expression

Information

Patent Number

Date Filed

Date Issued

Inventors

Original Assignees

Examiners

Agents

CPC

US Classifications

Field of Search

US

International Classifications

Abstract

Description

Claims

RELATED APPLICATIONS

Foreign Referenced Citations (1)

Non-Patent Literature Citations (34)